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Summary 
Natural killer cells are large granular lymphocytes of the innate immune system, which play 
an important role in the recognition and elimination of malignantly transformed and infected 
cells. The major activating NK cell receptor NKG2D, which is also expressed as co-
stimulatory receptor on T cell subsets, is thereby a key modulator for tumor recognition and 
immune cell cytotoxicity. NKG2D recognizes several structurally related cellular ligands 
(MICA, MICB and ULBP1-6) commonly overexpressed on tumor cells. However, soluble 
NKG2D (sNKG2D) ligands released from malignant cells by proteolytical shedding, or on 
exosomes, can inhibit NKG2D-dependent NK and T cell cytotoxicity. Consequently, previous 
studies showed a correlation of elevated individual sNKG2D ligand plasma levels with im-
paired NK cell cytotoxicity in cancer patients. Moreover, in a phase I/II trial with high-risk 
neuroblastoma patients, sMICA was shown to inhibit not only autologous NK cells, but also 
adoptively transferred allogeneic NK cells after haploidentical stem cell transplantation.  
Head and neck squamous cell carcinoma (HNSCC) is a highly heterogeneous and aggressive 
tumor of the upper aero-digestive tract accounting for 300,000 annual deaths worldwide due 
to failure of current therapies. In a previous study, sMICA in HNSCC patients’ plasma was 
correlated with impaired NK cell function, indicating that NKG2D-dependent tumor immune 
escape might play a role for evasion of HNSCC from immunosurveillance. However, little is 
known about the cumulative role of all sNKG2D ligands and their impact during course of 
disease. Therefore, the aim of this thesis was the characterization of the NKG2D-dependent 
tumor immune escape in HNSCC to identify a patient cohort, which might benefit from resto-
ration of NKG2D-dependent tumor immunosurveillance. In this respect, a proof of concept 
for the depletion of sNKG2D ligands from patients’ plasma as future therapeutic intervention 
strategy to restore NKG2D-dependent antitumor immune cell function was established. 
In this thesis, profiling of the plasma from 44 HNSCC patients in comparison to age-matched 
healthy donors revealed significantly elevated levels of sMICA, sMICB and sULBP1-3. The 
cumulative levels of sNKG2D ligands were patient specific and correlated with disease pro-
gression and tumor load. Moreover, these data suggested a prominent role of sULBP1 and 
sULBP3 in NKG2D-dependent tumor immune escape in HNSCC. In addition, the immuno-
suppressive state of HNSCC patients augments NKG2D-dependent escape especially through 
high plasma levels of TGF-β1. 
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In in vitro cytotoxicity assays, high levels of sNKG2D ligands and TGF-β1 in patients’ plasma 
correlated with NK cell inhibition by blocking the NKG2D receptor. Importantly, the specific 
depletion of sNKG2D ligands by antibody-coupled magnetic beads successfully restored NK 
cell cytotoxicity of primary human NK cells against single tumor cell suspensions and in a 3D 
tumor spheroid model. Consequently, all sNKG2D ligands are indicative for NKG2D-
dependent tumor immune escape in HNSCC and determine a time point at which malignant 
cells critically benefit from bypassing immunosurveillance. Based on tumor spheroids, it 
could be shown that inhibition of NKG2D-dependent cytotoxicity correlated with drastically 
reduced NK cell infiltration. These data were in accordance with low infiltration frequencies 
found in primary tumors of HNSCC patients. Therefore, interference with NKG2D-dependent 
tumor immune escape might boost both, NK cell cytotoxicity and redirect NK cells to infil-
trate tumors. 
As proof of concept, a biofunctionalized matrix for adsorption apheresis based on a monoclo-
nal antibody for the representative ligand MICA was generated and showed high depletion 
capacity of soluble MICA allelic variants from human plasma in vitro. The data from HNSCC 
patients indicate that the simultaneous depletion of all sNKG2D ligands might be crucial for a 
clinical intervention strategy. Therefore, a pan-specific bioreactive surface using recombinant 
human IgG1-Fc fusion proteins of the NKG2D ectodomain was generated. In vitro depletion 
experiments demonstrated quantitative depletion of sMICA/B and sULBPs from human 
plasma. To validate adsorption apheresis of sNKG2D ligands, the anti-MICA antibody ad-
sorber was used in a proof of concept study in rhesus monkeys (Macaca mulatta). The pre-
clinical study in rhesus monkeys infused with soluble human MICA demonstrated that ad-
sorption apheresis of sNKG2D ligands is technically feasible and that quantitative removal of 
sMICA can be achieved after three plasma volume exchanges.  
In conclusion, the cumulative level of sNKG2D ligands and TGF-β1 might provide a novel 
diagnostic and/or prognostic marker combination to decipher a patient cohort, which benefits 
from restoration of NKG2D-dependent tumor immunosurveillance. Adsorption apheresis of 
sNKG2D ligands is proposed as therapeutic intervention strategy to improve the efficacy of 
autologous immune cells by restoration of tumor infiltration and cytotoxicity. Furthermore, 
adsorption apheresis as preconditioning strategy combined with cellular immunotherapies 
might help to improve the efficacy of therapeutically administered wildtype or engineered 
cytotoxic lymphocytes. 
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Summary (German) 
Natürliche Killerzellen (NK-Zellen) des angeborenen Immunsystems sind große granuläre 
Lymphozyten die maßgeblich an der Immunabwehr von transformierten und infizierten Zellen 
beteiligt sind. Die Erkennung und Zerstörung dieser Zellen wird durch die relative Intensität 
von agonistischen und antagonistischen Signalen Keimbahn-kodierter aktivierender und inhi-
bitorischer Rezeptoren reguliert. Für die Zerstörung von Tumorzellen durch NK-Zellen spielt 
dabei der aktivierende NKG2D-Rezeptor eine wichtige Rolle. Neben NK-Zellen exprimieren 
auch verschiedene T Zellsubtypen NKG2D als ko-stimulierenden Rezeptor. Die Liganden von 
NKG2D sind die strukturell verwandten Tumorantigene MICA, MICB und ULBP1-6, die auf 
der Oberfläche von Tumorzellen überexprimiert werden. Hochmaligne Tumore können jedoch 
die NKG2D-vermittelte Immunabwehr durch einen Tumor-Immun-Escape-Mechanismus 
basierend auf der Freisetzung löslicher NKG2D-Liganden durch proteolytische Spaltung 
(oder auf der Oberfläche von freigesetzten Exosomen) überwinden. Die molekularen Konse-
quenzen der Freisetzung von NKG2D-Liganden sind vielfältig: 1.) Die Zahl der Liganden auf 
der Zelloberfläche wird reduziert und somit die Anzahl der Interaktionsstellen für NKG2D+ 
Immunzellen, und 2.) lösliche Liganden können an den NKG2D Rezeptor binden und führen 
zur Blockierung und Degradation des Rezeptors auf den Immunzellen. Somit vermindern lös-
liche NKG2D-Liganden maßgeblich die zytotoxische Aktivität von NKG2D+ Immunzellen. 
Folglich zeigten verschiedene Studien einen Zusammenhang zwischen verringerter NK-
Zellfunktionalität und erhöhten Plasmakonzentrationen einzelner NKG2D-Liganden bei Pati-
enten mit verschiedenen Tumorentitäten. Dies betrifft neben den autologen Immunzellen aber 
auch die im Rahmen einer Zelltherapie transferierten NKG2D+ Immunzellen wie bei einer 
NK-Zelltherapie nach haploidenter Stammzelltransplantation in einer klinischen Phase I/II 
Studie bei Patienten mit Hochrisiko-Neuroblastom im Zusammenhang mit löslichem MICA 
gezeigt wurde. 
Das Plattenepithelkarzinom des Kopf-Hals-Bereiches (head and neck squamous cell carci-
noma; HNSCC) ist ein solider und hochaggressiver Tumor, der aus den Epithelien des oberen 
Atemwegs- und Verdauungstraktes hervorgeht. HNSCC steht mittlerweile an sechster Stelle 
der Malignomerkrankungen mit jährlich über 650.000 neuen Fällen weltweit. Die 5-Jahres 
Überlebensrate liegt seit langem unverändert bei 40-50% und hat somit 300.000 Todesfälle 
pro Jahr zur Folge. Eine vorangegangene Studie konnte auch im Plasma von HNSCC Patien-
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ten erhöhte Werte an sMICA nachweisen. Daher ist davon auszugehen, dass der NKG2D-
vermittelte Tumor-Immun-Escape auch für diese Krebsart von Bedeutung ist.  
Das Ziel der vorliegenden Arbeit war die Charakterisierung des NKG2D-abhängigen Tumor-
Immune-Escape-Mechanismus bei Patienten mit HNSCC und die Etablierung eines Aphere-
severfahrens als therapeutische Interventionsstrategie zur Entfernung der löslichen NKG2D-
Liganden aus dem Patientenplasma.  
Die Analyse der Plasmen von 44 HNSCC Patienten zeigte signifikant erhöhte Level der lösli-
chen NKG2D-Liganden MICA/B und ULBP1-3 im Vergleich zu alterskorrelierten Gesund-
spendern. Dabei korrelierten die kumulativen Plasmalevel mit dem Krankheitsverlauf und der 
Tumorlast. Im Vergleich zu MICA/B konnten die löslichen Liganden ULBP1/3 als mögliche 
Hauptmediatoren des Tumor-Immun-Escapes bei HNSCC identifiziert werden. Die weiterge-
hende Analyse von immunsuppressiven Faktoren zeigte zudem signifikant erhöhte TGF-β1 
Plasmawerte, die zur Hemmung der NKG2D-vermittelten Immunabwehr beitragen. 
In funktionalen in vitro Analysen wurde die Zytotoxizität von primären humanen NK-Zellen 
in Folge der Blockierung des NKG2D-Rezeptors durch lösliche NKG2D-Liganden und TGF-
β1 im Patientenplasma deutlich inhibiert. In diesem Zusammenhang konnte gezeigt werden, 
dass eine spezifische Entfernung der löslichen NKG2D-Liganden, mit Hilfe von mo-
noklonalen Antikörpern, die Zytotoxizität der NK-Zellen gegenüber Tumorzellen in Suspen-
sion und im 3D Tumorsphäroid-Modell nahezu vollständig wiederherstellen konnte. Folglich 
ist das Level an löslichen NKG2D-Liganden ein Indikator für das Ausmaß, in dem Tumore 
der NKG2D-vermittelten Immunabwehr entgehen. In Infiltrationsstudien im Tumorsphäroid-
Modell konnte nachgewiesen werden, dass die Inhibition der NKG2D-vermittelten Zytotoxi-
zität gegenüber den Tumorsphäroiden mit einer stark verminderten NK-Zellinfiltration korre-
lierte. Die Daten der Tumorsphäroide spiegeln die Situation in Patienten wieder. In weiter-
genden Studien an primären Tumoren von HNSCC Patienten, konnte ebenfalls eine strak 
verminderte oder abwesende NK-Zellinfiltration nachgewiesen werden. Daher ist davon 
auszugehen, dass die Intervention mit dem Tumor-Immun-Escape sowohl zytotoxische als 
auch Infiltrations-Eigenschaften von NK-Zellen deutlich verbessern kann.  
Zur Entfernung von löslichen NKG2D-Liganden aus Patientenplasma wurde ein Plasmaphe-
reseverfahren entwickelt. Hierzu wurde, als proof of concept, eine biofunktionalisierte Ober-
fläche basierend auf der Kopplung monoklonaler Antikörper gegen den repräsentativen Lig-
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anden MICA generiert, die eine hohe Depletionseffizienz für verschiedene MICA Allele aus 
humanem Plasma in vitro aufwies. Bei der Untersuchung der löslichen NKG2D-Liganden im 
Patientenplasma zeigte sich jedoch eine individuelle Zusammensetzung der Plasmaspiegel. 
Für eine therapeutische Intervention könnte folglich die simultane Entfernung mehrerer lösli-
cher NKG2D-Liganden aus Patientenplasma notwendig werden. Aus diesem Grund wurden in 
einem zweiten Ansatz Fusionsproteine aus einem humanen IgG1-Fc-Teil und der Ektodomäne 
des NKG2D-Rezeptors als panspezifischer Adsorber entwickelt. Dabei bindet der an die Mat-
rix gekoppelte Rezeptor die löslichen NKG2D-Liganden mit der gleichen Effizienz wie der 
Rezeptor auf den NK-Zellen und verhindert somit die Auswirkungen des Tumor-Immun-
Escape-Mechanismus. Die Apherese ist folglich unabhängig vom jeweiligen Patientenstatus 
bzw. dem Expressionslevel der Liganden effizient durchführbar. Die an eine Matrix gekoppel-
ten NKG2D-Fusionsproteine konnten alle löslichen NKG2D-Liganden effizient aus humanem 
Plasma in vitro entfernen. Zur Validierung der Apherese wurde der Antikörper-basierte Ad-
sorber als proof of concept in einem Rhesusaffen (Macaca mulatta) Modell mit injiziertem 
löslichen, humanem MICA getestet. Die präklinische Studie zeigte, dass die Apherese von 
löslichen NKG2D-Liganden aus dem Plasma eines Organismus technisch praktikabel ist und 
eine quantitative Entfernung des löslichen MICAs bereits nach dreimaligem Plasmaaustausch 
durch den Adsorber erfolgte. 
Zusammenfassend konnten die löslichen NKG2D-Liganden und TGF-β1 als eine neue prog-
nostische und/oder diagnostische Tumormarker-Kombination für HNSCC identifiziert wer-
den. Die Tumormarker könnten zur Identifikation einer Patientengruppe dienen, die von einer 
Interventionsstrategie zur Überwindung des NKG2D-vermittelten Tumor-Immun-Escape zur 
Steigerung der anti-tumoralen Eigenschaften autologer Immunzellen profitieren kann. In 
diesem Zusammenhang stellt die Apherese löslicher NKG2D-Liganden ein vielver-
sprechendes therapeutisches Konzept dar, das in Kombination mit Immunzelltherapien auch 
zur Steigerung der Effizienz allogener Immunzellen sowie genetisch modifizierter (autolo-
ger/allogener) Immunzellen beitragen kann. 
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1 Introduction 
1.1 The Immune System 
The human immune system is a complex network comprising cellular and humoral defense 
mechanisms to protect the host against infectious pathogens (e.g. viruses, bacteria, fungi and 
parasites) or degenerated self-cellsa. It can be divided into two parts determined by the speed 
and specificity of reactions - namely the innate and adaptive immunity [2]. The innate immun-
ity is the first line of defense including physical, chemical and microbiological barriers such 
as the epithelial and mucosiliary blankets. The immediate host defense is not antigen-specific 
and encoded in the hosts’ germline genes. Innate immunity relies on a highly regulated inter-
play of cellular components such as leukocytes of the myeloid linage (e.g. neutrophils, eosin-
ophils, mast cells, myeloid dentritic cells (DCs), monocytes and macrophages) or lymphoid 
linage (plasmacytoid DCs and natural killer (NK) cells) and humoral mediators such as chem-
okines and cytokines, the complement and acute-phase proteins. In contrast, the adaptive im-
munity is highly specific and develops during exposure against specific antigens by somatic 
rearrangement of gene elements encoding antigen-specific receptors expressed on T and B 
lymphocytes and the production of antibodies [3]. Due to the clonal expansion of antigen-
specific cells, the adaptive immunity represents the late response encompassing immune 
memory leading to a rapid immune reaction after subsequent exposure to known antigens. 
The tightly regulated synergy between innate and adaptive immune response is essential for 
an intact and effective immunity [4].  
Phagocytic macrophages and neutrophils along with the complement system are the first line 
of defense against intruding microorganisms. The complement cascade becomes activated by 
pathogenic surface structures leading directly to their osmotic lysis by assembly of the mem-
brane-attack complex or to the opsonization of pathogens for the recognition by phagocytes 
[5]. Phagocytes recognize common pathogen-associated molecular patterns (PAMPs) ex-
pressed by many microbes, but not on host cells, or danger-associated molecular patterns 
(DAMPs) induced by infections, tissue injury or malignant cells via invariant pattern-
recognition receptors (PRRs) such as mannose receptors, scavenger receptors and toll-like 
                                                 
 
a Unless otherwise denoted, “The Immune System” was reviewed in Janeway et al. (2005) [1]. 
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receptors [6]. Engagement leads to the direct phagocytosis and to the activation of macro-
phages releasing cytokines and chemokines to recruit further immune cells to the site of in-
flammation [7, 8]. Furthermore, macrophages and mainly DCs initiate the adaptive immune 
response upon infection or cellular transformation to antigen-presenting cells (APCs). Inter-
nalized antigens are processed into peptide fragments, which are presented on major histo-
compatibility (MHC) complexes on the cell surface of APCs which then migrate through the 
lymphatics from the site of infection to the secondary lymphoid tissues (e.g. lymph nodes, 
spleen, tonsils or mucosa associated lymphoid tissue). There, naïve T and B cells, having un-
dergone gene rearrangement and positive selection in the thymus or bone marrow, respective-
ly, are located in lymphoid follicles. They become activated and further differentiate to gain 
antigen specificity upon stimulation by APCs and cytokines [9]. Mature naïve B cells express 
immunoglobulin B cell receptors (BCRs), which recognize native pathogenic antigen struc-
tures brought to the secondary lymphoid tissues. These antigens can be internalized and fur-
ther processed leading to antigen presentation on MHC class II complexes for T cell activa-
tion. T cells in turn secrete cytokines for B cell differentiation and maturation to antibody 
producing plasma cells. Antibodies play a central role in boosting the innate and adaptive 
immunity by i) opsonization of pathogens, and infected or degenerated cells for the induction 
of antibody-dependent cellular cytotoxicity (ADCC) by killer cells, ii) neutralization of toxins 
and pathogens, and iii) the activation of the classical pathway of the complement cascade. 
During subsequent exposure to antigens, B cells can also be activated by follicular DCs in the 
germinal centers of lymph nodes.  
The main T cell population is characterized by the surface expression of αβ T cell receptors 
(TCRs) with single specificity after somatic rearrangement. T cells undergo positive selection 
in the thymus and differentiate into two main subpopulations with distinct functions according 
to the expression of the co-receptors cluster of differentiation (CD) 4 (T helper (TH) cells) or 
CD8 (cytotoxic T cells, CTLs). T cell activation is mediated through the recognition of linear 
antigen peptides (8-11 amino acids long) presented in the groove of MHC I complexes on 
APCs by the TCR and the co-receptor. The MHC molecule and co-receptor thereby determine 
the effector response. CD4+ T cells recognize exogenous peptides on MHC class II complexes 
(mainly on B cells) resulting in cytokine secretion and activation/regulation of different cellu-
lar (TH1 response) and humoral (TH2 response) immune responses [10]. In contrast, CD8
+ 
CTLs become activated by endogenous peptides on MHC class I complexes upon viral infec-
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tion or malignant cell transformation [11]. CTL activation leads to target cell lysis by release 
of cytotoxic granules containing perforin and granzymes or Fas/Fas-ligand induced apoptosis. 
To prevent tissue damage and autoimmune response, an effective T cell activation is depend-
ent on further co-stimuli by molecules (e.g. CD80, CD86 and CD40) upregulated on APCs 
exposed to an inflammatory environment [12]. Some of the activated B and T cells remain 
within the body as long-lived memory cells mediating a fast immune response to subsequent 
antigen exposure. 
Apart from the lymphocytes of the adaptive immunity, NK cells belonging to the innate im-
munity play a central role in immunosurveillance of viral infections and malignant cells [13-
15]. They share many functional features of T cells such as an immune regulatory role by cy-
tokine secretion or cytotoxic activity against target cells, therefore bridging the adaptive and 
innate immunity [16-18]. They contribute to a rapid initial immune response by recognition of 
microbial molecules after infections or stress-induced changes in autologous cells, thereby 
discriminating self from degenerated self. But unlike CTLs, NK cell activation does not need 
prior sensitization [19, 20].  
 
1.2 Natural Killer Cells 
NK cells were first described 1975 in mice as innate effector cells capable of killing target 
cells in the absence of antigen-specific priming [21, 22]. Like T and B cells, they arise from 
lymphatic progenitor (CD34+ hematopoietic) cells in the bone marrow and were found to de-
velop and differentiate in secondary lymphoid organs such as the liver, spleen, decidua and 
lymph nodes [23, 24]. Traditionally, NK cells are defined as large granular lymphocytes ex-
pressing the neural cell adhesion molecule (NCAM; CD56) and the FcγRIIIA receptor 
(CD16), but show absence of CD3 expression. More recently, they were grouped into the fam-
ily of innate lymphoid cells (ILCs), which require the common γ (γc) chain of the interleukin-
2 (IL-2) receptor and the transcriptional repressor Id2 for their development [25-27]. NK cells 
are therefor subsets of group 1 ILCs characterized based on the expression and requirement of 
eomesodermin (EOMES) and IL-15 for development, and the secretion of interferon γ (IFN-γ) 
and tumor necrosis factor α (TNF-α) upon IL-12 stimulation [28]. In humans, NK cells consti-
tute 5-15% of peripheral blood mononuclear cells (PBMC) and have a life span of two weeks 
in circulation [29, 30]. Based on the expression levels of CD56, they can be subdivided into 
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two major subsets, the CD56dimCD16+ and CD56brightCD16– population with distinct mor-
phology, development, localization and function in the body [31]. CD56dimCD16+ cells are 
predominant in the peripheral blood, spleen and non-lymphoid tissues such as the lung and 
liver, and have a strong cytotoxic potential [32, 33]. In contrast, CD56brightCD16– NK cells are 
enriched in lymphoid organs and display immune regulatory roles by cytokine secretion to 
enhance tissue inflammation, induce differentiation of T helper cells into TH1 and TH2 cells 
and ensure maturation of antigen presenting DCs [34-38]. The crosstalk of NK cells and other 
immune cells is a prerequisite for the regulation of an effective immune response. On the one 
hand, activated NK cells select for a functional DC population by killing of immature and 
tolerogenic DCs, further ensuring a TH1-biased adaptive immune response [39-41]. On the 
other hand, they secrete cytokines as IFN-γ and TNF-α leading to the maturation of antigen-
presenting DCs and their protection from killing [42]. In turn, resting NK cells become acti-
vated through type I interferons (IFN-α and IFN-β), IL-12, IL-18 and IL-15, or IL-2 produced 
by mature DCs and activated TH cells, respectively [43-47]. NK cell activation leads to cell 
proliferation, secretion of high amounts of cytokines and a higher cytolytic potential [45, 48]. 
Besides their regulatory role to boost innate and adaptive immune responses, NK cells direct-
ly eradicate virus-infected and malignantly transformed cells. NK cell cytotoxicity is thereby 
tightly regulated by the integration of signals from a limited repertoire of invariant germ line-
encoded inhibitory and activating receptors [49]. In general, NK cells are self-tolerant due to a 
prevalence of inhibitory signals upon engagement of MHC molecules expressed on healthy 
cells by inhibitory NK cell receptors (Figure 1A). NK cells become activated by degenerated 
cells with low or absent expression of MHC class I (‘missing-self hypothesis’, Figure 1B) 
and/or stress-induced expression of ligands for activating NK cell receptors that overcome 
inhibitory signals (‘induced-self hypothesis’, Figure 1C) [50-54]. Thus, NK cells recognize 
infected and transformed cells, which would normally evade antigen-specific CTL response, 
while protecting healthy tissues [55-58]. Furthermore, NK cells can recognize altered cells 
opsonized by antigen-specific antibodies via CD16 (FcγRIII) and induce ADCC (Figure 1D). 
Killing requires the formation of a complex immunological synapse between the target cell 
and the NK cell, which is highly organized in time and space [59-61]. Likewise to CTLs, lysis 
of target cells is mediated by the polarized release of cytotoxic granules containing perforin 
and granzymes into the synaptic cleft [62, 63], or by apoptosis induction through Fas ligand 
(Fas-L) and TNF-related apoptosis-inducing ligand (TRAIL) [64].   
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Figure 1: Schematic representation of physiological NK cell functions.  
(A) A balance of signals delivered by activating and inhibitory receptors regulates the recognition of 
healthy cells by natural killer (NK) cells. (B) Tumor cells that downregulate major histocompatibility 
complex (MHC) class I molecules are detected as ‘missing self’ and are lysed by NK cells by the re-
lease of lytic granules containing perforin and granzyme. (C) Tumor cells can overexpress induced 
stress ligands recognized by activating NK cell receptors, which override the inhibitory signals and 
elicit target cell lysis. (D) Tumor antigen-specific antibodies bind to CD16 and elicit antibody-
dependent NK cell-mediated cytotoxicity. The figure is reprinted from Morvan and Lanier 2016 [65]. 
 
The engagement of a variety of activating ligands mediates an immediate cytolytic response 
within minutes and can be repeated leading to serial killing of multiple target cells by one NK 
cell [66, 67]. Interestingly, NK cells were shown to exhibit also adaptive immune features 
upon activation in mice by a clonal-like expansion of long-lived memory NK cells, which 
reside in multiple organs for a fast and robust antigen-specific secondary immune response 
[68-70]. 
NK cells are known to contribute to the control of viral infections such as human cytomegalo-
virus (HCMV), herpes virus and human immunodeficiency virus (HIV) [71-73]. Several stud-
ies support the important role of NK cells in tumor recognition and elimination [74-76]. 
Along this line, high activity of peripheral blood NK cells was shown to be associated with a 
10% lower incidence of tumors for men and 4% for women [77]. Moreover, NK cell infiltra-
tion into tumors represents a positive prognostic marker in several carcinomas [78-80]. The 
physiological importance of NK cell immunosureveillance is further illustrated by the finding 
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that patients with NK cell deficiency or impaired NK cell activity suffer from severe recurrent 
systemic and life-threatening infections mainly caused by HCMV or herpes virus [81-83] and 
have a higher incidence for various carcinomas [84-88]. Furthermore, viruses and tumor cells 
employed several escape mechanisms to evade immunosurveillance by NK cells [89-92]. 
 
1.3 NK cell Receptors and Function 
NK cell recognition involves the consecutive steps of the initial binding to potential target 
cells, the formation of an immunological synapse, interactions between activating and inhibi-
tory receptors with available ligands leading to the integration of signals transmitted by these 
receptors, which determines whether the NK cell detaches or responds by secretion of cyto-
toxic granules or pro-inflammatory cytokines [50, 93]. In contrast to T and B cell activation, 
which relies on exquisite antigen-specific receptors, NK cell activation is more complex and 
mediated by numerous receptors acting in synergy [50, 53, 94]. NK cell receptor families 
thereby achieved recognition flexibility through rapid genetic evolution and promiscuity of 
ligand binding instead of somatic rearrangement of gene clusters [95, 96]. 
NK cell receptors are highly conserved throughout species and are encoded in two main gene 
clusters. In humans, the NK C-type lectin receptor family members are encoded by the NK 
gene complex located on chromosome 12p12-p13 [97], and the Ig-like leukocyte receptor 
family cluster on chromosome 19q13.4 [98]. The mouse homologs receptor genes are found 
on syntenic regions on chromosome 6 and chromosome 7, respectively [99]. 
Inhibitory receptors mainly recognize classical and some “non-classical” MHC class I mole-
cules, also named human leukocyte antigens (HLAs), expressed on all nucleated cells [100, 
101]. Self-tolerance is thereby attained during maturation in the bone marrow by binding to 
cognate MHC class I molecules, a process termed licensing [102, 103]. NK cells must express 
at least one inhibitory receptor specific for an MHC molecule to become responsive to later 
encounters with target cells. 
The two main inhibitory receptor families in humans are i) the inhibitory killer cell Ig-like 
receptors (KIRs) recognizing the different allelic groups HLA-A, -B and -C [104-107], and ii) 
the C-type lectin-like CD94/natural killer group 2 (NKG2)A heterodimer recognizing non-
classical HLA-E molecules [108-110] (Figure 2). Inhibitory KIRs are type I transmembrane 
glycoproteins with two (KIR2DL) or three (KIR3DL) Ig-like domains and a long cytoplasmic 
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tail containing two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) for signal trans-
duction [111]. The KIR gene family is highly polymorphic and the repertoire of KIR genes 
expressed within an individual forms the KIR haplotype [112-114]. Moreover, the expression 
of KIR allelic variants can differ on NK cells within one individual and therefore each indi-
vidual has different populations of NK cells that express an assortment of KIRs [115]. Inter-
estingly, no KIR homologs are found in mouse, whereas CD94/NKG2 family members are 
conserved within the two species, with mouse CD94/NKG2A recognizing the mouse Qa1b 
[116]. In mouse, the major inhibitory receptor family comprises the polymorphic C-type lec-
tin-like Ly49 receptors, which are structurally distinct from, but share the same functions as 
KIRs [117-119].  
Upon engagement, inhibitory receptors rapidly accumulate in the inhibitory immunological 
synapse and mediate signal transduction [120-122]. The tyrosine within the ITIM consensus 
sequence (S/I/V/LxYxxI/V/L) (x represents any amino acid, slashes separate alternative ami-
no acids occupying the given position) becomes thereby phosphorylated by a kinase of the Src 
(sarcoma) family, which leads to the recruitment of the Src homology 2 (SH2)-domain con-
taining phosphatases SHP-1 or SHP-2 [121]. Subsequent dephosphorylation of molecules 
(e.g. Vav-1) involved in downstream signaling of activating receptors results in blocking of 
activating signal cascades and prevents actin-dependent processes, such as cell adhesion to 
target cells and cell polarization [123] (Figure 2).  
Both receptor families moreover comprise molecules without ITIM motifs, namely the 
KIR2DS/KIR3DS (short cytosolic tail) and the NKG2C/E heterodimers. For signal transduc-
tion, they are associated with the adaptor DNAX-activation protein (DAP) 12 bearing immu-
noreceptor tyrosine-based activation motifs (ITAM) [124]. These receptors therefore trans-
duce activating signals while recognizing the same HLA ligands as their inhibitory 
counterparts [125]. Several other activating or co-stimulatory receptors are known such as the 
signaling lymphocytic activation molecule (SLAM) receptor 2B4 [126], DNAX accessory 
molecule (DNAM)-1 [127], NKp80 [128], and NKp65 [129]. These receptors recognize non-
MHC molecules upregulated on tumor cells. 
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Figure 2: Human inhibitory and activating receptors. 
Simplified overview of the major NK cell receptors and their identified ligands involved in regulation 
of NK cell functions. The major inhibitory receptors are the KIR family members KIR2DL and 
KIR3DL, and the heterodimer CD94/NKG2A. KIRs possess two (KIR2DL) or three (KIR3DL) Ig-like 
domains and bind their cognate ligands human leukocyte antigen (HLA)-A, -B or -C molecules. The 
heterodimer CD94/NKG2A containing two lectin-like domains recognizes HLA-E. All inhibitory re-
ceptors have two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) within their cytoplasmic 
tail for signal transduction via the Src homology 2 (SH2)-domain containing phosphatases SHP-1/2 
leading to subsequent dephosphorylation of Vav. The major activating receptors are CD16, NKG2D 
and the natural cytotoxicity receptor (NCR) family members NKp30, NKp44 and NKp46. CD16 and 
the NCRs contain either one (NKp30 and NKp44) or two (CD16 and NKp46) Ig-like domains. All of 
the NCRs bind to viral hemagglutinins (HA). Additionally, the human cytomegalovirus (HCMV) teg-
ument protein pp65, the BCL2-associated anthanogene 6 (BAG-6) and a structural homolog of the B7 
family (B7-H6) were described as ligands for NKp30. For NKp44 the proliferating cell nuclear anti-
gen (PCNA) and the mixed-lineage leukemia-5 (MLL-5) protein, and for NKp46 vimentin were dis-
covered. The disulfide-linked homodimer NKG2D contains two lectin-like domains and binds to the 
MHC class I chain-related proteins A/B (MICA/B) and to the UL16 binding proteins (ULBPs). The 
activating receptors associate with signaling adaptor molecules via oppositely charged amino acids in 
their transmembrane domains. CD16, NKp30 and NKp46 can associate with a CD3ζ homodimer or 
CD3ζ/FcϵRIγ heterodimer, whereas NKp44 interacts with DNAX-activation protein (DAP) 12 and 
NKG2D with two DAP10 molecules. Signaling is mediated by phosphorylation of immunoreceptor 
tyrosine-based activating motifs (ITAMs) or in case of DAP10 the YINM motif leading to the recruit-
ment of the spleen tyrosine kinase (Syk) or zeta chain-associated protein 70 (ZAP70) kinase pathways, 
mitogen-activated protein kinase (MAPK) cascade through growth factor receptor-bound protein-2 
(Grb-2) and Vav, phosphoinositide 3-kinase (PI3K)/Akt pathway as well as phospholipase Cγ (PLCγ)-
1/2. The figure is modified from Hartmann 2012 [130] and Vivier et al. (2004) [131]. 
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The major activating receptors are represented by the natural cytotoxicity receptors (NCRs) 
NKp30 (NCR3, CD337) [132], NKp44 (NCR2, CD336) [133, 134] and NKp46 (NCR1, 
CD335) [135, 136], the NKG2 member NKG2D, and CD16 which are involved in recognition 
and killing of malignantly transformed or infected cells (Figure 2). 
The NCRs are type I membrane glycoproteins comprised of an ectodomain with one (NKp30 
and NKp44) or two (NKp46) Ig-like domains connected to a transmembrane-spanning α-helix 
via a short flexible stalk domain. The NCRs are primarily expressed on NK cells and cetrain 
ILC subsets [137-141]. While NKp44 is only expressed on activated NK cells, NKp30 and 
NKp46 are constitutively expressed [142, 143]. Interestingly, NKp46 is the only NCR that has 
a functional orthologue in mice [144, 145]. NKG2D is a type II transmembrane glycoprotein, 
which forms disulfide-linked homodimers containing two C-type lectin-like domains. All ac-
tivating receptors have short cytoplasmic tails without signaling domains and associate with 
adaptor proteins via an opposing charge contact within the corresponding transmembrane 
segments [91]. CD16, NKp30 and NKp46 are associated either with ITAM-bearing CD3ζ 
disulfide-bonded homodimers or CD3ζ/FcεRIγ heterodimers [136, 146] and NKp44 with 
DAP12 homodimers [134, 147] (Figure 2). Ligation of ITAM-bearing receptor complexes 
leads to Src-family kinase (e.g. Lck, Fyn and Src) mediated tyrosin phosphorylation of the 
ITAM consensus sequence (YxxI/Lx6-12YxxI/L) and subsequent recruitment of spleen tyro-
sine kinase (Syk) or zeta chain-associated protein 70 (ZAP70) kinase. Downstream signaling 
events include phospholipase Cγ (PLCγ)-1/2 mediated calcium signaling or activation of the 
mitogen-activated protein kinase (MAPK) cascade through recriutment of growth factor re-
ceptor-bound protein-2 (Grb-2) and Vav-1/2 (guanine nucleotide exchange factor) [131, 148]. 
In contrast, NKG2D associates with two DAP10 homodimers containing two YINM tyrosin-
based motifs [149], which leads to Syk-independent signaling pathways by recruitment of 
Grb-2/Vav-1 and initiation of the MAPK cascade or the p85 regulatory subunit of the phos-
phoinositide 3-kinase (PI3K) and subsequent activation of the anti-apoptotic kinase (AKT)-
dependent signaling pathway [150, 151] (Figure 2).  
The NKG2D ligands including MHC class I chain-related proteins (MIC) A and B and the 
UL16 binding proteins (ULBPs) are structurally related and well characterized [152]. In con-
trast, a large number of structurally unrelated activating pathogen-associated ligands have 
been identified for the NCRs including viral hemagglutinins (HA) [153-155], or bacterial and 
fungal structures [156-159] and the HCMV tegument protein pp65 as inhibitory ligand for 
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NKp30 [160]. Several studies revealed that NCRs are triggered by self-molecules overex-
pressed by various primary tumors and cell lines [161-163]. However, the number of known 
cellular NCR ligands and knowledge about their mode of action is still scarce [91]. All NCRs 
were shown to bind heparin/heparan sulfate upregulated on tumor cells [164-168]. For NKp30 
the tumor antigens B7-family member B7-H6 [169, 170] and B-cell lymphoma (BCL)2-
associated athanogene 6 (BAG-6) released by stressed or transformed cells and immature DCs 
(iDCs) were identified as ligands [171, 172]. Recently galectin-3 was proposed as an inhibito-
ry ligand for NKp30 [173]. NKp44 recognize the nuclear protein proliferating cell nuclear 
antigen (PCNA) [174] and the mixed lineage leukemia-5 (MLL-5) protein [175]. So far, only 
the intermediate filament protein vimentin was shown to contribute as cellular ligand to 
NKp46-mediated lysis of tuberculosis-infected monocytes and activated CD4+ T cells [176, 
177]. The importance of NCRs in tumor recognition is shown by association of reduced NCR 
expression with resistance to NK cell cytotoxicity in patients with acute myeloid leukemia 
(AML) [178-181], cervical cancer and precursor lesions [182], gastrointestinal stromal tumors 
[183, 184] as well as melanoma [185] or impaired NK cell function in HIV-1 infected patients 
[186].  
 
1.4 The NKG2D/NKG2D Ligand System 
The NKG2D receptor was first described as transcript encoding a 216 amino acid long type II 
transmembrane glycoprotein preferentially expressed by NK cells [187-189]. The KLRK1 
(killer cell lectin-like receptor subfamily K member 1) gene is evolutionary highly conserved 
throughout species and located in the NKG complex on human chromosome 12 and on the 
syntenic region on mouse chromosome 6 [190, 191]. Although grouped into the NKG2 C-
type lectin receptor family, NKG2D differs markedly in sequence, receptor complex for-
mation and ligand recognition from the CD94/NKG2A/C/E heterodimeric members [152]. In 
human, NKG2D is constitutively expressed on all NK cells, most NKT cells, CD8+ T cells, 
peripheral γδ T cells and on a subset of intestinal intraepithelial γδ T cells [192-196]. Howev-
er, in mice the expression pattern of NKG2D is more selective and found on all NK cells, only 
on activated or memory CD8+ T cells, on 25% of splenic γδ T cells, and on a subset of perito-
neal exudate macrophages upon lipopolysaccharide (LPS) or type I IFN stimulation [197, 
198]. CD4+ T cells normally lack NKG2D expression in human and mice, but can be found on 
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a small subset of human CD4+ T cells that expand under certain pathophysiological conditions 
as seen in patients with rheumatoid arthritis or Crohn`s disease [192, 199, 200]. Like most 
activating receptors, NKG2D lacks a functional motif for signal transduction in its cytoplas-
mic tail and forms a multi-subunit immunoreceptor complex by association with specialized 
signaling adaptors also required for cell surface expression [201]. In humans, the disulfide-
linked homodimeric NKG2D associates exclusively with two DAP10 homodimers to form a 
hexameric complex [149, 202] (see Figure 2). Formation of the non-covalent assembly is me-
diated by a conserved arginine residue in the transmembrane domain of each NKG2D mono-
mer interacting with both transmembrane aspartic acids of DAP10 [202]. Engagement of the 
NKG2D-DAP10 complex triggers calcium-dependent granule release, cytotoxicity, and cyto-
kine production via activation of the PI3K/Akt and Grb-2/Vav-1 pathways [150, 203, 204] 
(see Figure 2). In mouse a splice variant lacking 13 amino acids at the N-terminus of NKG2D 
can be expressed on activated NK cells, which can also associate with DAP12 homodimers 
indicating distinct functions of NKG2D in mice [205-209]. Furthermore, cytokine stimulation 
with IL-2, IL-12 or IL-15 leads to the upregulation of NKG2D-DAP10 complexes on NK and 
T cells and increases NKG2D-mediated killing of target cells [210-214]. Whereas NKG2D 
functions as primary activating receptor in NK cells, which is sufficient to overcome inhibito-
ry signals [192, 197, 205], it rather acts as co-stimulatory receptor in T cells enhancing TCR-
mediated activation [194, 215, 216]. However, NKG2D can also mediate TCR-independent T 
cell cytotoxicity as seen for some γδ T cells, or long-termed cultured or cloned human CTLs 
and chronically activated CTLs from patients with celiac disease [215, 217-219]. Thus, the 
mode of NKG2D activation can be regulated by additional signaling inputs and is dependent 
on the cellular activation status.  
A variety of stress-induced cellular NKG2D ligands are known, which are structurally related 
to MHC class I molecules. In human, the non-classical MHC class I molecules MICA/B are 
encoded in the MHC gene complex on chromosome 6 and are highly polymorphic, with 
around 70 and 30 allelic variants described [220-222]. Similar to MHC class I, they are type I 
transmembrane glycoproteins comprising three Ig-like α-helical ectodomains (Figure 3A). In 
contrast, they do not associate with β2-micorglobulin and play no known role in antigen 
presentation [223-225]. In mice, no functional MIC homologs are found, whereas they are 
conserved in non-human primates, cattle and pig [222, 226-228]. The second group of human 
ligands comprises the ULBP protein family (also known as retinoic acid early transcript 1; 
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RAET1) with 6 functional (ULBP1-6) and four pseudogenes [229-234]. The ULBPs are lo-
cated on the long arm of human chromosome 6 [235] and are homolog to the mouse NKG2D 
ligand family located on syntenic region on mouse chromosome 10, including the polymor-
phic RAE-1α-ε (retinoic acid early inducible-1) isoforms, histocompatibility antigen 60 
(H60)a-c and mouse ULBP-like transcript 1 (MULT1) [236-242]. All of these ligands struc-
turally share the MHC-like α1/α2 domains, but in contrast to the MICs lack the membrane-
proximal α3 domain (Figure 3A). Moreover, human ULBP1–3/6, mouse RAE1α–ε and H60c 
are glycosylphosphatidylinositol (GPI)-linked, whereas human ULBP4/5, mouse MULT1 and 
H60a/b are transmembrane proteins.  
 
Figure 3: NKG2D ligands in humans and mice and the NKG2D-MICA complex.  
(A) The human ligands MHC class I chain-related proteins MICA and MICB are transmembrane pro-
teins with three domains analogous to the α1–α3 domains of MHC class I proteins (MICA structure 
shown on left; PDB 1HYR [243]). The remaining ligands contain two domains analogous to α1 and α2 
of MHC class I proteins but no α3-like domain (the RAE-1β α1 and α2 domains are depicted in both 
the middle and right structures; PDB 1JFM [244]). Human ULBP1–3 and 6, mouse RAE1α–ε and 
H60c are glycosylphosphatidylinositol (GPI)-linked, whereas human ULBP4–5, mouse MULT1 and 
H60a/b are transmembrane proteins. In some cases (e.g. ULBP2 and possibly others), both GPI-linked 
and transmembrane forms of the protein are found on the same cell [245]. The image is reprinted from 
Raulet et al. (2013) [246]. (B) Crystal structure of the human NKG2D-MICA complex. The extracellu-
lar domain of the NKG2D homodimer binds diagonally to the asymmetric α1/α2 domains of MICA 
(PDB 1HYR). Color code: blue = NKG2D-A monomer; purple = NKG2D-B monomer; yellow = α1 
domain; red = α2 domain; green = α3 domain.  
 
Although the different NKG2D ligands vary considerably in sequence and different allelic 
variants exist, they are all recognized by the invariant NKG2D receptor. Structural studies of 
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different NKG2D-ligand complexes revealed that the NKG2D homodimer binds diagonally 
across the asymmetric α1/α2-helical surface of the different monomeric ligands (Figure 3B). 
Furthermore, most amino acid residues of the receptor that dominate binding to the ligands 
are conserved [243, 244, 247, 248]. In contrast, binding affinities vary significantly with dis-
sociation binding constants ranging from 9x10-6 to 6x10-9 M for the interactions investigated, 
and studies suggest that the ligands might even compete for receptor binding [246, 249-252]. 
However, there is no evidence so far that the ligands induce qualitatively different effector 
responses, but maybe the different affinities account for quantitative differences by fine-
tuning NK and T cell activation [152]. 
NKG2D ligands are generally absent or rarely expressed on normal cells, but upregulated by 
infected, transformed and/or stressed cells indicating a rational for NKG2D-mediated detec-
tion of pathological alterations in autologous cells [253]. In normal tissue, MICA/B are found 
only on gastrointestinal or bronchial epithelial cells, maybe due to stimulation by the neigh-
boring microbial flora [223, 254], whereas the other ligands are found mainly on mRNA level 
in adult healthy tissues [235]. Consequently, inappropriate signaling through NKG2D and 
aberrant NKG2D ligand expression in healthy cells could lead to autoimmune diseases [255]. 
In contrast, overexpression of NKG2D ligands is commonly found on tumor cell lines and 
primary tumors of various epithelial and non-epithelial origins (e.g. carcinoma such as breast, 
lung, colon, ovary, and prostate, glioma, melanoma or leukemia) [193, 256-262], as well as 
upon viral infections [263-265]. Several studies showed that ectopic NKG2D ligand expres-
sion on cancer cells leads to tumor rejection by NK and T cells in vitro and in vivo irrespec-
tive of MHC class I expression, but in a perforin-dependent manner [192, 193, 218, 257, 258, 
266-269]. The importance of the NKG2D/NKG2D ligand system in tumor immunosurveil-
lance and prevention of tumor formation was further underlined by studies showing that 
NKG2D-deficient mice or in vivo blockade of NKG2D led to a higher incidence of spontane-
ous or carcinogen-induced cancer development [270, 271]. Moreover, in early stages of breast 
and colorectal cancer NKG2D ligand expression was shown to correlate with good prognosis 
[259, 272, 273]. However, differential expression patterns of the individual ligands in differ-
ent tumor types and even throughout one tumor entity indicate that the ligands are not redun-
dant in function and may have evolved as a consequence of evolutionary pressure due to tis-
sue-specificity, malignant transformation or viral immunoevasins. Along this line, it was 
shown that apart from stress-induced expression via activation of the DNA damage pathway 
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[274] NKG2D ligands are differentially regulated on transcriptional and post-translational 
level during malignant transformation [246]. Furthermore, viruses have evolved strategies, 
which interfere with NKG2D ligand expression to escape NK cell recognition [275-277]. 
 
1.5 Cancer Immunoediting and NKG2D-dependent Tumor Im-
mune Escape 
Cancer immunoediting is a dynamic process of immunosurveillance and tumor progression 
comprising three phases - elimination, equilibrium and escape [278]. During elimination, 
transformed cells are destroyed by a competent immune system, whereby NKG2D plays a key 
role for tumor immunosurveillance by NK and T cells (Figure 4). In the equilibrium phase, 
tumor editing by immune selection occurs leading to less immunogenic tumor variants or im-
paired immune cell functions. These tumors evade the immune system, grow progressively, 
become clinically apparent and establish an immunosuppressive tumor microenvironment 
[279, 280]. Thereby, NKG2D-mediated cytotoxicity is impaired by cytokines, the cellular 
crosstalk with tumor-associated cells and specific tumor immune escape mechanisms [90, 
278, 281-283] (Figure 4). Besides selection for low NKG2D ligand expressing tumor variants 
during cancer progression [284-286], also chronic stimulation of NKG2D can lead to im-
paired NKG2D-mediated functions of NK and T cells [287-289]. In addition, downregulation 
of NKG2D could be mediated by cytokines of the tumor microenvironment as shown for IFN-
γ, which is secreted by activated immune cells in course of a negative regulation loop [290, 
291]. In this respect, inhibition of antitumor functions could also be correlated to the major 
immunosuppressive cytokine transforming growth factor β1 (TGF-β1), which mediates 
NKG2D downregulation either through the direct interaction of NKG2D+ immune cells with 
regulatory T cells (Tregs) or as soluble factor secreted by the tumor cells itself [292-295].  
Moreover, a tumor immune escape mechanism evolved based on the release of NKG2D lig-
ands from the plasma membrane of tumor cells. Thereby, members of the matrix metallopro-
teases (MMP-9 and MMP-14) and ADAMs (a disintegrin and metalloprotease; ADAM10/17) 
proteolytically shed NKG2D ligands [14, 296-302] leading to soluble NKG2D (sNKG2D) 
ligand ectodomains frequently found in the plasma of patients suffering from different types 
of cancer [303-309]. In the case of MICA, cleavage requires the association of MICA with the 
membrane-associated disulphide isomerase endoplasmic reticulum protein 5 (ERp5) [299].  
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Figure 4: Immunosuppressive tumor microenvironment and tumor immune escape. 
Simplified overview of the crosstalk between immune cells mediating tumor immunosurveillance, and 
tumor escape strategies. During the elimination phase immune effector cells such as CD8+ T cells 
(CTLs) and NK cells with the help of dendritic and CD4+ T cells are able to recognize and eliminate 
tumor cells. Tumor cell killing thereby mainly relies on the recognition of stress-induced ligands by 
the NKG2D receptor and recognition of MHC class I molecules by the TCR complex. As a result of 
tumor heterogeneity, tumor cells, which are less immunogenic or have upregulated immunosuppres-
sive factors, are selected. These cells are able to subvert the immune response and escape immunosur-
veillance. On the one hand, tumor cells downregulate MHC molecules, loose expression of antigenic 
molecules and upregulate inhibitory molecules such as PD-L1 (programmed cell death protein lig-
and 1) to directly evade cytotoxic lymphocyte recognition. Moreover, the release of soluble NKG2D 
ligands leads to tumor escape by loss of surface antigens and subsequent blocking and downregulation 
of the NKG2D receptor on immune cells. On the other hand, tumor cells can secrete cytokines (e.g. 
TGF-β1 or IL-10) to generate an immunosuppressive tumor microenvironment and further recruit 
suppressive cells such as regulatory T (Treg) cells, immature myeloid cells (including immature den-
dritic cells (iDC) and myeloid-derived suppressor cells (MDSCs)), and M2 macrophages. iDC can 
cause T cell anergy due to lack of co-stimulatory molecules. M2 macrophages and MDSCs inhibit T 
cell responses through a variety of mechanisms, including reactive oxygen species (ROS) generation 
and secretion of immunosuppressive cytokines, which contribute to a microenvironment where im-
mune responses are difficult to instigate an sustain. The figure is adapted and modified from Monjazeb 
et al. (2013) [310]. 
 
Besides proteolytical shedding, some NKG2D ligands are released on exosomes, as shown for 
the shedding resistant MICA allelic variant MICA*08 and for the GPI anchored ULBP3 [311, 
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312], or can be secreted as soluble forms due to alternative splicing as shown for ULBP4/5 
[313, 314]. NKG2D ligand release results in impaired tumor immunosurveillance by 
NKG2D+ immune cells due to i) reduced tumor recognition by the loss of antigenic NKG2D 
ligands on the tumor cell surface and ii) blocking and downregulation of the NKG2D receptor 
on cytotoxic immune cells by engagement of sNKG2D ligands [287, 315-317]. Consequently, 
previous studies with patients suffering from leukemia [256], neuroblastoma [305], cervical 
carcinoma [318, 319], multiple myeloma [303] or head and neck squamous cell carcinoma 
[304, 320, 321] demonstrated that elevated plasma levels of sMICA correlated with impaired 
NKG2D-dependent NK and T cell cytotoxicity.  
The biological relevance of NKG2D ligand release in oncogenesis was further confirmed in 
vivo by implanting a mouse prostate cancer cell line overexpressing wildtype MICB, sMICB 
or a shedding-resistant MICB variant in severe combined immunodeficient (SCID) mice. 
Mice receiving the cancer cells expressing the shedding-resistant MICB variant did not devel-
op prostate cancer, whereas sMICB promoted tumor growth [322]. Moreover, elevated sMI-
CA/B levels could be correlated to severe disease progression in patients with malignant dis-
ease [323-325]. However, the diagnostic and prognostic value of individual sNKG2D ligand 
plasma levels is limited due to ligand polymorphism and heterogeneity. 
 
1.6 Cancer Immunotherapies 
Cancer remains the leading cause of death globally and the development of effective cancer 
therapies is still challenging. Besides standard cancer therapies comprising surgery, chemo-
therapy and radiotherapy, new combinatorial immunotherapies evolved to overcome tumor 
immune escape and enhance the antitumor functions of immune cells. These therapies includ-
ing chemical compounds such as histone deacetlyase (HDAC) inhibitors [326] and protein 
tyrosine kinase inhibitors [327], which lead to inhibition of tumor cell proliferation and apop-
tosis induction, showed beneficial effects in several clinical trials with patients suffering from 
leukemia and some solid tumors. Moreover, anticancer therapies based on the use of mono-
clonal blocking antibodies as monotherapy or in combination with radio- or chemotherapy 
were invented. Antibodies targeting tumor antigens lead directly to tumor growth arrest, apop-
tosis, or induction of ADCC by cytotoxic immune cells. Consequently, clinical trials with an-
tibodies against the tumor antigens epidermal growth factor receptor (EGFR) [328] or CD20 
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[329] demonstrated an improved survival of patients with colorectal cancer and head and neck 
squamous cell carcinoma, or B cell lymphoma, respectively. On the other hand, checkpoint 
blockade antibodies targeting the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) 
[330, 331] or programmed cell death protein 1 (PD-1) [332], which are negative regulators of 
T cell activation, enhance antitumor functions of T cells and improved the clinical outcome of 
patients with different malignancies. Along this line, also bispecific proteins, which simulta-
neously bind to specific antigens on tumor cells and immunoreceptors on NK or T cells, are of 
great interest for immunotherapies. These molecules either combine antibody fragments (sin-
gle-chain variable fragment, scFv) specific for a tumor antigen and an immunoreceptor, or 
ectodomains of an activating ligand or receptor (e.g. ULBP2-BB4 or NKG2D-CD3ζ scFv) 
leading to enhanced tumor recognition and immune cell cytotoxicity [333-336]. 
In recent years, cell-based cancer therapies (e.g. allogeneic hematopoietic stem cell transplan-
tation (HSCT) or adoptive transfer of autologous and allogeneic T and NK cells) became 
more and more important. Adoptive cell therapies mainly rely on the transfer of clinical grade 
ex vivo IL-2 expanded autologous or allogeneic NK or T cells isolated from leukapheresis 
products. They are conducted either as monotherapy or in combination with HSCT or chemo-
/immunotherapies. In the case of CTLs, further ex vivo antigen-stimulation is required to gen-
erate tumor-specific T cells or autologous tumor-specific T cells could be directly extracted 
from tumor samples (tumor-infiltrating T cells, TILs) of melanoma patients and showed 
promising effects in clinical trials [337-339]. However, the improvement of T cell therapies is 
still challenging due to the requirement for antigen-specificity, MHC-restriction, the availabil-
ity of TILs extracted from tumor biopsies, tumor immune escape mechanisms and several 
occurring side effects [340]. In case of NK cells, several clinical trials showed the safety and 
feasibility of adoptive transfer of mainly ex vivo expanded allogeneic NK cells without or 
post-HSCT with improved graft vs. leukemia/tumor (GvL/T) but no graft vs. host disease 
(GvHD) effects in hematological disease and some solid tumors [341, 342].  
Moreover, genetic engineering to redirect NK and T cells to tumor targets and enhance their 
cytotoxic functions is of great interest to further improve cellular therapies. In this respect, a 
main focus relies on NK and T cells modified to express recombinant chimeric antigen recep-
tors (CARs), which are comprised of an extracellular antigen-specific scFv fused to intracellu-
lar signaling domains (mostly the CD3-derived ITAM signaling motif and a co-stimulatory 
molecule). Clinical trials using CD19-specific CAR T cells in hematological malignancies 
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were successful and induced even long-term remissions [343, 344] and several trials against 
different tumor antigens (e.g. CD138, HER2, ErB2 or EGFRvIII) expressed by solid tumors 
are ongoing [345]. Moreover, T cells equipped with NKG2D-CARs showed tumor elimina-
tion and activation of the host’s immune response and even induced tumor-specific memory 
in pre-clinical studies [346-348]. However, genetically engineered T cells also increased se-
vere side effects such as GvHD [340]. Therefore, CAR modified NK cells can represent a 
complementary therapeutic option as shown in pre-clinical studies with CD19-, CD20- or 
CD138-CAR expressing NK cells [349-352]. Furthermore, the transduction of an NKG2D-
CAR markedly increased NKG2D surface expression in NK cells, which showed higher cyto-
toxicity against leukemia and solid tumor cell lines [353]. 
 
1.7 Head and Neck Squamous Cell Carcinoma 
Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive solid tumor origi-
nating from the epithelial lining of the upper aero-digestive tract, regularly involving the nasal 
and oral cavity, lip, pharynx, larynx, and paranasal sinuses. HNSCC is characterized by phe-
notypic, etiological, biological and clinical heterogeneity [354, 355]. The relative frequency 
of HNSCC correlates with tobacco and alcohol consumption, chewing betel nut (particularly 
in South Asia) as well as infection with high-risk human papillomavirus (HPV) subtypes 
[356-358]. With approximately 650,000 new patients and 300,000 deaths annually, HNSCC is 
the sixth most common cancer worldwide [356, 357, 359, 360]. Moreover, the incidence of 
HNSCC in younger adults (< 45 years) is increasing and can be correlated to rising HPV in-
fections [361, 362]. Current therapeutic regimens for patients with HNSCC combine chemo-
therapy, radiotherapy and surgery with 5-year survival rates of 30–65% and 5–58% for the 
tumor stages T1–T4 and N0–N3, respectively [363]. Due to the broad range of epithelial ma-
lignant neoplasms of HNSCC, the identification of biomarkers for early diagnosis and thera-
peutic strategies to improve HNSCC treatment remains challenging. Prognosis remains poor 
due to (i) decreased leukocyte numbers, (ii) impaired proliferation of leukocytes, and (iii) in-
creased numbers of CD4+CD25+Foxp3+ regulatory T cells, which are immunosuppressive to T 
cells, NK and NKT cells [19, 364-369]. The impaired immune cell function is associated with 
the high secretion potential of cytokines and chemokines from HNSCC tumors, causing an 
immunosuppressive tumor microenvironment and aggressive nature of HNSCC [370-372].  
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1.8 Objectives 
The NKG2D receptor recognizes several cellular NKG2D ligands overexpressed on tumor 
cells and is therefore important for tumor immunosurveillance. However, soluble NKG2D 
ligands released from malignant cells by proteolytical shedding or on exosomes can inhibit 
NKG2D-dependent NK and T cell cytotoxicity. Consequently, elevated individual sNKG2D 
ligand plasma levels correlated with impaired NK cell cytotoxicity in patients suffering from 
different cancers [373]. In this respect, a clinical phase I/II trail of adoptive transfer of alloge-
neic NK cells post-HSCT in patients with high-risk neuroblastoma showed inhibition of do-
nors’ NK cell cytotoxicity by blocking the NKG2D receptor through sMICA in patients’ 
plasma [305]. Furthermore, previous studies on sMICA indicated a role of NKG2D-dependent 
tumor immune escape in HNSCC [320, 321], one of the most common cancers worldwide. So 
far, little is known about the role of cumulative plasma levels of all sNKG2D ligands and 
whether the impact of NKG2D-related escape strategies changes with course of disease. This 
knowledge is of particular importance to estimate the efficacy of NKG2D-dependent anti-
tumor functions of autologous and adoptively transferred NKG2D+ cytotoxic lymphocytes. 
Therefore, the aim of this thesis was the characterization of the NKG2D-dependent tumor 
immune escape in HNSCC patients and the development of an adsorption apheresis to deplete 
sNKG2D ligands from patients’ plasma. Adsorption apheresis as therapeutic intervention 
strategy should improve NKG2D-dependent antitumor functions of autologous immune cells, 
and as preconditioning strategy, if combined with cellular immunotherapies, the efficacy of 
adoptively transferred immune cells. The following points should be investigated: 
1. Evaluation of the levels of the sNKG2D ligands sMICA/B and sULBP1-3 in the plasma of 
HNSCC patients to elucidate the time course of sNKG2D ligand release during disease pro-
gression and to identify a patient cohort, which benefits from restoration of NKG2D-
dependent tumor immunosurveillance. In this respect, also immunosuppressive factors should 
be monitored to further gain insights on additional mechanisms, which might influence tumor 
immune escape.  
2. Determination of the impact of sNKG2D ligands on NK cell functions. The influence of 
sNKG2D ligands in patients’ plasma on NK cell cytotoxicity should be addressed using in 
vitro cytotoxicity experiments with primary human NK cells. In order to study NK cell cyto-
toxicity and tumor infiltration, a 3D multicellular tumor spheroid model, which resembles 
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poorly vascularized and avascular regions of solid tumors and micrometastases, should be 
established based on HNSCC cell lines. The tumor spheroids should allow for the molecular 
determination of antitumor functions of NK cells in a well-defined in vivo-like system. 
3. Generation of a bioreactive surface for adsorption apheresis of sNKG2D ligands from pa-
tients’ plasma. As proof of concept, monoclonal anti-MICA antibodies should be screened to 
find a suitable candidate with high sMICA depletion efficacy. In a second approach, recombi-
nant NKG2D proteins should be generated and characterized for the generation of a pan-
specific adsorber matrix, which can deplete all sNKG2D ligands from patients’ plasma simul-
taneously. 
4. Pre-clinical validation of adsorption apheresis in a rhesus monkey (Macaca mulatta) mod-
el. As proof of concept, rhesus monkeys should be infused with recombinant, soluble human 
MICA to estimate the depletion kinetics and efficacy of the anti-MICA antibody-
functionalized adsorber matrix to remove sMICA from plasma in vivo. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals, Consumables and Instruments 
Unless otherwise denoted, all chemicals for laboratory use and cell culture were obtained in 
p.a. quality from the companies AppliChem (Darmstadt, Germany), Carl Roth GmbH (Karls-
ruhe, Germany), GE Healthcare (Buckinghamshire, UK), Miltenyi Biotec GmbH (Bergisch-
Gladbach, Germany), PAA (Cölbe, Germany), PAN Biotech GmbH (Aidenbach, Germany), 
Roche (Mannheim, Germany), Sigma-Aldrich GmbH (Saint Louis, USA) and Thermo Fisher 
Scientific Inc. (Waltham, USA). Consumables for cell culture, molecular biology and protein 
biochemistry were obtained from BioRad Laboratories (Hercules, USA), Greiner Bio-One 
(Kremsmünster, Austria), Merck Millipore (Darmstadt, Germany), Lonza (Basel, Switzer-
land), Sarstedt AG & Co (Nümbrecht, Germany) or Whatman (Dassel, Germany). Unless oth-
erwise mentioned, all instruments were common lab equipment. 
 
2.1.2 Enzymes, Inhibitors, Antibiotics, Additives and Cytokines 
Enzymes Supplier 
Fast Digest® restriction endonucleases Thermo Fisher Scientific 
FastAP™ thermo sensitive alkaline phosphatase Thermo Fisher Scientific 
DreamTag™ polymerase Thermo Fisher Scientific 
Phusion® polymerase Thermo Fisher Scientific 
Pfu polymerase Thermo Fisher Scientific 
T4 DNA ligase Thermo Fisher Scientific 
 
Inhibitor Supplier 
cOmplete™ protease inhibitor cocktail Roche 
 
Antibiotic Supplier 
Ampicillin AppliChem 
Gentamycin Gibco 
Geneticin Gibco 
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Antibiotic Supplier 
Penicillin/Streptomycin Gibco 
Puromycin Gibco 
Zeocin Invivogen 
 
Cytokine Supplier 
Interleukin-2 (IL-2) PromoKine 
 
Additive Supplier 
L-Glutamine Gibco 
NEAA (non essential amino acids) Gibco 
Sodium Pyruvate Gibco 
Human AB Serum PAA 
Fetal calf serum (FCS) PAA / PAN Biotech 
IPTG AppliChem 
 
2.1.3 Antibodies, Isotype controls and Cell Staining Reagents 
Antibodies are indicated with respective clone number and IgG-isotype. Antibodies were used 
in different applications as indicated: CA = cytotoxicity assay, ELISA = enzyme linked im-
munosorbent assay, FC = fluorescence cytometry, IB = immunoblotting, IP = immuno-
precipitation, IHC = immunohistochemistry, PS = peptide spot array.  
Primary Antibody, conjugate Subtype / Clone Application Supplier 
anti-human NKG2D (CD314), APC mouse IgG1; BAT221  FC Miltenyi Biotec 
anti-human NKG2D (CD314), PE mouse IgG1; BAT221  FC Miltenyi Biotec 
anti-human NKG2D (CD314) mouse IgG1; MAB139 FC, CA R&D Systems 
anti-human MICA mouse IgG2b; MAB1300 ELISA R&D Systems 
anti-human MICA mouse IgG1; AMO1 
ELISA, FC, 
IP 
A. Steinleb 
                                                 
 
b The antibodies were kindly provided by A. Steinle, Institute for Molecular Medicine, Goethe-University, Frankfurt am Main, Germany. 
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Primary Antibody, conjugate Subtype / Clone Application Supplier 
anti-human MICA goat (polyclonal);AF1300 ELISA, IB R&D Systems 
anti-human MICA/B mouse IgG2a; BAMO3 
ELISA, FC, 
IP 
A. Steinleb 
anti-human MICA/B mouse IgG2a; BMO2 ELISA A. Steinleb 
anti-human MICB mouse IgG1; BAMO1 ELISA, FC A. Steinleb 
anti-human MICB mouse IgG2b; MAB1599 ELISA, IP R&D Systems 
anti-human MICB 
goat (polyclonal); 
AF1599 
ELISA, IB R&D Systems 
anti-human ULBP1 
mouse IgG2a; 
MAB1380 
ELISA, IP R&D Systems 
anti-human ULBP1 
goat (polyclonal); 
AF1380 
ELISA, IB, 
IP 
R&D Systems 
anti-human ULBP1 mouse IgG2a; AUMO2 ELISA A. Steinleb 
anti-human ULBP1 mouse IgG1; AUMO5 ELISA A. Steinleb 
anti-human ULBP2/5/6 
mouse IgG2a; 
MAB1298 
ELISA, IB, 
IP 
R&D Systems 
anti-human ULBP2/5/6 
goat (polyclonal); 
AF1298 
ELISA, IB R&D Systems 
anti-human ULBP2 mouse IgG1; BUMO1 ELISA A. Steinleb 
anti-human ULBP2 rabbit IgG; 27080002 IHC Novus biologicals 
anti-human ULBP3 
mouse IgG2a; 
MAB1517 
ELISA, IB, 
IP 
R&D Systems 
anti-human ULBP3 
goat (polyclonal); 
AF1517 
ELISA, IB R&D Systems 
anti-human ULBP3 mouse IgG1; CUMO3 ELISA A. Steinleb 
anti-human CD45, APC mouse IgG2a; 5B1  FC, CA Miltenyi Biotec 
anti-human CD45, PE eFluor610 mouse IgG1; HI30  FC eBioscience 
anti-human CD45 
mouse IgG; 
2B11+PD7126 
IHC Dako 
anti-human CD56 mouse IgG1; 123C3 IHC Invitrogen 
anti-human CD56, PeCy7/APC mouse IgG1; HCD56 FC BioLegend 
anti-human CD16, FITC/PE mouse IgG1; 3G8 FC BioLegend 
anti-human CD3, PE mouse IgG1; SP34.2 FC BD Pharmingen 
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Primary Antibody, conjugate Subtype / Clone Application Supplier 
anti-human CD3 rabbit (polyclonal); SP7 IHC Thermo Scientific 
anti-human CD3, APC-Cy7 mouse IgG2a; HIT3a FC BioLegend 
anti-human CD4, PacificBlue mouse IgG2b; OKT4 FC BioLegend 
anti-human CD8a, AlexaFluor700 mouse IgG1; HIT8a FC BioLegend 
anti-human CD8 mouse IgG1; C8/144B IHC Dako 
anti-human CD14, PerCP Cy5.5 mouse IgG2a; M5E2 FC BD Pharmingen 
anti-human CD20, FITC mouse IgG2b; 2H7 FC BioLegend 
anti-human CD20 mouse IgG2a; L26 IHC Dako 
anti-human CD68 mouse IgG3; PG-M1 IHC Dako 
anti-human CD163 mouse IgG1; MRQ-26 IHC Cell Marque 
anti-human p16 mouse IgG2a; E6H4 IHC Ventana-Roche 
anti-human cleaved caspase 3 rabbit (polyclonal); SA1E IHC 
Cell Signaling 
Technologies 
anti-His, HRP mouse IgG2a; HIS-1 ELISA, IB Sigma-Aldrich 
anti-Biotin, HRP goat (polyclonal) ELISA, IB Sigma-Aldrich 
 
Secondary Antibody / Reagent, 
conjugate 
Clone  Supplier 
anti-goat IgG, HRP rabbit (polyclonal) IB Sigma-Aldrich 
anti-mouse IgG, HRP goat (polyclonal) IB, PS Sigma-Aldrich 
anti-mouse IgG1, FITC rat IgG1; X-56 FC Miltenyi Biotec 
anti-mouse IgG1, PE rat IgG1; X-56 FC Miltenyi Biotec 
anti-mouse IgG1, APC rat IgG1; X-56 FC Miltenyi Biotec 
anti-mouse IgG1, HRP  goat (polyclonal) ELISA Southern Biotech 
anti-mouse IgG2a/b, APC rat IgG1; X-57 FC Miltenyi Biotec 
anti-mouse IgG2a/b, PE rat IgG1; X-57 FC Miltenyi Biotec 
anti-mouse IgG2a, HRP goat (polyclonal) ELISA Southern Biotech 
anti-human IgG-Fc, HRP goat (polyclonal) IB, ELISA Sigma-Aldrich 
anti-human IgG-Fc, DyLight649 goat (polyclonal) FC Dianova 
anti-monkey IgG, HRP goat (polyclonal) ELISA Sigma-Aldrich 
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Secondary Antibody / Reagent, 
conjugate 
Clone  Supplier 
anti-monkey IgM, HRP goat (polyclonal) ELISA Sigma-Aldrich 
Streptavidin, HRP 31334288 ELISA Immunotools 
Streptavidin, HRP streptavidin polymer IB Sigma-Aldrich 
 
Isotype control  Supplier 
mouse IgG1, APC κ-isotype; MOPC-21 BioLegend 
mouse IgG1, PE κ-isotype; MOPC-21 BioLegend 
mouse IgG1, APC 130-092-214 Miltenyi Biotec 
mouse IgG2a, APC 130-098-850 Miltenyi Biotec 
mouse IgG2b, APC 130-098-890 Miltenyi Biotec 
 
Cell Stains / Counting beads  Supplier 
CellTrace™ CFSE Cell Proliferation Kit  Thermo Fisher Scientific 
Sytox® Blue Dead Cell Stain  Thermo Fisher Scientific 
LIVE/DEAD® Fixable Aqua Dead Cell Stain  Thermo Fisher Scientific 
CountBright™ Absolute Counting Beads  Thermo Fisher Scientific 
 
2.1.4 Kits 
Kit Supplier 
BD™ CBA Human Soluble Protein Master Buffer Kit BD Bioscience 
BD™ CBA Human IFN-γ Flex Set BD Bioscience 
BD™ CBA Human TNF Flex Set BD Bioscience 
BD™ CBA Human IL-1β Flex Set BD Bioscience 
BD™ CBA Human IL-6 Flex Set BD Bioscience 
BD™ CBA Human IL-8 Flex Set BD Bioscience 
BD™ CBA Human IL-10 Flex Set BD Bioscience 
BD™ CBA Human MCP-1 Flex Set BD Bioscience 
BD™ CBA Human MIP-1α Flex Set BD Bioscience 
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Kit Supplier 
BD™ CBA Human MIP-1β Flex Set BD Bioscience 
BD™ CBA Human RANTES Flex Set BD Bioscience 
BD™ CBA Human TGF-β1 Single Plex Flex Set BD Bioscience 
CD45 MicroBeads, human Miltenyi Biotec 
EnVision+ HRP.Mouse (AEC+) Dako 
EnVision+ HRP.Rabbit (DAB+) Dako 
EnVision G/2 Doublestain System Rabbit/Mouse  
(DAB+/Permanent Red) 
Dako 
GeneJET™ Plasmid Miniprep Kit Thermo Fisher Scientific 
GeneJET™ Gel Extraction Kit Thermo Fisher Scientific 
Human MICB DuoSet ELISA R&D Systems 
Human ULBP-1 DuoSet ELISA R&D Systems 
Human ULBP-2 DuoSet ELISA R&D Systems 
Human ULBP-3 DuoSet ELISA R&D Systems 
INNOTEST® HIV Antigen mAb INNOGENETICS 
NucleoBond Xtra Midi / Maxi Kit Macherey-Nagel 
NK Cell Isolation Kit, human Miltenyi Biotec 
NK Cell Activation/Expansion Kit, human Miltenyi Biotec 
Pierce™ LAL Chromogenic Endotoxin Quantitation Kit Thermo Fisher Scientific 
Rapid ELISA Mouse mAb Isotyping Kit Thermo Fisher Scientific 
ToxinSensor™ Chromogenic LAL Endotoxin Assay Kit Genscript 
 
2.1.5 Bacterial strains and Culture media 
Strain Genotype Supplier 
DH5α 
K-12 strain derivative: F- θ80lac ZΔ M15 lac ZYA-) 
Δ(argF U169 recA1 and A1 hsdR17 (rK -mK+) phoA 
supE44 λ - thi -1 gyrA96 relA1 
Thermo Fisher Scientific 
BL21(DE3) B strain derivative: F- ompT hsdSB (rB-mB-) gal dcm (DE3) Thermo Fisher Scientific 
 
For the cultivation of bacteria, lysogeny broth (LB) medium [374] and agar with the low salt-
formulation of Lennox [375] were purchased from Carl Roth.  
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2.1.6 Cell lines and Culture media 
2.1.6.1 Unmodified Mammalian Cell Lines 
Unless otherwise noted, all cell lines were purchased from the American Type Culture Collec-
tion (ATCC). 
Cell Line Characterization Supplier 
CAL-27 human tongue squamous cell carcinoma cells (CRL-2095) ATCC 
Detroit562 human pharyngeal carcinoma cells (CCL-138) ATCC 
FaDu human pharynx squamous cell carcinoma cells (HTB-43) ATCC 
SiHa 
grade II, human cervix squamous cell carcinoma cells  
(HTB-35) 
A. Cerwenkac 
UKF-NB3 human neuroblastoma cells J. Cinatld [376] 
C1R human B cell lymphoma (CRL-2369) ATCC 
 
2.1.6.2 Genetically Modified Cell Lines 
Cells Insertion Supplier 
HEK 293T/17 
human embryonic kidney cells expressing large T anti-
gen (CRL-11268) 
ATCC 
C1R-neo Neomycin resistance; mock transduced  A. Steinlee 
C1R-MICA01 MICA*01 ligand A. Steinlee 
C1R-MICA04 MICA*04 ligand A. Steinlee 
C1R-MICA07 MICA*07 ligand A. Steinlee 
C1R-MICA08 MICA*08 ligand A. Steinlee 
C1R-MICB MICB ligand A. Steinlee 
C1R-ULBP1 ULBP1 ligand A. Steinlee 
C1R-ULBP2 ULBP2 ligand A. Steinlee 
C1R-ULBP3 ULBP3 ligand A. Steinlee 
C1R-MICA01-His MICA*01 ligand with N-terminal hexahistidine tag this thesis 
                                                 
 
c The cell line was kindly provided by A. Cerwenka, Innate Immunity, German Cancer Research Center, Heidelberg, Germany. 
d The cell line was kindly provided by J. Cinatl, Institute for Medical Virology, Goethe-University, Frankfurt am Main, Germany. 
e The cell lines were kindly provided by A. Steinle, Institute for Molecular Medicine, Goethe-University, Frankfurt am Main, Germany. 
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Cells Insertion Supplier 
C1R-MICA04-His MICA*04 ligand with N-terminal hexahistidine tag this thesis 
C1R-MICA07-His MICA*04 ligand with N-terminal hexahistidine tag this thesis 
C1R-MICA08-His MICA*04 ligand with N-terminal hexahistidine tag this thesis 
C1R-MICB-His MICB ligand with N-terminal hexahistidine tag this thesis 
C1R-ULBP1-His ULBP1 ligand with N-terminal hexahistidine tag this thesis 
C1R-ULBP2-His ULBP2 ligand with N-terminal hexahistidine tag this thesis 
C1R-ULBP3-His ULBP3 ligand with N-terminal hexahistidine tag this thesis 
UKF-NB3-iMICA doxycycline MICA01 with N-terminal decahistidine tag this thesis 
 
2.1.6.3 Culture Media 
DMEM compl. 
Dulbecco’s modified Eagle medium (DMEM, Gibco) supplemented with 2 mM L-glutamine 
(Gibco), 100 U/ml penicillin, 100 µg/ml streptomycin (Gibco), 10% fetal calf serum (FCS, 
PAA or PAN Biotec) for culturing 293T/17 and SiHa cells. 
 
HNSCC medium 
Minimum Essential Medium (MEM, Gibco) supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 10% FCS and 1 mM sodium pyruvate (Gibco) for 
HNSCC cell lines FaDu, CAL27 and Detroit562. 
 
UKF-NB3 medium 
Iscove’s modified Dulbecco’s medium (IMDM, Gibco) supplemented with 100 U/ml penicil-
lin, 100 µg/ml streptomycin and 10% FCS for UKF-NB3 cells. 
 
C1R medium 
RPMI 1640 medium supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 10% FCS was used for culturing C1R cells. For C1R transfectants 1.8 mg/ml 
gentamicin (G418, Gibco) were added to the media. 
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pNK medium 
X-Vivo10 medium (Lonza) supplemented with 5% human AB serum (PAA) and 1000 U/ml 
IL-2 for culturing of primary human NK cells. 
 
2.1.7 Buffers 
Unless otherwise denoted, all buffers were prepared in deionized water and the pH was ad-
justed with HCl or NaOH. 
Buffer / Solution  Formulation 
Agarose Gel Electrophoresis   
TAE buffer 
0.04 M 
0.01 M 
1.14% (v/v) 
TRIS 
EDTA 
acetic acid 
EtBr stain 0.01% (v/v) EtBr in TAE buffer 
Biotinylation of proteins in vitro   
Biotin assay buffer 
0.001 M 
0.001 M 
100 µM 
0.1 M 
0.025 M 
 
MgCl2 
ATP 
D-biotin 
Tris 
NaCl 
adjust to pH 8.0 
Competent Bacteria   
TFB I 
0.03 M 
0.01 M 
0.05 M 
0.1 M 
15% (v/v) 
 
potassium acetate 
CaCl2 
MnCl2 
RbCl 
glycerol 
adjust to pH 5.8 with acetic acid 
TFB II 
0.01 M 
0.075 M 
0.01 M 
15% (v/v) 
 
MOPS 
CaCl2 
RbCl 
glycerol 
adjust to pH 6.8 with KOH 
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Buffer / Solution  Formulation 
ELISA   
Coating Buffer mAb 
0.05 M 
0.05 M 
 
Na2CO3  
NaHCO3  
adjust to pH 9.6 
Blocking Buffer mAb 
0.2% (w/v) 
0.1% (v/v) 
gelatin 
NaN3 in PBS 
Sample Buffer 1% (w/v) albumin fraction V (BSA) in PBS 
PBS-T 0.05% (v/v) Tween20 in PBS 
Flow Cytometry / Cytotoxicity Assays 
FACS buffer 2% (v/v) FCS in PBS 
FACS fix 1% (v/v) formaldehyde in PBS 
Cytotoxicity medium 5% (v/v) human AB serum in X-Vivo10 
CFSE stain 1:1000 CFSE solution in PBS 
Dead stain solution 1:1000 Sytox® Blue in PBS 
Immunoblotting / Peptide Spot Arrays 
Transfer buffer 
0.192 M 
0.025 M 
20% (v/v) 
M glycin 
TRIS 
EtOH (≥ 99.8%, p.a.) 
TBS-T 
0.05 M 
0.15 M 
0.1% (v/v) 
TRIS 
NaCl 
Tween20 
WB blocking buffer  2% (w/v) skim milk powder in TBS-T 
Spot blocking buffer 
5% (w/v) 
5% (w/v) 
 
skim milk powder 
albumin fraction V 
in TBS-T 
Spot buffer 10% (v/v) Spot blocking buffer in TBS-T 
Coumarin solution 0.09 M p-coumaric acid in DMSO 
Luminol solution 0.25 M luminol in DMSO 
ECL I solution 
0.1 M 
396 µM 
0.005 M 
Tris pH 8.5 
coumarin 
luminol 
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Buffer / Solution  Formulation 
ECL II solution 
0.1 M 
0.2% (v/v) 
Tris pH 8.5 
H2O2 
Regeneration buffer A 
8 M 
1% (w/v) 
0.1% (v/v) 
urea 
SDS 
β-mercaptoethanol 
Regeneration buffer B 
50% (v/v) 
10% (v/v) 
EtOH 
acetic acid 
Immunoprecipitation   
PBS-T 0.05% (v/v) Tween20 in PBS 
IP buffer 0.02% (v/v) Tween20 in PBS 
Elution buffer I 
0.06 M 
2% (v/v) 
10% (v/v) 
0.001% (w/v) 
5% (v/v) 
0.3 mM 
TRIS pH 6.8 
SDS 
10% glycerol 
bromphenol blue 
β-mercaptoethanol 
DTT 
Elution buffer II 0.1 M glycin pH 2.7 
Isolation of pNK cells   
PBS/EDTA 0.002 M EDTA in PBS 
Protein Purification / Refolding   
Resuspension buffer (E. coli) 
0.02 M 
10 µg/ml 
0.001 M 
 
MgCl2 
DNAse 
PMSF 
in PBS, adjust to pH 8.0 at 4 °C  
Solubilization buffer (E. coli) 
0.05 M 
0.1 M 
 
glycin 
Tris 
adjust to pH 8.0 at RT 
Wash buffer (IMAC, denat.) 
8 M 
0.05 M 
0.1 M 
0.02 M 
 
urea 
glycin 
Tris 
imidazole 
adjust to pH 8.0 at RT 
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Buffer / Solution  Formulation 
Elution buffer (IMAC, denat.) 
8 M 
0.05 M 
0.1 M 
0.25 M 
 
urea 
glycin 
Tris 
imidazole 
adjust to pH 8.0 at RT 
Wash buffer (IMAC, sMICA) 
0.05 M 
0.5 M 
0.02 M 
 
Tris 
NaCl 
imidazole 
adjust to pH 7.5 at 4 °C 
Elution buffer (IMAC, sMICA) 
0.05 M 
0.5 M 
0.25 M 
 
Tris 
NaCl 
imidazole 
adjust to pH 7.5 at 4 °C 
Regeneration buffer (IMAC) 
0.5 M 
0.1 M 
NaCl 
EDTA pH 8.0 
Ni2+ solution (IMAC) 0.1 M NiSO4 
Dialysis buffer A (sMICA)  
0.05 M 
0.5 M 
 
Tris 
NaCl 
adjust to pH 7.5 at 4 °C 
Dialysis buffer I (E. coli) 
4 M 
0.1 M 
0.4 M 
0.01 M 
 
urea 
Tris 
L-arginine 
EDTA 
adjust to pH 8.0 at 4 °C 
Dialysis buffer II (E. coli) 
2 M 
0.1 M 
0.4 M 
0.01 M 
 
urea 
Tris 
L-arginine 
EDTA 
adjust to pH 8.0 at 4 °C 
Dialysis buffer III (E. coli) 
1 M 
0.1 M 
0.4 M 
0.01 M 
 
urea 
Tris 
L-arginine 
EDTA 
adjust to pH 8.0 at 4 °C 
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Buffer / Solution  Formulation 
Dialysis buffer IV (E. coli) 
0.1 M 
0.4 M 
0.01 M 
 
Tris 
L-arginine 
EDTA 
adjust to pH 8.0 at 4 °C 
Dialysis buffer V (E. coli) 
0.025 M 
0.1 M 
0.0025 M 
 
Tris 
L-arginine 
EDTA 
adjust to pH 8.0 at 4 °C 
TBS (E. coli) 
0.15 M 
0.01 M 
 
NaCl 
Tris 
adjust pH 8.0 at 4 °C 
Collection buffer (Protein A/G)) 1 M TRIS pH 8.8 
Elution buffer II (Protein A/G) 0.1 M glycin pH 2.7 
Regeneration buffer (Protein A/G) 
0.02 M 
0.05% (w/v) 
0.02 M 
NaH2PO4 
NaN3 
Na2HPO4 to adjust pH 7.4 
Storage buffer 0.01% (v/v) NaN3 
Size exclusion chromatography   
TBS 
0.05 M 
0.025 M 
 
Tris 
NaCl 
adjust to pH 7.4 at 4 °C 
SDS-PAGE   
SDS running buffer 
0.025 M 
0.192 M 
0.1% (w/v) 
Tris 
glycin 
SDS 
5x SDS sample buffer  
(non-reducing) 
0.3 M 
10% (w/v) 
50% (v/v) 
0.005% (w/v) 
TRIS pH 6.8 
SDS 
glycerol 
bromphenolblue 
5x SDS sample buffer  
(reducing) 
5x 
25% (v/v) 
SDS sample buffer (non-reducing)  
β-mercaptoethanol 
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Buffer / Solution  Formulation 
Transfection of Mammalian Cells   
TA-Trans 
0.018 M 
 
polyethylenimine, branched  
in cell culture grade H2O 
TA-glucose 
5% (w/v) 
 
glucose 
in cell culture grade H2O 
DMEM/Gln 2 mM L-glutamine in DMEM 
DMEM/FCS 5% (v/v) FCS in DMEM/Gln 
DMEM/Biotin 
5% (v/v) 
0.02 M 
 
PanexinNTA 
 D-Biotin 
in DMEM/Gln 
 
2.1.8 Oligonucleotides and Plasmids 
2.1.8.1 Oligonucleotides 
All oligonucleotides (primers) were synthesized by Sigma-Aldrich. Sequences and calculated 
melting temperatures are indicated (TM), numbers correspond to an intralaboratory database.  
No. Name Sequence (5’  3’) 
TM 
[°C] 
38 pET16b_seq_for AGCCAACTCAGCTTCCTTTC 62.4 
39 pEET16b_Colony_rev GGGAATTGTGAGCGGATAAC 63.1 
45 pFUSE_hIgG1_Fc2_seq_for TGCGCCGTTACAGATCCAAG 68.2 
46 pFUSE_hIgG1_Fc2_seq_rev ACCGTCAGTCTTCCTCTTCC 62.2 
47 pFUSE_hIgG1_Fc2_seq_rev_2 CGGGAGATCATGAGGGTGTC 66.9 
72 pET_upstream_for ATGCGTCCGGCGTAGA 64.3 
256 pFUSE_seq_rev TGTGGTTTGTCCAAACTCATC 62.4 
328 BglII_MICA_for CTCAGATCTTTTCCCAGAGGGCAC 56.0 
332 OE_pET20b_for CAGCAGCCAACTCAGCTTCC 67.5 
333 OE_NKG2D_K150M_rev CTTAAACTGGTGATGTCATATCATTGG 65.0 
334 OE_NKG2D_K150M_for CCAATGATATGACATCACCAGTTTAAG 65.0 
335 OE_NKG2D_K150R_rev CTTAAACTGGTGCGGTCATATCATTGG 70.2 
336 OE_NKG2D_K150R_for CCAATGATATGACCGCACCAGTTTAAG 70.2 
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No. Name Sequence (5’  3’) 
TM 
[°C] 
337 OE_NKG2D_K150W_rev CTTAAACTGGTGTGGTCATATCATTGG 66.8 
338 OE_NKG2D_K150W_for CCAATGATATGACCACACCAGTTTAAG 66.8 
339 OE_NKG2D_I182R_rev CCTACTAACAATACGTGAAATGCAGAAGG 67.7 
340 OE_NKG2D_I182R_for CCTTCTGCATTTCACGTATTGTTAGTAGG 67.7 
341 OE_NKG2D_I182W_rev CCTACTAACAATATGGGAAATGCAGAAGG 68.3 
342 OE_NKG2D_I182W_for CCTTCTGCATTTCCCATATTGTTAGTAGG 68.3 
343 OE_NKG2D_K186M_rev 
CAATAATTGAAATGCAGATGGGAGACTGTGCACTC
TATG 
77.3 
344 OE_NKG2D_K186M_for 
CATAGAGTGCACAGTCTCCCATCTGCATTTCAATTA
TTG 
77.3 
345 OE_NKG2D_S117E_rev CAATTTTTTGATGAGGAGAAAAACTGGTATGAG 70.3 
346 OE_NKG2D_S117E_for CTCATACCAGTTTTTCTCCTCATCAAAAAATTG 70.3 
347 OE_NKG2D_S151D_rev TAAACTGGTGAAGGACTATCATTGGATGG 69.7 
348 OE_NKG2D_S151D_for CCATCCAATGATAGTCCTTCACCAGTTTA 69.7 
350 BglII_MICA_His_STOP_for CTCAGATCTCTAATGGTGGTGATGATGGTGTTTCC 76.2 
351 sMICA_His_rev GGAGCCCCACAGTCTTCGTTATAACC 68.0 
409 NcoI_hIgG1-FcEQ_for CGATATCGGCCATGGTTAGATCTGAC 66.0 
410 
hIgG1-FcEQ-
ΔSTOP_BamHI_NheI_rev 
CTAGCTAGCGCCATATACAGGATCCTTTACCCGGA
GACAGGGAGAGG 
68.0 
411 BamHI_GS_NKG2D_EC_for 
TATAGGATCCTCCGGAAACTCATTATTCAACCAAG
AAG 
64.0 
412 NKG2D_EC_NheI_rev CGTGCTAGCTTACACAGTCCTTTGCATGC 56.0 
438 RSV.5neo_seq_for CGCCATTTGACCATTCACC 66.3 
439 RSV.5neo_seq_rev CATTCTAGTTGTGGTTTGTC 54.5 
480 SacII_His6_ULBP1_for 
GCCGCCGCGGACCATCACCATCACCATCACGACA
CACACTGTCTTTGCTATGACTTCATC 
94.0 
481 SacII_His6_ULBP2_for 
GCCGCCGCGGACCATCACCATCACCATCACGACC
CTCACTCTCTTTGCTATGACATCAC 
94.5 
482 SacII_His6_ULBP3_for 
GCCGCCGCGGACCATCACCATCACCATCACGACG
CTCACTCTCTCTGGTATAACTTCAC 
93.2 
483 SacII_His6_MICB_for 
GCCGCCGCGGACCATCACCATCACCATCACGAGC
CCCACAGTCTTCGTTAC 
94.8 
484 SacII_His6_MICA_for 
GCCGCCGCGGACCATCACCATCACCATCACGAGC
CCCACAGTCTTCGTTAT 
94.3 
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No. Name Sequence (5’  3’) 
TM 
[°C] 
485 XhoI_ULBP1_rev CCGATATCTCGAGTCATCTG 59.8 
486 XhoI_ULBP2/3_rev CCGATATCTCGAGTCAGATG 59.8 
487 XhoI_MICA/B_rev CGATATCTCGAGCTAGGCGCCCTCAGTG 77.1 
 
2.1.8.2 Plasmids 
All plasmids used in this thesis were amplified in the E. coli DH5α strain. Plasmid numbers 
correspond to an intralaboratory database. Corresponding plasmid maps are listed in the ap-
pendix. 
No. Expression Plasmid (E. coli) Resistance Supplier 
1901 pET16b-His10-NKG2D-EC Amp
R J. Havensteinf 
5802 pET20b-Avi-NKG2D-Flag/His AmpR A. Steinleg 
5701 pET11a-sMICA01-His AmpR A. Steinleg 
5801 pET20b-sMICA04-His AmpR A. Steinleg 
5901 pDEST26_HisMICA01 NeoR/KanR imaGenes 
130 pUC57-Avi-hIgG1-FcEQ-NKG2D AmpR Genscript 
3601 pCMV-SPORT6-NKG2D-EC AmpR imaGenes 
 
No. Expression Plasmid (mammalian cells) Resistance Supplier 
24 pFUSE-hIgG1-Fc2 ZeoR Invitrogen 
68 pFUSE-hIgG1-FcEQ ZeoR J. Hartmannh [377] 
6834 pFUSE-hIgG1-FcEQ-MICA01 ZeoR this thesis 
6835 pFUSE-hIgG1-FcEQ-MICA04 ZeoR this thesis 
8502 pFUSE-MICA01-His ZeoR this thesis 
8504 pFUSE-MICA04-His ZeoR this thesis 
                                                 
 
f The plasmid was kindly provided by J. Havenstein in the lab of J. Koch, Georg-Speyer-Haus, Frankfurt am Main, Germany. 
g The plasmids were kindly provided by A. Steinle, Institute for Molecular Medicine, Goethe-University, Frankfurt am Main, Germany.  
h The plasmid was kindly provided by J. Hartmann in the lab of J. Koch, Georg-Speyer-Haus, Frankfurt am Main, Germany. 
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No. Expression Plasmid (mammalian cells) Resistance Supplier 
6837a pFUSE-hIgG1-FcEQ-ΔStop ZeoR this thesis 
6837 pFUSE-hIgG1-FcEQ-GS-NKG2D ZeoR this thesis 
6838 pFUSE-hIgG1-FcEQ-NKG2D-K150M ZeoR this thesis 
6839 pFUSE-hIgG1-FcEQ-NKG2D-K150R ZeoR this thesis 
6840 pFUSE-hIgG1-FcEQ-NKG2D-K150W ZeoR this thesis 
6841 pFUSE-hIgG1-FcEQ-NKG2D-I182R ZeoR this thesis 
6842 pFUSE-hIgG1-FcEQ-NKG2D-I182W ZeoR this thesis 
6843 pFUSE-hIgG1-FcEQ-NKG2D-K182M ZeoR this thesis 
6844 pFUSE-hIgG1-FcEQ-NKG2D-S117E ZeoR this thesis 
6845 pFUSE-hIgG1-FcEQ-NKG2D-S151D ZeoR this thesis 
91 RSV.5neo AmpR A. Steinleg 
9101 RSV.5neo-MICA01 AmpR A. Steinleg 
9102 RSV.5neo-His6-MICA01 Amp
R
 this thesis 
9103 RSV.5neo-MICA04 AmpR A. Steinleg 
9104 RSV.5neo-His6-MICA04 Amp
R
 this thesis 
9105 RSV.5neo-MICA07 AmpR A. Steinleg 
9106 RSV.5neo-His6-MICA07 Amp
R
 this thesis 
9107 RSV.5neo-MICA08 AmpR A. Steinleg 
9108 RSV.5neo-His6-MICA08 Amp
R
 this thesis 
9109 RSV.5neo-MICB AmpR A. Steinleg 
9110 RSV.5neo-His6-MICB Amp
R
 this thesis 
9111 RSV.5neo-ULBP1 AmpR A. Steinleg 
9112 RSV.5neo-His6-ULBP1 Amp
R
 this thesis 
9113 RSV.5neo-ULBP2 AmpR A. Steinleg 
9114 RSV.5neo-His6-ULBP2 Amp
R
 this thesis 
9115 RSV.5neo-ULBP3 AmpR A. Steinleg 
9116 RSV.5neo-His6-ULBP3 Amp
R
 this thesis 
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No. Expression Plasmid (mammalian cells) Resistance Supplier 
6846 pFUSE-Avi-hIgG1-FcEQ-NKG2D ZeoR this thesis 
6902 pDisplay-BirA-ER AmpR J. Hartmanni 
6903 pDisplay-sBirA AmpR J. Hartmanni 
9201 pES.1-2(M2N) (M2, rtTA) AmpR A. Kinnerj 
9202 pES.1-T6-PGKPuro-MICA01 AmpR A. Giannattasiok 
 
2.1.9 Recombinant proteins 
Recombinant proteins are indicated with the plasmid number encoding for the corresponding 
DNA sequence and the theoretical molecular weigh (MW) calculated for monomeric proteins 
without posttranslational modifications. Corresponding protein sequences are listed in the 
appendix. 
Proteins expressed in E. coli No. MW [kDa] Supplier 
rNKG2D-His (N-terminal His-tag) 1901 18.3 this thesis 
rMICA*01-His (C-terminal His-tag) 5701 32.7 this thesis 
rMICA*04-His (C-terminal His-tag) 5801 32.7 this thesis 
rNKG2D-Biotin (N-terminal Avi-tag) 5802 20.2 this thesis 
BAG-6686-936  28.6 J. Binici
l [378] 
 
Proteins expressed in HEK293T/17 or  
UKF-NB3  
No. MW [kDa] Supplier 
sMICA*01-His (C-terminal His-tag) 8502 32.7 this thesis 
sMICA*04-His (C-terminal His-tag) 8504 34.9 this thesis 
MICA*01::hIgG1-FcEQ 6834 57.7 this thesis 
                                                 
 
i The plasmid was kindly provided by J. Hartmann in the lab of C. Buchholz, Paul-Ehrlich-Institut, Langen, Germany. 
j The plasmid was kindly provided by A. Kinner in the lab of M. Grez, Georg-Speyer-Haus, Frankfurt am Main, Germany. 
k The plasmid was kindly provided by A. Giannattasio in the lab of J. Koch, Georg-Speyer-Haus, Frankfurt am Main, Germany. 
l The protein was kindly provided by J. Binici in the lab of J. Koch, Georg-Speyer-Haus, Frankfurt am Main, Germany. 
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Proteins expressed in HEK293T/17 or  
UKF-NB3  
No. MW [kDa] Supplier 
MICA*04::hIgG1-FcEQ 6835 57.8 this thesis 
NKG2D::hIgG1-FcEQ 6837 44.7 this thesis 
NKG2D::hIgG1-FcEQ-K150M 6838 44.7 this thesis 
NKG2D::hIgG1-FcEQ-K150R 6839 44.7 this thesis 
NKG2D::hIgG1-FcEQ-K150W 6840 44.7 this thesis 
NKG2D::hIgG1-FcEQ-I182R 6841 44.7 this thesis 
NKG2D::hIgG1-FcEQ-I182W 6842 44.7 this thesis 
NKG2D::hIgG1-FcEQ-K186M 6843 44.7 this thesis 
NKG2D::hIgG1-FcEQ-S117E 6844 44.7 this thesis 
NKG2D::hIgG1-FcEQ-S151D 6845 44.7 this thesis 
NKG2D::hIgG1-FcEQ-Biotin 6846 47.0 this thesis 
NKp30::hIgG1-FcEQ  39.8 J. Hartmannm 
NKp46::hIgG1-FcEQ  52.7 J. Hartmannn 
B7H6::hIgG1-Fc  52.9 J. Hartmannm [377] 
shedMICA*01 (UKF-NB3; N-terminal His-tag) 9202 ~35 this thesis 
 
2.2 Methods of Microbiology 
2.2.1 Cultivation of Bacteria 
For the amplification of DNA or production of recombinant proteins, E. coli derivatives of the 
K12 strain or B strain, respectively, were cultured in LB medium overnight at 37 °C and 
200 rpm in a bacteria shaker. For the selection of single clone colonies, bacteria cultures were 
cultivated on LB-plates overnight at 37 °C in an incubator. Culture medium or LB-plates were 
supplemented with either 100 µg/ml ampicillin or zeocin for selection of bacterial clones car-
rying an antibiotic resistant gene.  
 
                                                 
 
m The proteins were kindly provided by J. Hartmann in the lab of J. Koch, Georg-Speyer-Haus, Frankfurt am Main, Germany. 
n The proteins were kindly provided by J. Hartmann in the lab of J. Koch, Georg-Speyer-Haus, Frankfurt am Main, Germany. 
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2.2.2 Generation and Transformation of Competent Bacteria 
Chemically competent bacteria were generated by the CaCl2/RbCl method [379] for the trans-
formation of DNA following subsequent amplification via cellular replication. Therefor, an E. 
coli culture in 100 ml of LB medium was incubated at 37 °C and 200 rpm until reaching an 
OD600 = 0.4 - 0.6. The bacteria culture was cooled down on ice for 10 min following centrifu-
gation at 2,000xg for 10 min at 0 °C. The bacteria pellet was resuspended in 7.5 ml of ice cold 
TFB I buffer and incubated for 1 h on ice. After centrifugation at 3,000xg for 10 min at 0 °C, 
the bacteria pellet was resuspended in 2 ml of ice cold TBF II buffer and aliquoted in 50 µl 
stocks. The aliquots were shock frozen in liquid nitrogen and stored at -80 °C. 
Rb-competent bacteria were transformed with either 50 - 100 ng of plasmid DNA, for plasmid 
DNA amplification, or 10 µl of ligation reaction (2.3.2.3) and incubated on ice for 20 min 
following a heat shock for 90 s at 42 °C and cooling down for 3 min on ice. After pre-
incubation of the transformation reaction in 500 µl of LB medium at 37 °C and 600 rpm for 
1 h, the bacteria suspension was either used for inoculation of 1 - 500 ml of LB medium cul-
tures or plated on LB agar supplemented with the respective antibiotic and incubated over-
night at 37 °C. Bacteria cultures were pelleted by centrifugation (9000xg, 5 min, 4 °C) and 
used for plasmid DNA purification (2.3.4.2). 
 
2.3 Methods of Molecular Biology 
2.3.1 Polymerase Chain Reaction (PCR) 
For the exponentially amplification of specific gene fragments from genomic or plasmid DNA 
in vitro the polymerase chain reaction (PCR) [380, 381] was used. PCR can further be used to 
introduce genetically modifications into the gene fragment (i.e. endonuclease restriction sites 
or point mutations) by primer engineering or to quickly verify the existence of a specific gene 
after transformation in bacterial colonies (termed Colony PCR). 
In this thesis, the thermostable polymerases DreamTag™ (no proof-reading activity) or 
Phusion® (3’ - 5’ exonuclease activity) (both Thermo Fisher Scientific) were used for analyti-
cal (Colony PCR) or preparative (for subsequent cloning or site directed mutagenesis) DNA 
amplification. For PCR protocols, the annealing temperature and elongation time was calcu-
lated individually, depending on the melting temperature (TM) of primers used, the length of 
DNA fragment to be amplified, and the elongation time of the polymerase. Standard sample 
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preparation and PCR reaction protocols for analytical (Table 1) and preparative PCR  (Table 
2) are depicted. All reagents and buffers were obtained from Thermo Fisher Scientific. 
Table 1: Standard reaction mixture and PCR protocol for analytical PCR (Colony PCR). 
Reaction mixture  PCR protocol 
1 bacterial colony  98 °C 30 s  initial denaturation 
1 µM forward primer  98 °C 10 s  denaturation 
1 µM reverse primer  55 °C 15 s 25x annealing 
0.2 mM dNTP mix (2 mM each)  72 °C 30 s  elongation (<0.5 kb) 
2.5% (v/v) DMSO  72 °C 5min  final elongation 
1x DreamTag™ green buffer  4 °C ∞   
0.025 U/µl DreamTag™ polymerase      
to 25 µl with H2O      
 
Table 2: Standard reaction mixture and PCR protocol for preparative PCR. 
Reaction mixture  PCR protocol    
20 ng template DNA  98 °C 30 s  initial denaturation 
0.5 µM forward primer  98 °C 10 s  denaturation 
0.5 µM reverse primer  55 °C 15 s 25x annealing 
0.2 mM dNTP mix (2 mM each)  72 °C 30 s  elongation (1 kb/15-30 s) 
3% (v/v) DMSO  72 °C 5 min  final elongation 
1x Phusion® GC buffer  4 °C ∞   
0.02 U/µl Phusion® polymerase      
to 100 µl with H2O      
 
The introduction of single amino acid exchanges (point mutations) in a gene segment results 
from overlap extension PCR (OE-PCR) [382]. Thereby, two overlapping DNA fragments 
covering the whole gene sequence are generated using a mutagenic primer (OE-primer) and 
the respective forward (OE-PCR 1) or reverse (OE-PCR 2) primer flanking the sequence at 
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the 5’ end and 3’ end, respectively. The mutagenic primers introduce the point mutation in the 
overlapping complementary region of the two PCR constructs generated. In a third round of 
PCR (OE-PCR 3) the whole gene sequence containing the mutation is amplified by the use of 
the two PCR fragments as templates, and the two flanking primers. In this thesis, the thermo-
stable Pfu Polymerase (Thermo Fisher Scientific) was used and standard reaction mixture and 
PCR protocol for the OE-PCR 1 - 3 are listed in Table 3. 
Table 3: Standard reaction mixture and PCR protocol for overlap extension PCR. 
Reaction mixture OE-PCR 1/2  PCR protocol    
50 ng template DNA  95 °C 3 min  initial denaturation 
0.5 µM flanking primer forward/reverse  95 °C 30 s  denaturation 
0.5 µM OE-primer reverse/forward  50 °C 30 s 30x annealing 
0.2 mM dNTP mix (2 mM each)  72 °C 60 s  elongation (1 kb/2 min) 
2.5% (v/v) DMSO  72 °C 5 min  final elongation 
1x Pfu buffer + MgSO4  4 °C ∞   
0.025 U/µl Pfu polymerase      
to 100 µl with H2O      
 
Reaction mixture OE-PCR 3  PCR protocol    
25 ng product OE-PCR 1  95 °C 3 min  initial denaturation 
25 ng product OE-PCR 2  95 °C 30 s  denaturation 
0.5 µM flanking primer forward  50 °C 30 s 35x annealing 
0.5 µM flanking primer reverse  72 °C 90 s  elongation (1 kb/2 min) 
0.2 mM dNTP mix (2 mM each)  72 °C 5 min  final elongation 
2.5% (v/v) DMSO  4 °C ∞   
1x Pfu buffer + MgSO4      
0.025 U/µl Pfu polymerase      
to 100 µl with H2O      
 
PCR reactions were analyzed by agarose gel electrophoresis (2.3.3) and amplified DNA frag-
ments from preparative PCR were purified (2.3.4) and used for subsequent cloning. 
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2.3.2 Restriction, Dephosphorylation and Ligation of DNA 
2.3.2.1 Enzymatic Restriction 
All restriction type II endonucleases used were FastDigest® enzymes (Thermo Fisher Scien-
tific) and are listed with corresponding restriction sites in Table 4. A standard restriction mix-
ture using two enzymes for double restriction is listed in Table 5. Unless otherwise noted, 
DNA restrictions were performed according to the manufacturer’s instructions using supplied 
10x FastDigest® buffer or 10x FastDigest® green buffer and incubation for 15 min at 37 °C 
and subsequent enzyme inactivation at 80 °C for 10 min. Restriction samples were either ana-
lyzed by agarose gel electrophoresis (2.3.3) or directly purified (2.3.4). 
Table 4: Type II restriction endonucleases and corresponding restriction sites. 
Enzyme Restriction site Enzyme Restriction site Enzyme  Restriction site 
BamHI 
5’…G|GATCC...3’ 
3’...CCTAG|G…5’ 
EcoRV 
5’...GAT|ATC…3’ 
3’...CTA|TAG…5’ 
XbaI 
5’…T|CTAGA…3’ 
3’…AGATC|T…5’ 
BglII 
5’…A|GATCT…3’ 
3’...TCTAG|A...5’ 
NcoI 
5’…C|CATGG…3’ 
3’…GGTAC|C…5’ 
  
EcoRI 
5’…G|AATTC...3’ 
3’…CTTAA|G…5’ 
NheI 
5’...G|CTAGC…3’ 
3’...CGATC|G…5’ 
  
 
Table 5: Reaction mixtures for preparative and analytical restriction. 
 preparative restriction analytical restriction 
DNA 1-5 µg 0.5-1 µg 
10x FastDigest® buffer 5 µl 2 µl 
FastDigest® enzyme I 2.5 µl 0.5 µl 
FastDigest® enzyme II 2.5 µl 0.5 µl 
adjust with H2O to 50 µl to 20 µl 
 
2.3.2.2 Enzymatic Dephosphorylation 
To enhance ligation specificity of DNA fragments and plasmid DNA by preventing recircula-
tion of the plasmid backbone, the phosphorylated 5’end of the linearized plasmid DNA was 
enzymatically dephosphorylated. Therefor, 1 - 5 µg of linearized plasmid DNA were mixed 
with 5 µl of 10x FastAP buffer (supplied with the enzyme) and 1 µl of FastAP alkaline phos-
phatase (Thermo Fisher Scientific) in a total volume of 50 µl in H2O and incubated for 10 min 
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at 37 °C. After enzyme inactivation for 5 min at 75 °C, dephosphorylated DNA was purified 
(2.3.4) and used for enzymatic ligation (2.3.2.3). 
 
2.3.2.3 Enzymatic Ligation 
For ligation of linearized DNA fragments generally 50 ng of vector DNA (maximal DNA 
amount of 100 ng) was used and the amount of insert DNA in a molar excess of 3:1 to vector 
DNA was calculated by the following equation: 
𝑖𝑛𝑠𝑒𝑟𝑡 𝐷𝑁𝐴 [𝑛𝑔] =
𝑚𝑜𝑙𝑎𝑟 𝑒𝑥𝑐𝑒𝑠𝑠 ×  𝑖𝑛𝑠𝑒𝑟𝑡 𝐷𝑁𝐴 [𝑏𝑝]  ×  𝑝𝑙𝑎𝑠𝑚𝑖𝑑 𝐷𝑁𝐴 [𝑛𝑔]
𝑝𝑙𝑎𝑠𝑚𝑖𝑑 𝐷𝑁𝐴 [𝑏𝑝]
 
The calculated insert DNA and 50 ng of vector DNA were mixed with 5 U T4 DNA ligase 
(Thermo Fisher Scientific) and 2 µl of the supplied T4 buffer in a total volume of 20 µl aque-
ous solution and incubated 1 h at 22 °C or overnight at 16 °C. After enzyme inactivation for 
10 min at 65 °C, the ligated DNA was used for transformation (2.2.2) or stored at -20 °C.  
 
2.3.3 Agarose Gel Electrophoresis  
DNA molecules were separated according to their size using agarose gel electrophoresis. De-
pending on the DNA size, agarose gels consisting of 0.8% or 1.2% (w/v) agarose in TAE 
buffer for DNA fragments > 1 kb or smaller were used, respectively. DNA samples were sup-
plemented with 6x DNA loading dye (Thermo Fisher Scientific) or already contained Dream-
Tag™ green buffer (2.3.1) or FastDigest® green buffer (2.3.2.1). Samples were loaded togeth-
er with GeneRuler 1kb Plus DNA ladder (Thermo Fisher Scientific) in the agarose gels and 
separated at 160 V for approximately 45 min in a WIDE MINI-SUB cell GT chamber (Bio-
Rad) with TAE buffer. For visualization of DNA fragments, agarose gels were incubated for 
15 min in EtBr stain and analyzed under UV light (254 nm) using a Gel Doc 2000 gel docu-
mentation system (BioRad). 
 
2.3.4 Isolation of DNA from Agarose Gels and DNA Purification 
2.3.4.1 Isolation of DNA from Agarose Gels 
Specific DNA fragments separated by agarose gel electrophoresis (2.3.3) can be isolated from 
the gel matrix and used for subsequent cloning. Therefor, gel slices containing the respective 
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DNA fragment were cut out under low intensity UV light (302 nm), to prevent DNA damage, 
and DNA was isolated using the GenJET™ Gel Extraction Kit (Thermo Science) according to 
the manufacturer’s instructions. The DNA was eluted from the silica membrane with 50 µl of 
pre-warmed H2O (50 °C) and DNA concentration was determined (2.3.5). 
 
2.3.4.2 Purification of DNA 
Plasmid DNA from 1 - 5 ml bacteria cultures was purified using the GeneJET™ Plasmid Min-
iprep kit (Thermo Fisher Scientific) according to the manufacturer’s instruction. Plasmid 
DNA from 100 - 1000 ml bacteria cultures was purified with the NucleoBond Xtra Midi/Maxi 
kit (Macherey-Nagel) according to the manufacturer’s protocol for high copy plasmid ampli-
fication.  
DNA fragments of PCR (2.3.1), restriction or dephosphorylation reactions (2.3.2) were puri-
fied using the GeneJET™ Gel Extraction kit according to the manufacturer’s instructions, to 
remove disturbing buffer components and enzymes for further applications. After purification, 
the DNA molecules were reconstituted in an appropriate volume (0.02 - 1 ml) of pre-warmed 
H2O (50 °C) and DNA concentration was determined (2.3.5). 
 
2.3.5 Determination of DNA Concentration 
For the spectrophotometric determination of the DNA concentrations 1 - 2 µl of DNA aqueous 
solution was measured at the UV absorbance spectrum between 220 nm and 300 nm using a 
NanoDrop 1000 device against H2O as blank. The purity of the DNA solution was determined 
by the absorbance ratio of 260/280 nm (260 nm = absorbance of purine and pyrimidin bases; 
280 nm = absorbance of aromatic amino acids), with a value of approximately 1.8 accounting 
for pure DNA. 
 
2.3.6 Nucleic Acid Sequencing 
Sequencing samples were prepared by mixing 0.5 µg of DNA (100 ng/µl) with 25 pmol of the 
respective primer in a total volume of 10 µl. Sequencing of DNA fragments or plasmid DNA 
was performed by the sequencing service of GATC Biotech.  
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2.3.7 Cloning Strategies 
All used oligonucleotides for PCR amplification and generated plasmids are listed with their 
corresponding numbers (2.1.8.1 and 2.1.8.2). After each cloning step, the DNA was purified 
according to the protocols in 2.3.4. All constructs were verified by nucleotide sequencing 
(2.3.6) and corresponding protein sequences are listed in the appendix (6.2). 
For the generation of soluble human IgG1-Fc (hIgG1-Fc) fusion proteins, the pFUSE-hIgG1-
Fc2 (no.24) expression plasmid system (Invitrogen) was used. The plasmid contains an N-
terminal IL-2 secretion signal and a C-terminal hIgG1-Fc tag under the control of the hEF1-
HTLV promoter allowing for the long lasting expression of soluble bivalent hIgG1-Fc fusion 
proteins in mammalian cell lines. In this thesis, the plasmid pFUSE-hIgG1-FcEQ (no. 68, 
kindly provided by J. Hartmann) was used for transgene expression, containing a modified Fc 
variant incapable of Fc receptor binding due to the two point mutations L118E/N180Q [377]. 
 
2.3.7.1 Generation of soluble MICA Variants for Production in Mammalian Cell 
Lines 
The MICA ligand is a highly polymorphic and glycosylated protein. To ensure high affinity 
binding of the ligand to the NKG2D receptor, the allelic MICA variants MICA*01 and 
MICA*04 were generated for the production as soluble MICA (resembling the naturally shed 
MICA) or full-length proteins in mammalian cell lines.  
For the generation of soluble MICA variants, the gene sequence encoding the extracellular 
domain of MICA*01 or MICA*04 was amplified via PCR (2.3.1) using the plasmids 5701 or 
5801 as templates, respectively. For the generation of soluble MICA-His variants, a C-
terminal histidine (His) tag followed by a STOP codon as well as the restriction sites EcoRV 
and BglII were introduced using the primer pair 350/351. Prior to ligation (2.3.2.3), the PCR 
products and the plasmid 68 were enzymatically digested with EcoRV/BglII (2.3.2.1), follow-
ing plasmid dephosphorylation (2.3.2.2). The DNA sequences of the newly generated plas-
mids 8502 and 8504 were verified using the primers 45, 46 and 256. 
For the generation of MICA::hIgG1-FcEQ fusion proteins, the sequences of MICA*01 and 
MICA*04 ectodomains were amplified (2.3.1) using the primer pair 328/351 introducing the 
restriction sites EcoRV/BglII without histidine tag or STOP codon to allow for the fusion of 
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the MICA ectodomain to the hIgG1-FcEQ part. The PCR products were enzymatically re-
stricted and ligated into the plasmid 68 as described earlier, generating the plasmids 6834 and 
6835.  
 
2.3.7.2 Generation of NKG2D::hIgG1-FcEQ Fusion Proteins 
The NKG2D receptor is a type II transmembrane protein forming functional active homodi-
mers. To generate functional bivalent human Fc fusion proteins, the NKG2D ectodomain must 
therefor be fused to the C-terminal region of the hIgG1-Fc part. For this purpose, the STOP 
codon of the human IgG1-FcEQ gene segment was removed while additional BamHI/NheI 
restriction sites were introduced at the 3’ end via PCR amplification (2.3.1) using plasmid 68 
as template and the primer pair 409/410. The PCR fragment and the plasmid 24 (pFUSE-
hIgG1-Fc2) were enzymatically digested (2.3.2.1) with the enzymes NcoI and NheI, removing 
the original hIgG1-Fc2 gene sequence from the plasmid. After dephosphorylation (2.3.2.2) of 
the linearized plasmid DNA it was enzymatically ligated (2.3.2.3) with the PCR fragment. 
Positive clones were identified using colony PCR (2.3.1) with the primer combination 45/47 
and DNA sequence of the generated pFUSE-hIgG1-FcEQ-ΔSTOP (no. 6837a) was verified 
(2.3.6).  
For the introduction of the human NKG2D ectodomain into the newly generated plasmid 
6837a, the gene fragment was amplified (2.3.1) using the plasmid 3601 as template. Addition-
ally, the restriction sites BamHI and NheI as well as an N-terminal GSSG linker sequence was 
introduced by the primer pair 411/412. The PCR fragment and plasmid were enzymatically 
digested (2.3.2.1) with BamHI/NheI and after dephosphorylation (2.3.2.2) of the linearized 
plasmid both DNA molecules were enzymatically ligated (2.3.2.3). The DNA sequence of the 
generated plasmid 6837 and positive clones were again verified using the primer pair 45/256. 
To ensure directed immobilization of the hIgG1-Fc part of NKG2D::hIgG1-FcEQ fusion pro-
teins an additional Avi-tag sequence was introduced at the N-terminal region of the Fc part. 
Using the Avi-tag technology, the proteins can be biotinylated in vivo during protein produc-
tion. The whole gene sequence of the Avi-hIgG1-FcEQ-NKG2D construct was synthesized by 
the company GenScript and delivered in the pUC57 plasmid (130). For ligation (2.3.2.3) of 
the Avi-hIgG1-FcEQ-NKG2D DNA fragment into the pFUSE expression plasmid, the pUC57 
plasmid 130 and pFUSE plasmid 24 were enzymatically digested (2.3.2.1) using EcoRV and 
Materials and Methods 53 
  
 
NheI enzymes, following plasmid dephosphorylation (2.3.2.2) of the pFUSE plasmid prior to 
ligation. The DNA sequence of the generated plasmid 6846 was verified using primers 
45/256. 
 
2.3.7.3 Generation of NKG2D mutant Proteins (MICA Affinity Maturation) 
To improve the binding affinity of the NKG2D receptor to its ligand MICA, mutant proteins 
were generated introducing single mutations in the binding interface of NKG2D. The single 
amino acid mutations showing higher binding affinities were calculated bioinformatically by 
A. Metz in the group of H. Gohlke (Computational Pharmaceutical Chemistry and Molecular 
Bioinformatics, Heinrich-Heine University, Düsseldorf, Germany). 
In this thesis eight single amino acid mutations (K150M, K150R, K150W, I182R, I182W, 
K186M, S117E and S151D) were introduced into the human NKG2D ectodomain for protein 
production of NKG2D::hIgG1-FcEQ fusion proteins using OE-PCR (2.3.1) with the template 
pCMV-SPORT6-NKG2D (no. 3601). For the introduction of the single point mutations, two 
overlapping DNA fragments were amplified using the respective OE-primer 333-348 (intro-
duced mutations depicted in primer name (2.1.8.1)) and the flanking primer 412 (in combina-
tion with OE-primers with even numbers for OE-PCR 1) and 411 (in combination with OE-
primers with odd numbers for OE-PCR 2). The generated PCR fragments containing the mu-
tation from the respective OE-PCR 1 and 2 reactions were further used as templates for the 
OE-PCR 3 with the flanking primer pairs 411/412. The PCR products comprising the whole 
gene sequence and expression plasmids were enzymatically digested (2.3.1.1) with the com-
bination BamHI/NheI for ligation into plasmid 6847a. Sequences were analyzed using primers 
45/256. The generated plasmids 6838-6845 are listed in 2.1.8.2. 
 
2.4 Methods of Cell Biology 
2.4.1 Protein Production in Escherichia Coli 
E. coli are a well-established expression system for the production of high amounts of pure 
proteins. In this study, recombinant human NKG2D or rMICA proteins were produced in 
BL21 (DE3) strains. An aliquot of BL21 (DE3) were transformed (2.2.1.2) with the respective 
pET plasmid (proteins and corresponding plasmid numbers denoted in table 2.1.9) to generate 
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an overnight culture in 10 ml of LB medium supplemented with ampicillin. The pre-cultured 
bacteria were used to inoculate 1 L of LB medium. Bacteria were cultivated at 37 °C and 
200 rpm until the culture reached an OD600 = 0.6. Next, protein expression was initiated by 
adding 0.5 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) to the culture. Bacteria cul-
tures were harvested after 4 h incubation at 37 °C and 200 rpm by centrifugation (6000xg, 
10 min, 4 °C). Cell pellets were either stored at -20 °C or directly used for protein purification 
(2.2.4.2). 
 
2.4.2 Cultivation of Cell Lines 
All cell lines were cultivated in the appropriate medium (2.1.6.3) at 37 °C and 5% CO2 in 
saturated water atmosphere under sterile conditions in a cell culture incubator. Cells were split 
on a regular basis every two to three days, depending on cell growth, to maintain optimal 
growth conditions. Adherent cells were washed in PBS and detached using TrypLETM Express 
(Thermo Fisher Scientific) or Accutase (PAA) treatment and an appropriate amount of cells 
was seeded in a new culture flask and fresh medium. For suspension cultures, cells were 
counted in a Neubauer counting chamber (Carl Roth), pelleted and resuspended in fresh me-
dium in the appropriate cell density. For cryo-preservation, cells were frozen in FCS contain-
ing 10% DMSO at -80 °C and stored in liquid nitrogen or remained at -80 °C. Cells were 
thawed on a regular basis. 
 
2.4.3 Transfection of Mammalian Cell Lines 
2.4.3.1 Transient Transfection 
For the transient expression of proteins, mammalian cell lines were chemically transfected 
using polyethylenimine (PEI) [383, 384]. Therefor, HEK293T/17 cells were seeded at a densi-
ty of 1x107 cells per flask into T175 culture flask with 20 ml of pre-warmed DMEM compl. 
medium 24 h prior transfection. Two PEI transfection protocols were used for the generation 
of soluble proteins or for co-transfection to produce proteins with in vivo biotinylation. On 
day of transfection, the medium was exchanged with 13 ml (for soluble proteins) or 11 ml (for 
biotinylated proteins) of pre-warmed DMEM/Gln. Next the transfection solutions A and B 
were prepared (Table 6). Both solutions were mixed for 1 min at maximum speed on a Vortex 
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Genie 2 (Scientific Industry) and incubated for 10 min at RT. After incubation, both solutions 
were combined, mixed again for 1 min following incubation for 10 min at RT. Directly before 
application to the cells, 1 ml of pre-warmed DMEM/Gln medium was added to the transfec-
tion mixture. After 4 - 6 h incubation at 37 °C, the transfection medium was exchanged with 
25 ml of DMEM/FCS or 25 ml of DMEM/Biotin for in vivo biotinylation of proteins and cells 
were further cultivated. 
Table 6: Formulation of transformation solutions for the production of secreted proteins. 
Ingredient soluble (Fc fusion) proteins  biotinylated proteins 
 Solution A Solution B Solution A Solution B 
pFUSE 65 µg  7 µg  
pDisplay-BirA-ER   14 µg  
pDisplay-sBirA   14 µg  
TA-trans  65 µl  140 µl 
TA-glucose 310 µl 310 µl   
DMEM/Gln  2.3 ml 2.2 ml 
 
2.4.3.2 Electroporation 
For the stable integration of full-length MICA*01, UKF-NB3 cells were electroporated using 
the Neon Transfection System (Thermo Fisher Scientific). Therefor, 1x106 cells were co-
transfected with 2.5 µg of pES.1-T6-PGKPuro-MICA01 and 2.5 µg of pES1-2(M2N) (M2, 
rtTA) in 100 µl of resuspension buffer R (Neon® Kit 100 µl, Thermo Fisher Scientific) and 
electroporated using protocol 16 (including electroporation parameters: voltage: 1400 V; 
pulse width: 20, pulse numbers: 2). Directly after electroporation, cells were transferred in 
900 µl of pre-warmed UKF-NB3 medium and cultured in T25 flasks coated with fibronectin 
(5 µg/cm2). Two days after electroporation UKF-NB3-indMICA cells were selected by addi-
tion of 0.25 mg/ml G418 and 1 µg/ml puromycin (Life Technologies) to the culture medium. 
For the generation of C1R cells expressing full-length NKG2D ligands containing an N-
terminal hexahistidine tag, 1x106 cells were electroporated with 2 µg of the respective 
RSV.5neo plasmids (plasmid 9102-9116 even numbers; see table 1.6.8.2) using the Amaxa® 
Nucleofector® device (program D-023) with Nucleofector Kit V (both Lonza) according to the 
manufacturer’s protocol. Two days after electroporation cells were selected in C1R medium 
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containing G418. Two weeks after selection, cells were stained with respective anti-NKG2D 
ligand antibodies and cells were further selected on a FACSAria II cell sorter (BD Bioscience) 
for high NKG2D ligand expression.  
 
2.4.4 Protein Production in Mammalian Cell Lines 
For the production of soluble MICA*01, MICA*04 or the NKG2D- or MICA::hIgG1-Fc fu-
sion protein variants, 20 - 100 T175 culture flasks of HEK293T/17 cells were transfected with 
the respective pFUSE plasmid (proteins and corresponding plasmid numbers see table 2.1.9) 
using the PEI method described in 2.4.4.1. For the production of in vivo biotinylated 
NKG2D::hIgG1-FcEQ the pFUSE plasmid no.6846 was used for transfection. Three days 
after transfection, cell culture supernatants were collected and cell debris was removed by 
centrifugation (5,000xg, 5 min, 4 °C) following sterile filtration (0.22 µm). Filtered superna-
tants were supplemented with 0.01% (v/v) sodium azide and protease inhibitor (Roche) and 
directly used for protein purification (2.5.2.2 for His-tagged MICA*01/04; 2.5.2.3 for hIgG1-
Fc fusion proteins). 
To generate shedMICA*01 from UKF-NB3-indMICA cells, MICA expression was induced 
by addition of 2 µg/ml doxycycline (Sigma-Aldrich) to the cell culture medium. Cells were 
stressed by serum starvation for 72 h to induce MICA shedding. sMICA was purified as de-
scribed in 2.5.2.2 from cell culture supernatant.  
Cell culture supernatants containing shed NKG2D ligands were generated from CAL27 cells 
or C1R transfectants (2.1.6.2) expressing the NKG2D ligands MICA allelic variants, MICB or 
ULBP1-3. Therefor, 100 - 300 ml of C1R suspension cultures at a density of 1 -
 2x106 cells/ml or CAL27 tumor spheroids and confluent monolayer cultures were stressed by 
serum starvation for 72 h to induce shedding. Cell culture supernatants were collected, centri-
fuged (5,000xg, 5 min, 4 °C) and sterile filtered (0.22µm). Cell culture supernatants were 10x 
concentrated using amicon centrifugal filter units with a MWCO of 10 kDa (Merck Millipore) 
at 4 °C. 
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2.4.5 Isolation and Expansion of primary human NK cells 
Primary human NK cells were isolated from peripheral blood mononuclear cells (PBMCs) by 
negative selection at high purity and pre-activated and expanded under IL-2 as described pre-
viously for clinical applications [385]. Buffy coats, derived from whole blood donations of 
healthy volunteers were kindly provided by the German Red Cross Blood Service (Institute 
for Transfusion Medicine and Immunohematology, Goethe-University Frankfurt am Main, 
Germany). They were used in an anonymized fashion with written donor approval and ap-
proval by the Ethics Committee of the Goethe-University Frankfurt (Frankfurt am Main, 
Germany, permit #329/10). First, PBMCs were isolated via density gradient centrifugation 
(400xg, 1 h, RT) using Biocoll reagent (Biozol) following subsequent washing steps in 
PBS/EDTA (300xg, 15 min, RT). NK cells were purified from 2x108 PBMCs via indirect 
magnetic immunoselection using the human NK Cell Isolation Kit (Miltenyi Biotec) accord-
ing to the manufacturer’s protocol. NK cells were cultured in pNK medium at a cell density of 
1 - 2x106 cells/ml for up to 10 days. For pNK cell activation and expansion the NK Cell Acti-
vation and Expansion Kit (Miltenyi Biotec) was used. For maintenance of optimal growth and 
activation conditions, cell density was adjusted every two days by adding medium with 
1000 IU/ml IL-2. At day 7 of culture, cells were used for cytotoxicity assays (2.4.8). 
 
2.4.6 Tumor Spheroid Formation 
Multicellular tumor spheroids were generated from the HNSCC cell lines FaDu, CAL27 and 
Detroit562 or the cervical carcinoma cell line SiHa. Cells were washed with PBS dissociated 
from cell culture flasks by TrypLE™ Express (Life Technologies) and cell number was de-
termined. For fluorescent labeling, 1x106 cells were stained with Cell Trace CFSE Prolifera-
tion kit (Life Technologies) according to the manufacturer’s protocol. Afterwards, 5x103 
cells/well were seeded in a volume of 150µl/well respective culture medium in 96-well plates 
coated with 1.5% agarose in basal MEM or DMEM medium, respectively. Solid tumor sphe-
roids formed within approximately 24 - 48 h after initial seeding (d0) and were used in func-
tional assays. Growth was monitored by transmission and fluorescence microscopy. For tumor 
spheroid growth curves, phase contrast pictures of independent solid spheroids were analyzed 
by ImageJ software [386].  
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2.4.7 Flow Cytometry 
For detection of NKG2D ligands, 1 - 5x105 cells of single-cell suspensions or TrypLETM Ex-
press-treated (Life Technologies) tumor spheroids were stained with mouse monoclonal anti-
bodies (2.1.3: AMO1, MAB1599, MAB1380, MAB1298, MAB1517; at 0.25 µg/106 cells in 
FACS-buffer) or NKG2D proteins (2.4.5: 50 µg/ml in FACS-buffer) for 45 min at 4 °C, 
washed three times in FACS-buffer (centrifugation 300xg, 3 min, 4 °C) and probed with re-
spective fluorochrome-conjugated secondary antibodies (2.1.3) for 30 min at 4 °C under light 
protection. For the detection of primary human NK cells 1x104 - 5x105 NK cells were stained 
with anti-human CD45-APC and/or anti-human NKGD-PE antibodies (both Miltenyi Biotec) 
in FACS-buffer for 30 min at 4 °C. Viability of cells was determined by SytoxBlue (Life 
Technologies) stain according to the manufacturer’s protocol. As negative control, samples 
incubated with secondary antibodies only or respective isotype controls were used. Cells were 
resuspended in FACS-buffer and measured on a FACS Canto II instrument (BD Bioscience) 
equipped with a 96-well plate high throughput sampler (HTS) and analyzed with FlowJo 
software. 10.000 events of viable cells were analyzed of individual experiments to calculate 
the median fluorescence intensity (MFI) over background.  
For infiltration studies (2.4.8.3), primary human NK cells were stained with anti-human CD56 
and anti-human CD16 on day 7 of cultivation and 1x107 cells were sorted according to the 
expression levels for the CD56bright/CD16dim/- or CD56dim/CD16+ population on a FACSAria II 
cell sorter (BD Bioscience). 
For the staining of rhesus macaque PBMCs, 100 µl of whole blood samples were incubated 
with an antibody cocktail (2.1.3: anti-human CD3-PE, anti-human CD14-PerCp Cy5.5, anti-
human CD20-FITC, anti-human NKG2D-APC) in PBS for 30 min at RT under light protec-
tion. Afterwards, erythrocytes were lysed using ACK Lysis Buffer (Thermo Fisher Scientific) 
according to the manufacturer’s instructions for 30 - 60 min at RT. Cells were washed three 
times in PBS (centrifugation 400xg, 4 min, 4 °C), resuspended in FACS fix and measured on 
a FACS Canto II or LSRII instrument (BD Bioscience). Cells were analyzed with FlowJo 
software of 50.000 events to calculate MFI over background. 
Cryo-preserved PBMCs of healthy volunteers or HNSCC patients and corresponding disinte-
grated primary tumor samples were stained with an antibody cocktail (2.1.3: anti-human 
CD3-APC-Cy7, anti-human CD4-PacificBlue, anti-human CD8a-AlexaFluor700, anti-human 
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CD16-FITC, anti-human CD56-PE-Cy7, anti-human CD45-Pe-Flour610 and anti-human 
NKG2D-PE). For cell viability Aqua Dead Cells stain (Thermo Fisher Scientific) was used. 
Cellular events were measured on a Gallios cytometer and analyzed using Kaluza software 
(both Beckmann Coulter). Percentage of NK cell subsets and MFI ratios for NKG2D expres-
sion were calculated from CD45+ lymphocyte fraction. The analyses were kindly performed 
by A. Lechner (Department of Otorhinolaryngology, Head and Neck Surgery, University Co-
logne, Medical Faculty, Cologne, Germany). 
 
2.4.8 Cytotoxicity Assay 
2.4.8.1 Cytotoxicity Assay of Single Cell Suspension 
For monolayer cell cytotoxicity assays, FaDu, CAL27, Detroit562 or SiHa cells were washed 
with PBS, dissociated from cell culture flasks using TrypLE™ Express (Life Technologies), 
and 1x106 cells were fluorescently labeled with CFSE (Life Technologies) according to the 
manufacturer’s instructions. After staining, 10,000 target cells were co-cultured overnight 
(FaDu, CAL27 and Detroit562 cells) or for 2 h (SiHa cells) at 37 °C with primary human NK 
cells at appropriate effector-to-target (E:T) ratios in NK cell medium without IL-2.  
For blocking experiments, primary human NK cells were pre-incubated for 30 min with anti-
human NKG2D antibodies (MAB139). For NK cell inhibition experiments, primary human 
NK cells were pre-incubated overnight with plasma of HNSCC patients or healthy donors 
before and after depletion of sNKG2D ligands prior to co-culturing with SiHa target cells for 
2 h. At the endpoint of the cytotoxicity assay, NK cells were labeled with anti-human CD45-
APC antibody (clone 5B1). Live/dead cell discrimination was achieved by staining with 
SytoxBlue (Life Technologies). 10,000 events of target cells were analyzed on a FACS Canto 
II instrument (BD Bioscience) equipped with a 96-well plate HTS. The percentage of target 
cell lysis was calculated by gating on target cells (CFSE+) and analysis of SytoxBlue+ and 
SytoxBlue- cells.  
 
2.4.8.2 Cytotoxicity Assay of Tumor Spheroids 
Cytotoxicity experiments in tumor spheroids were performed, as previously described [387]. 
After tumor spheroid formation (2.4.6), FaDu, CAL27, Detroit562 and SiHa tumor spheroids 
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at solid spheroidal state (d0) were co-cultured with primary human NK cells at appropriate 
E:T ratios in NK cell medium without IL-2. For NK cell inhibition experiments, primary hu-
man NK cells were pre-incubated overnight with 10x concentrated non- and sNKG2D ligand-
depleted CAL27 culture supernatant (2.4.5). Cytotoxicity and spheroid destruction was meas-
ured after 24 - 48 h of single tumor spheroids dissociated with TrypLETM Express (Life Tech-
nologies). NK cells in these single-cell suspensions were labeled with anti-human CD45-APC 
antibody. Live/dead cell discrimination was achieved by staining with SytoxBlue (Life Tech-
nologies). The percentage of viable cells was calculated with FlowJo software by evaluation 
of the gates for NK cells (CD45+/SytoxBlue-) and target cells (CFSE+/SytoxBlue-) from com-
plete samples measured on a FACS Canto II instrument (BD Bioscience) equipped with a 96-
well plate HTS.  
 
2.4.8.3 Tumor Spheroid Infiltration and MACS-based NK cell Isolation 
For infiltration studies under inhibitory conditions, NK cells were pre-treated overnight with 
CAL27 supernatant or shed MICA*01 (2.4.4) and seeded with HNSCC or SiHa cells at an 
E:T ratio of 1:1 into 96-well plates coated with 1.5% agarose in medium. For infiltration stud-
ies of NK cell sub-populations, FaDu tumor spheroids were co-cultured with pre-sorted 
(2.4.7) primary human NK cells (CD56bright/CD16dim/- or CD56dim/CD16+ populations) at an 
E:T ratio of 1:1. Tumor spheroid formation was monitored for 48 h by light microscopy. Cry-
osections were stained for cleaved caspase 3 and/or for human CD45 by standard histology 
techniques (2.5.11). The number of infiltrated NK cells was calculated by counting CD45+ 
NK cells of cryosections from single tumor spheroids and by calculating the percentage of 
NK cells from whole cell numbers using ImageJ software.  
Isolation of tumor spheroid infiltrated NK cells was performed after the previously published 
protocol [387]. In brief, tumor spheroids of CFSE-labeled SiHa cells were co-cultured with 
primary human NK cells at an E:T ratio of 3:1 for 24 h. Tumor spheroids were harvested with 
a cut 1000 µl-tip, pooled, and separated from the supernatant containing peripheral NK cells 
by mild centrifugation at 300xg for 10 s. Following two washing steps in 50 ml of FACS 
buffer, tumor spheroids were dissociated by TrypLETM Express-treatment for 5 min. The sin-
gle cell suspension was washed again and subjected to CD45 MACS-bead isolation according 
to the manufacturer’s instructions. Cells from the periphery, MACS flow through and elution 
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fractions were analyzed by flow cytometry. Tumor spheroids without NK cells served as con-
trols and were treated with the same procedure. NK cells were labeled with anti-human 
CD45-APC antibody prior to addition of counting beads to calculate cell numbers according 
to the manufacturer’s instructions. Cell suspensions were analyzed for viable target cells and 
NK cells as described in 2.4.8.2. 
 
2.5 Methods of Protein Biochemistry 
2.5.1 Determination of Protein Concentration 
Protein concentrations were determined using UV absorbance-based quantification at 280 nm 
or fluorometric quantification, depending on the protein characteristics and buffer composi-
tion (i.e. pH, ionic strength and additives). For spectrophotometric quantification, 2 µl of pro-
tein solution were measured at 280 nm on a NanoDrop ND1000 (PeqLab Biotechnology) us-
ing the corresponding buffer solution as blank. For fluorometric quantification, the Qubit 
Protein Assay Kit (Thermo Fisher Scientific) was used according to the manufacture’s instruc-
tions and protein concentration was determined on a corresponding Qubit® Fluorometer 
(Thermo Fisher Scientific). 
 
2.5.2 Protein Purification from Inclusion Bodies or Cell Culture Superna-
tants 
2.5.2.1 IMAC and Refolding of Proteins produced in E. coli 
Proteins produced in E. coli (2.4.1) containing either an N- or C-terminal histidine tag were 
purified via immobilized metal ion affinity chromatography (IMAC) under denaturating con-
ditions. Therefor, bacterial cell pellets were thawed on ice and resuspended in 50 ml of resus-
pension buffer. To isolate inclusion bodies, cells were sonified on ice (duty cycle 90%, output 
control 5, pulse 5x 1 min, 30 s pause) and centrifuged (9000xg, 20 min, 4 °C). The pellet, 
containing the inclusion bodies was resuspended in 100 ml of solubilization buffer and incu-
bated for 1 h at 50 °C while shaking and insoluble fragments were removed by centrifugation 
(9000xg, 20 min, RT). For IMAC purification, the protein solution was supplemented with 
5 mM imidazole and incubated with wash buffer equilibrated Ni-NTA agarose (Macherey-
Nagel) for 1 h at RT on a roller shaker. After incubation, the Ni-NTA slurry was subjected 
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onto an Econo-Pac gravity flow column (Bio-Rad) including a bed support frit (30 µm poly-
ethylene), washed with 5 column volumes (CV) of wash buffer and bound proteins were elut-
ed with 150 ml of elution buffer. Afterwards, the Ni-NTA agarose was regenerated with 5 CV 
of regeneration buffer and 2 CV of Ni2+-solution. The agarose was stored in 20% ethanol at 
4 °C until re-use.  
To initiate refolding of the purified proteins, the solution was incubated with 0.5 mM oxidized 
glutathione (GSSG) and 5 mM reduced glutathione (GSH) overnight at 4 °C under rotation. 
For refolding using dialysis steps against buffers containing descending urea concentrations, 
the protein solution was filled in dialysis membranes with a molecular weight cut-off of 3 -
 4 kDa (Carl Roth) and dialyzed against a 1:100 volume of dialysis buffer I - V. Buffers were 
exchanged every 24 h. In the last step, dialysis buffer V was exchanged through 2 steps of 
dialysis for 12 h in TBS. Refolded proteins were collected and precipitates containing unfold-
ed and aggregated proteins were removed via centrifugation (18000xg, 30 min at 4 °C). Pro-
tein concentration was measured as described (2.5.1). Protein concentration was adjusted to 
1 mg/ml by centrifugal concentration steps (5000xg, at 4 °C) using amicon centrifugal filter 
units (Merck Millipore) with MWCO of 10 kDa.  
The refolded rNKG2D protein containing an Avi-tag was in vitro biotinylated. The protein 
was diluted in biotin assay buffer to a final protein concentration of 40 - 100 µM, incubated 
for 16 h at 27 °C and centrifuged for 5 min at 3200xg and 4 °C. For further purification and 
removal of excess biotin, proteins were subjected to size exclusion chromatography (2.5.3). 
 
2.5.2.2 IMAC of Protein Produced in Mammalian Cell Lines 
Soluble or shed proteins containing an N- or C-terminal histidine tag (2.4.5) were purified 
from mammalian cell culture supernatants using IMAC under native conditions. To ensure 
integrity of the proteins, all steps were carried out at 4 °C with ice-cold buffers. Cell culture 
supernatants were dialyzed for 24 h in dialysis buffer A to remove disturbing medium addi-
tives. Afterwards, the protein solution was supplemented with 5 mM imidazole and Ni-NTA 
agarose and incubated for 1 h at 4 °C. The Ni-NTA slurry was subjected to an Econo-Pac 
gravity flow column (Bio-Rad) including a bed support frit (30 µm polyethylene), washed 
with 5 CV of wash buffer and bound proteins were eluted in elution buffer. Finally, the elution 
buffer was exchanged to TBS or PBS during protein concentration using amicon centrifugal 
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filter units (Merck Millipore) with a molecular weight cut off (MWCO) of 10 kDa (5000xg, 
steps of 10 min, 4 °C). Protein concentration was determined as described in 2.5.1 and pro-
teins were used for flow cytometry and ELISA measurements. For the use of sMICA*04 in 
the in vivo apheresis study (2.6.2), the protein was further subjected to size exclusion chroma-
tography (2.5.3) and tested for endotoxin levels with the Pierce™ LAL Chromogenic Endo-
toxin Quantification Kit and ToxinSensor™ Chromogenic LAL Endotoxin Assay Kit accord-
ing to the manufacturer’s protocols. Additionally, viral contents were excluded using the 
INNOTEST® HIV Antigen mAb ELISA according to the manufacturer’s instructions.  
 
2.5.2.3 Protein A Purification 
All human IgG1-Fc fusion proteins produced in HEK293T/17 cells (2.4.5) were purified from 
cell culture supernatants via rec-Protein A-Sepharose® 4B Conjugate (Thermo Fisher Scien-
tific). Protein A binds with high affinity to the constant human IgG1-Fc-part. All steps were 
performed at 4 °C with ice-cold buffers. In brief, cell culture supernatants were supplemented 
with 20 µl of sepharose slurry per 25 ml of supernatant and incubated for 2 - 4 h at 4 °C on a 
tilt/roller mixer. After collecting the sepharose matrix in an Econo-Pac gravity flow column 
(Bio-Rad) including a bed support frit (30 µm polyethylene), the matrix was washed with 
10 CV of PBS. Bound proteins were eluted from the matrix using 10 ml of elution buffer II. 
Eluates were collected in conical tubes containing 1 ml (1:10 of elution volume) of collection 
buffer for pH neutralization. Protein A-sepharose was regenerated using regeneration buffer 
and stored in PBS containing 0.01% azide at 4 °C. Directly after purification, the buffer was 
exchanged to PBS using amicon centrifugal filter units (Merck Millipore) with a MWCO of 
50 kDa and subsequent centrifugation steps (5000xg, 10 min, 4 °C) following determination 
of protein concentration (2.5.1). 
  
2.5.3 Size Exclusion Chromatography (SEC) 
Size exclusion chromatography was used for further purification of proteins [388]. In this 
thesis, a HiLoad 16/600 Superdex® 200 pg or Superdex® 200 10/300 GL column (fractiona-
tion range: 1x104 - 6x105 kDa) was used for protein fractionation on an Äkta Prime FPLC 
System (all GE Healthcare). For separation of hIgG1-Fc fusion proteins and sMICA from 
mammalian cells SEC was performed in PBS, for proteins produced in E. coli TBS was used. 
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All buffers were prepared at 4 °C and sterile filtered (filter size 0.22 µm). The columns were 
washed and equilibrated with 1.5 CV of deionized water and TBS or PBS, respectively. The 
protein samples were injected into an appropriate sample loop and chromatography was per-
formed with flow rates of 0.3 or 0.5 ml/min. Elution fractions of 1 ml were collected and re-
tention volume (Vr), molecular weight and void volume (V0) determinations form recorded 
UV absorption spectrum at 280 nm were carried out according to the manufacturer’s instruc-
tions using the Gel Filtration LMW Calibration Kit (GE Healthcare) as standard. For long-
term storage, the columns were washed with 1.5 CV of deionized water and stored in 20% 
(v/v) EtOH at 4 °C. 
 
2.5.4 Circular Dichroism (CD) Spectroscopy 
Circular dichroism (CD) spectroscopy is a quick method for analysis of secondary structure 
and protein folding properties based on the differential absorption of circularly polarized light 
by optically active molecules according to the Beer’s law [389]. The change in polarization is 
expressed as degrees of ellipticity θ. Secondary structure motives show characteristic elliptici-
ty patterns. Predominant α-helical proteins have minima of ellipticity at 222 nm and 207 nm 
and a maximum at 192 nm. In contrast, proteins with antiparallel β-sheets have a minimum at 
215 - 220 nm and a maximum at 195 nm. Disordered proteins have very low ellipticity above 
210 nm and negative values near 195 nm. For the CD measurement, refolded rNKG2D-His 
protein was re-buffered in 20 mM sodium phosphate buffer (pH 8) using amicon centrifugal 
filter units with a MWCO of 10 kDA, filtered through a 22 µM filter (Merck Millipore) and 
10 µl of protein solution (2 mg/ml) were mounted into a CaF2 cuvette with a path length of 
50 µm. The far-UV spectra of 10 scans were collected from 180 to 250 nm on a J-720 spec-
trometer (Jasco) with a resolution of 0.1 nm. The sample holder was temperature controlled 
by an external water bath, allowing analyzing protein stability with time at different tempera-
tures. The experiments were kindly performed in the group of W. Mäntele (Institute of Bio-
physics, Goethe-University, Frankfurt am Main, Germany).  
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2.5.5 Immunoprecipitation and ex vivo Depletion of sMICA 
2.5.5.1 Depletion of sNKG2D Ligands using monoclonal Antibodies 
To test the depletion efficacy of monoclonal mouse anti-MICA antibodies (AMO1, BAMO3) 
with different epitopes, 1 µg of the respective antibodies in IP buffer was coupled to 
20 µl/sample Protein A/G PLUS-Agarose beads (Santa Cruz) for 2 h at 4 °C and 5 rpm. After 
three washing steps with PBS-T and subsequent centrifugation (1,000xg, 5 min, 4 °C) the 
antibody-coupled beads were incubated overnight at 4 °C with 5 rpm rotation in either cell 
culture supernatants containing sMICA variants or human plasma supplemented with sMI-
CA*01/sMICA*04 proteins. Beads were removed from supernatants by centrifugation 
(1,000xg, 7 min, 4 °C). Levels of sMICA in non-depleted and depleted supernatants were 
measured by Sandwich ELISA (2.5.9.1). 
In order to deplete sNKG2D ligands from plasma of HNSCC patients, healthy donors or cell 
culture supernatants, Protein A Dynabeads (20 µg/sample; Thermo Scinetific) were pre-coated 
with 3 µg of the respective antibodies (anti-human MICB (MAB1599), anti-human ULBP1 
(MAB1380), anti-human ULBP2 (MAB1298) or anti-human ULBP3 (MAB1517)) in IP buff-
er for 2 h at 4 °C with 5 rpm. Beads were removed and washed three times in PBS-T. Coated 
Dynabeads were resuspended in 20 µl of PBS. Depletion of sMICA was performed using anti-
human MICA (AMO1) covalently coupled to magnetic MACSxpress beads (3 µg AMO1 per 
20 µl beads; especially produced for this project by Miltenyi Biotec). The respective antibody 
coated beads were mixed in equal amounts, transferred to the samples and incubated over-
night at 4 °C with 5 rpm. Magnetic beads containing bound ligands were removed from plas-
ma samples by magnetic separation on a MACSxpress Seperator (Miltenyi Biotec). Residual 
beads were washed three times with 1 ml of PBS-T and bound ligands were eluted either with 
elution buffer I for subsequent immunoblot analysis (2.5.7) of ligands or in elution buffer II 
for ELISA measurements (2.5.9.1). For further use of depleted cell culture supernatants or 
plasma in cytotoxicity assays (2.4.8), a final centrifugation step (1000xg, 10 min, 4 °C) was 
applied to ensure the complete removal of magnetic beads. The levels of NKG2D ligands in 
depleted and non-depleted samples were analyzed by Sandwich ELISA (2.5.9.1).   
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2.5.5.2 Depletion of sNKG2D Ligands using NKG2D Proteins 
In a second approach, the depletion capacity of the pan-specific human NKG2D proteins was 
tested. Therefor, 10 µg of biotinylated NKG2D produced in E. coli (2.4.1) or NKG2D::hIgG1-
Fc-Biotin (2.4.5) were coupled to 20 µl Dynabeads M-280 Streptavidin (Thermo Fisher Sci-
entific) or rNKG2D-His to anti-His Dynabeads, respectively, for 2 h at 4 °C and 5 rpm. For 
the simultaneous depletion of different NKG2D ligands, human plasma samples supplement-
ed with recombinant NKG2D ligands (soluble His-tagged or hIgG1-Fc fusion proteins), pa-
tients’ plasma or cell culture supernatants were used. Immunoprecipitation was performed as 
described earlier (2.5.4.1) and samples were analyzed accordingly.  
 
2.5.5.3 Ex vivo Depletion of sMICA under Apheresis-like Conditions 
For the in vitro depletion of sNKG2D ligands under apheresis-like conditions, an adsorber 
cartridge containing the anti-MICA antibody functionalized sepharose matrix was generated. 
The anti-MICA antibody (AMO1) was covalently coupled to sepharose Cl-4B at 0.95 mg 
AMO1/g sepharose (Miltenyi Biotec). To test the depletion efficacy, 200 ml of human plasma 
(kindly provided by the German Red Cross Blood Service Frankfurt am Main, Germany) was 
supplemented with 100 µg of sMICA*04 (500 ng/ml). The plasma reservoir and the adsorber 
cartridge were connected to an Äkta Prime System (GE Healthcare) and the plasma volume 
was exchanged six times through the cartridge with a flow rate of 25 ml/min. The plasma lev-
els of sMICA, before and after each plasma volume exchange, were analyzed by Sandwich 
ELISA (2.5.9.1). After PBS wash, bound sMICA was eluted from the sepharose matrix with 
elution buffer II and the regenerated cartridge was stored in PBS supplemented with 15% 
EtOH and 0.01% azide at 4 °C. 
  
2.5.6 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
To separate proteins with a molecular mass of 5 to 250 kDa discontinuous SDS-PAGE was 
used at reducing or non-reducing conditions [390]. Protein samples (i.e. IP eluates, 2 µg of 
purified proteins or cell culture supernatants) were mixed with an appropriate amount of ei-
ther reducing or non-reducing 5x SDS sample buffer to a final concentration of 1x SDS sam-
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ple buffer. For analysis of samples at reducing conditions, SDS sample buffers were further 
supplemented with 300 mM DTT and samples were heated for 5 min at 95 °C and centrifuged 
to remove precipitates (20,000xg, 5 min). Polyacrylamide gels were prepared as depicted in 
Table 7 and 20 - 30 µl samples were loaded into the gel together with a PageRuler Protein 
Ladder (Thermo Fisher Scientific) as size standard. The electrophoresis was performed at 
200 V for 45 - 60 min (depending on pore size) in a Mini-PROTEAN II electrophoresis cell 
(BioRad) filled with SDS running buffer.  
For visualization of separated proteins, polyacrylamide gels were stained with InstantBlue 
protein staining solution (Expedeon) for 1 h according to the manufacturer’s protocol. For the 
specific detection of proteins, polyacrylamide gels were further used for immunoblotting 
(2.5.7). 
Table 7: Polyacrylamide gel composition. 
The formulation is for the preparation of 2 polyacrylamide gels (100 x 100 x 1 mm). 
Ingredients 
Resolving Gel 
         12%                      10% 
Stacking Gel 
5% 
30% acrylamide 4.0 ml 3.3 ml 1 ml 
 H2O 3.3 ml 4.0 ml 4.0 ml 
1.5 M Tris pH 8.8 2.5 ml 2.5 ml -- 
1.5 M Tris pH 6.8 -- -- 0.75 ml 
20% SDS 50 µl 50 µl 30 µl 
10% ammonium persulfate (APS) 100 µl 100 µl 60 µl 
 TEMED 4 µl 4 µl 6 µl 
 
2.5.7 Immunoblotting 
For immunodetection, separated proteins were transferred from SDS polyacrylamide gels onto 
a nitrocellulose membrane using a Trans-Blot SD Semi-Dry transfer cell (BioRad) according 
to the manufacturer’s instructions [391]. A stack consisting of transfer buffer pre-soaked blot-
ting paper, nitrocellulose membrane, polyacrylamide gel and blotting paper were prepared on 
the transfer cell and blotted for 15 min at 15 V. After blotting, the membrane was incubated in 
blocking buffer for 30 min at RT following incubation with the appropriate primary antibody 
diluted in blocking buffer for 2 h at RT or overnight at 4 °C. Membranes were washed three 
times in TBS-T for 5 min at RT. For the specific detection of unconjugated primary antibod-
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ies, membranes were further incubated with the appropriate horseradish peroxidase (HRP) 
conjugated secondary antibodies for 2 - 4 h at RT. Membranes were washed again three times 
in TBS-T prior to incubation with Novex ECL HRP-Chemiluminescent detection kit after the 
manufacturer’s protocol. Chemiluminescence signals were detected using Super RX medical 
x-ray film 100NIC (Fuji Film Europe GmbH) on a XR 24 NDT Automatic x-ray Film Proces-
sor (Dürr NDT) or using the Fusion FX7 system (Peqlab). 
 
2.5.8 Peptide Spot Array 
In this study, peptide arrays were used for antibody epitope mapping of the monoclonal anti-
MICA antibodies AMO1 and BAMO3. Therefor, the human MICA sequence (UniProtKB ref. 
no. Q29983; aa23 - aa308; spots: 18 amino acids with off-set by four amino acid) was synthe-
sized on cellulose membranes using Fmoc chemistry at activated PEG spacers by automated 
parallel peptide synthesis on a MultiPep RS instrument (Intavis) [392, 393]. For epitope map-
ping, synthesized membranes were placed in pure ethanol and then rehydrated by stepwise 
substitution with deionized water. Membranes were washed three times in TBS-T for 5 min 
and subsequently incubated for 1 h at RT in spot blocking buffer. Afterwards, antibody incu-
bation (antibodies and dilutions Table 8) and ECL detection were performed as described for 
immunoblotting (2.5.7).  
Membranes were regenerated by three washing steps of 10 min in regeneration buffer A, fol-
lowing three washing steps for 10 min in regeneration buffer B and a final flush in pure etha-
nol. After complete drying, the membranes were stored at -20 °C and reused after rehydration. 
Table 8: Antibodies and dilutions for Peptide Spot Arrays. 
All antibodies were diluted in spot buffer. 
Antibody concentration/dilution 
anti-MICA (AMO1) 5 µg/ml 
anti-MICA/B (BAMO3) 5 µg/ml 
anti-mouse IgG, HRP conjugated  (for detection) 1:20,000 
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2.5.9 Enzyme Linked Immunosorbent Assay (ELISA) 
2.5.9.1 Sandwich ELISA for Detection of individual sNKG2D Ligands 
To analyze the levels of sNKG2D ligands in the plasma of HNSCC patients and healthy do-
nors, samples were diluted 1:2 for analysis and measured in duplicates. To analyze shedding 
of NKG2D ligands, supernatants of 96 solid tumor spheroids or monolayer cultures were col-
lected at different time points within 72 h (d0, d1, d2) and concentrated 10-fold using amicon 
centrifugal filter units with a molecular weight cut-off of 10 kDa (Merck Millipore).  
Soluble MICA was analyzed as described [296] with slight modifications. Soluble MICB, 
ULBP1, ULBP2 and ULBP3 were detected with a similar protocol [256, 298, 394]. All anti-
body combinations and protein standards for the detection of the respective NKG2D ligands 
are listed in Table 9. Briefly, 96 well MICROLON600 plates (Greiner Bio-One) were coated 
with 100 µl/well of the respective capture antibody diluted in PBS overnight at 4 °C. After 
saturation with 200 µl/well of BSA blocking solution (Candor) for 1 h at RT, the plates were 
washed three times with 200 µl/well of PBS-T. For sampling, 100 µl/well of the respective 
plasma diluted 1:2 in 1% BSA-PBS or cell culture supernatants and standard proteins were 
incubated for 2 h at 37 °C following three washing steps with PBS-T. For detection and quan-
tification of soluble ligands, 100 µl/well of sandwich antibodies were incubated for additional 
2 h at 37 °C following subsequent washing steps and incubation with 100 µl/well of respec-
tive detection antibodies for 1 h at 37 °C. After plate washing, visualization was performed 
with 100 µl/well of TMB substrate (KPL) and 50 µl/well of 1 N H2SO4 and signals were 
measured in a microtiter plate reader (Anthos) at λ = 450 nm (reference filter 650 nm) and 
analyzed with Prism 6 software (GraphPad). Data for tumor spheroids or monolayer cultures 
were calculated as mean ± SEM per 10.000 cells (per spheroid) of three independent experi-
ments (n = 3), measured in duplicates. Data for plasma levels were calculated as mean ± SEM 
of duplicates. 
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Table 9: Antibodies and standard proteins for respective NKG2D ligand ELISA. 
Standard 1:2 dilution series (8 dilutions starting at 20 ng/ml) were used. All Fc fusion proteins were 
purchased from R&D Systems, sMICA*04 was produced as described in 2.4.5. Capture antibodies 
were diluted in PBS, all other reagents in 1% BSA-PBS. 
NKG2D ligand 
standard 
protein 
capture  
antibody 
sandwich 
antibody 
detection antibody 
MICA sMICA*04 
AMO1 
[5 µg/ml] 
BAMO3 
[1 µg/ml] 
anti-mouse IgG2a-HRP 
1:10,000 
MICB MICB-Fc 
BAMO1 
[2 µg/ml] 
BMO2 
[1 µg/ml] 
ULBP1 ULBP1-Fc 
AUMO5 
[2 µg/ml] 
AUMO2 
[4 µg/ml] 
ULBP2 ULBP2-Fc 
BUMO1 
[2 µg/ml] 
MAB1298 
[1 µg/ml] 
ULBP3 ULBP3-Fc 
AF1517 
[2 µg/ml] 
CUMO3 
[2 µg/ml] 
anti-mouse IgG1-HRP 
1:10,000 
 
2.5.9.2 Determination of Binding Affinities for NKG2D Proteins 
Binding affinities of NKG2D proteins to the individual NKG2D ligands were determined by 
ELISA. Therefor, 96 well MICROCOLON600 plates (Greiner Bio-One) were coated over-
night at 4 °C with sMICA*01/04, MICA*01/04::hIgG1-Fc (2.4.4) or the hIgG1-Fc fusion 
proteins of MICB and ULBP1-3 (R&D Systems) at 10 µg/ml in PBS with 100 µl/well. The 
plates were blocked with 200 µl/well of BSA Blocking Solution (Candor) for 1 h at RT and 
washed three times with 200 µl/well of PBS-T. Plates were incubated for 1 h at RT with serial 
dilutions strating from 2 nM of either rNKG2D-His, rNKG2D-Biotin or NKG2D::hIgG1-
FcEQ proteins in PBS. After three washing steps with 200 µl/well of PBS-T, NKG2D proteins 
were detected using anti-His-HRP, Streptavidin-HRP or anti-humanIgG-Fc-HRP, respectively, 
for 1 h at RT. Plates were washed again three times and incubated with 100 µl/well of TMB 
substrate (KPL) followed by 50 µl/well of 1 N H2SO4. Signals were measured at 450 nm with 
a microtiterplate reader. Data were represented as mean ± SEM of duplicates. 
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2.5.9.3 Detection of Rhesus Monkey anti-MICA IgG and IgM Antibodies 
For the analysis of anti-MICA rhesus macaque IgG/IgM antibodies MICROCOLON600 
plates (Greiner Bio-One) were coated with 10 µg/ml of sMICA*04 in PBS overnight and 
blocked for 1 h at RT with 200 µl/well of BSA blocking solution (Candor). After three wash-
ing steps with 200 µl/well of PBS-T, plates were incubated with rhesus macaque plasma (pri-
or and three weeks after sMICA*04 injection) in different dilutions (1:2; 1:10; 1:50; 1:100; 
1:500; 1:1000 in PBS). After three washing steps with PBS-T, bound antibodies were detected 
with either anti-monkey-IgG or anti-monkey-IgM HRP-conjugated antibodies for 1 h at RT. 
Plates were washed again three times and incubated with 100 µl/well of TMB substrate (KPL) 
followed by 50 µl/well of 1 N H2SO4. Signals were measured at 450 nm with a microtiter 
plate reader. Data were represented as mean ± SEM of duplicates. 
 
2.5.10 Cytometric Bead Array (CBA) 
The cytometric bead array (CBA) is a highly sensitive flow cytometry-based assay to quantify 
various soluble factors in low amounts of human plasma or culture supernatants. The concen-
trations of IFNγ, TNFα, IL-1, IL-6, IL-8, IL-10, MCP-1, RANTES, MIP-1α, MIP-1β and 
TGF-β1 in plasma of HNSCC patients and healthy donors were determined using the BDTM 
CBA Flex Set System (BD Bioscience). Each BDTM CBA Flex Set contained a one-bead pop-
ulation with distinct fluorescence intensity and the appropriate phycoerythrin (PE) detection 
reagent and standard. The tests were performed according to the manufacturer’s instructions 
and samples were diluted 1:30 for TGF-β1 Flex set or 1:4 for all other Flex sets and measured 
in duplicates. Samples were measured with the BD FACS ArrayTM (BD Bioscience) and ana-
lyzed with FCAP Array Software (BD Bioscience). Cytokine levels of HNSCC patient sam-
ples were normalized to healthy controls and data are represented as x-times median control. 
CBA measurements were kindly performed by P. Schön in the group of R. Schubert (Division 
of Allergology, Pneumology and Cystic Fibrosis, Department of Children and Adolscents, 
University Hospital Frankfurt, Goethe-University, Frankfurt am Main, Germany).  
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2.5.11 Immunohistochemistry 
Individual spheroids (n > 8) were collected and embedded into OCT compound (Sakura). 
Cryosections (7 µm) of solid tumor spheroids were analyzed by standard two-step polymer 
methods with Envision kits (DAKO). 3,3'-Diaminobenzidine (DAB) and Permanent Red or 3-
Amino-9-Ethylcarbazol (AEC) were used as chromogen. Tumor spheroid cryosections were 
stained with anti-human cleaved caspase 3 and anti-human CD45 diluted in Ab-Diluent 
(Dako). For counterstaining, Mayer’s Hematoxylin (Lillie’s Modification) (DAKO) was used 
according to the manufacturer’s instructions. Immunohistological stainings were kindly per-
formed by A. Giannattasio in the lab of J. Koch (Georg-Speyer-Haus, Frankfurt am Main, 
Germany). 
Paraffin-embedded primary tumor tissues were stained with anti-human CD3 (1:50 in citrate 
buffer pH 6), anti-human CD8 (1:200 in citrate buffer pH 6), anti-human CD20 (1:250 in cit-
rate buffer pH 6) and anti-human CD56 (1:500 in citrate buffer pH 6) antibodies (2.1.3) for 
the lymphocyte markers as well as anti-human CD68 (1:400 in 1 mM EDTA pH 8) and anti-
human CD163 (1:100 in 1 mM EDTA pH 8) antibodies for the macrophage markers using the 
BOND-MAX automated IHC-stainer (Leica Biosystems) according to the manufacturer’s 
instructions. For evaluation of the HPV status, tumor tissues were stained with anti-human 
p16 antibodies (CINtec® p16 Histology kit) and HPV type 16-DNA was detected via PCR. 
Immunohistochemical stainings were kindly performed in the group of A. Quaas (Institute of 
Pathology, University of Cologne, Cologne, Germany). 
 
2.6 In vivo Experiments and primary human Samples 
2.6.1 HNSCC Patients and healthy Volunteer Samples 
Plasma samples from 39 male and 5 female HNSCC patients (Department of Otorhinolaryn-
gology, Head and Neck Surgery, University of Cologne, Medical Faculty, Cologne, Germany) 
were analyzed (2.5.9.1) and used for experiments in this thesis. Patients’ age ranged from 39 
to 88 years with most patients in their 60 - 80s. HNSCC patient demographics and tumor 
characteristics are summarized in Table 10. Tumor staging was assigned according to the 
TNM classification of the International Union Against Cancer. A random patient cohort was 
included in this study with treatment naïve patients at initial diagnosis, recurrent disease and 
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patients under palliative treatment at time of sample collection. Sample collection of HNSCC 
patients (blood samples and paraffin sections of primary tumors) was in accordance and ap-
proved by the Ethics Committee of the University Clinic Cologne (Immuncan study 11-116, 
2011). Plasma samples of 12 age-matched healthy volunteers (mean age: 55 years) were used 
with informed consent. 
 
2.6.2 Adsorption Apheresis in an in vivo Rhesus Macaque Model 
Three male rhesus macaque animals (age 6 years) from the German Primate Center breeding 
colony (German Primate Center, Göttingen) were used for the in vivo experiments with the 
approval by the Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicher-
heit (33.19-42502-04-14/1715). All experimental and medical procedures were done under 
narcosis initiated with ketamine, (Dex-) medetomidine, Robinul and during the experimental 
procedures with isoflurane for inhalation anesthesia with 1 l O2/min. The blood volume was 
calculated in ml as 7% of total body weight in kg according to the GV-SOLAS table. For cal-
culation of the plasma volume the individual hematocrit of the animals was used. For the pilot 
study and apheresis experiments, the animals were intravenously (i.v.) injected with 100 µg of 
sMICA*04 (2.5.2.2) per liter of blood volume. In the pilot study the body distribution and 
renal clearance of the administered sMICA*04 was determined. Three animals were moni-
tored over three to six hours and 1 ml blood samples were taken from a catheter in the vena 
saphena every 15 min. Moreover, urine samples were taken from a bladder catheter. Three 
weeks after the experiment, blood samples were taken for the detection of anti-MICA monkey 
IgG/IgM antibodies (2.5.8.4).  
For the apheresis experiment, two animals were connected to a Life18™ apheresis unit 
equipped with an anti-MICA adsorber cartridge (anti-MICA antibody covalently coupled to 
sepharose Cl-4B at 0.95 mg AMO1/g sepharose) via a double lumen catheter in the vena 
femoralis. During the experiment, animals got heparin (50 U/kg) i.v. injection as anticoagu-
lant. Apheresis was started 15 min post-injection of sMICA*04 with a flow-rate of 25 -
 30 ml/min over a time period of 90/120 min (until three complete plasma volume exchanges 
through the apheresis unit were reached). Blood samples were taken every 15 min during the 
apheresis. The sMICA*04 plasma and urine levels of all samples were determined by Sand-
wich ELISA (2.5.8.1).  
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3 Results 
The NKG2D/NKG2D ligand system is important for tumor immunosurveillance by NK cells 
and other NKG2D+ cytotoxic lymphocytes. Therefore, the aim of the current study was the 
characterization of a NKG2D-dependent tumor immune escape in head and neck squamous 
cell carcinoma and the establishment of an adsorption apheresis for depletion of soluble 
NKG2D ligands from patients’ plasma. For this purpose, primary samples of HNSCC patients 
were analyzed for sNKG2D ligand levels showing a correlation with disease progression as 
well as NK cell inhibition. Moreover, multicellular tumor spheroids were used to determine 
the impact of sNKG2D ligands on NK cell cytotoxicity and infiltration. As proof of concept, 
an adsorption apheresis based on monoclonal anti-MICA antibodies was established and fur-
ther, a pan-specific approach for the simultaneous depletion of all sNKG2D ligands was de-
veloped using NKG2D fusion proteins. The successful depletion of sNKG2D ligands in vitro 
could be validated in a pre-clinical study using a rhesus macaque model. The generation of 
recombinant protein variants of sMICA and the NKG2D receptor ectodomain is described in 
detail in “Cloning Strategies” (2.3.7) and not further mentioned in the “Results” section (pro-
tein sequences depicted in 5.2). Parts of this thesis are published in Giannattasio et al. 2015 
and Weil et al. (submitted). 
 
3.1 The NKG2D/NKG2D ligand system in HNSCC 
3.1.1 HNSCC Patients have elevated sNKG2D Ligand Plasma Levels 
Previous studies revealed an NKG2D-dependent tumor immune escape mechanism in various 
types of cancers mediated by proteolytical shedding of NKG2D ligands [256, 303, 305, 318]. 
Recently, elevated sMICA plasma levels were correlated to disease progression and NK cell 
dysfunction in HNSCC [304, 320, 321]. Although many studies investigated tumor escape 
from immunosurveillance by NKG2D-expressing cells in different tumor entities, little is 
known about the impact of all sNKG2D ligands and their cumulative role as diagnostic and/or 
prognostic marker in cancer progression. This is partly due to the lack of reliable commercial-
ly available assays for the detection of ligands in plasma samples and the high polymorphism 
and heterogeneous expression of the different ligands [395]. To identify the levels of the shed 
NKG2D ligands sMICA, sMICB and sULBP1-3, the plasma of 44 HNSCC patients was ana-
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lyzed. A random patient cohort was included in the study with primary neoplasms mainly in 
the oral cavity (22.7%), oropharynx (20.5%), hypopharynx (27.3%) and larynx (15.9%). Sev-
enty-seven percent of patients were diagnosed with primary tumors compared to 23% with 
recurrent disease. The majority of patients was diagnosed with stage IVA HNSCC (43.2%), 
while the other patients were classified as stage I (6.8%), stage II (9.1%), stage III (15.9%), 
stage IVB (4.5%) and stage IVC (13.6%) exhibiting distant metastases. Four patients (9.1%) 
were tested positive for human papillomavirus infection. Whereas 68% of patients were 
treatment naïve at the time of sample collection, 32% got standard treatment with most of the 
patients in palliative radio- or chemotherapy. Case history and patients’ characteristics are 
summarized in Table 10. 
Table 10. Clinical parameters and frequencies of HNSCC patients. 
n.d. = not defined; T = primary tumor size, N = spread to regional lymph nodes, M = distant metasta-
sis, RTx = radiotherapy, CTx = chemotherapy, RCTx = radio-chemotherapy, HPV = human papilloma-
virus 
Parameter 
Absolute 
numbers and 
frequency (%) 
Parameter 
Absolute  
numbers and 
frequency (%) 
Parameter 
Absolute 
numbers and 
frequency (%) 
Parameter 
Absolute 
numbers and 
frequency (%) 
Age 
(Ø 65 years)  
TNM 
classification  
Status  HPV status  
20 - 40 1 (2.3) T  primary 34 (77.3) positive 4 (9.1) 
40 - 60 15 (34.1) 1 5 (11.4) relapse 10 (22.7) negative 34 (77.3) 
60 - 80 24 (54.5) 2 8 (18.2) Disease stage   n.d. 6 (13.6) 
> 80 4 (9.1) 3 9 (20.5) I 3 (6.8) 
  
Sex   3 - 4 / 4 17 (38.6) II 4 (9.1) 
male 39 (88.6) n.d. 5 (11.4) III 7 (15.9) 
female 5 (11.4) N  IVA 19 (43.2) 
Therapy  0 16 (36.4) IVB 2 (4.5) 
no therapy 30 (68.2) 1 6 (13.6) IVC 6 (13.6) 
post surgery 2 (4.5) 2 1 (2.3) other 3 (6.8) 
post surgery 
and RCTx 
2 (4.5) 2b 9 (20.5) Localization   
palliative 
RTx/CTx 
10 (22.7) 2c 7 (15.9) Oral cavity 10 (22.7) 
Noxa   3 3 (6.8) Oropharynx 9 (20.5) 
none 11 (25.0) n.d. 2 (4.5) Hypopharynx 12 (27.3) 
Smoking 16 (36.4) M  Larynx 7 (15.9) 
Alcohol  1 (2.3) 0 38 (86.4) 
Larynx/ 
Hypopharynx 
3 (6.8) 
Smoking and 
alcohol 
16 (36.4) 1 6 (13.6) other 3 (6.8) 
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For the determination of sNKG2D ligand levels, different commercially available ELISA kits 
were tested for the detection of the sNKG2D ligands sMICA/B and sULBP1-3 in plasma. 
Whereas most of the ELISA kits provided reproducible results analyzing ligand levels in cell 
culture supernatants, high detection variances could be seen especially for the sULBPs in hu-
man plasma (data not shown). Therefore, sandwich ELISAs using ligand-specific antibody 
pairs were optimized for the stable and reproducible detection in human plasma after previ-
ously published protocols [256, 296, 298, 394]. For reference, plasma of 12 age-matched 
healthy volunteers (mean age 55 years) was analyzed and the plasma levels of HNSCC pa-
tients were correlated (Figure 5). 
Figure 5: Elevated sNKG2D ligand plasma levels in HNSCC patients. 
Quantification of the sNKG2D ligands sMICA, sMICB and sULBP1-3 in HNSCC patients’ plasma 
(n = 44) compared to age-matched healthy plasma (n = 12) by respective Sandwich ELISAs. Each dot 
represents one plasma sample as mean of duplicates. Statistical significance was determined by Stu-
dent’s t-test for p < 0.05. ** p < 0.005, *** p < 0.0001. 
 
Compared to healthy donors, significantly elevated levels of all sNKG2D ligands were detect-
ed in patients’ plasma. Interestingly, levels of sMICA (0.899 ± 0.130 ng/ml vs. 
0.175 ± 0.054 ng/ml), sMICB (0.365 ± 0.041 ng/ml vs. 0.144 ± 0.069 ng/ml) and sULBP2 
(0.778 ± 0.113 ng/ml vs. 0.186 ± 0.059 ng/ml) showed a 2.5 - 5-fold increase compared to 
healthy plasma, whereas the most prominent sNKG2D ligands in HNSCC were sULBP1 
(2.500 ± 0.454 ng/ml vs. 0.112 ± 0.076 ng/ml) and sULBP3 (1.750 ± 0.379 ng/ml vs. 
0.025 ± 0.011 ng/ml) with over 20-fold increase (Figure 5). Importantly, sNKG2D ligand 
plasma levels showed high patient-to-patient variation suggesting that the composition and 
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total level of sNKG2D ligands represents an important patient-specific clinical parameter 
(Figure S1). 
 
3.1.2 sNKG2D Ligand Levels correlate with HNSCC Disease Staging  
To further elucidate the role of NKG2D ligand release in the course of disease, the total bur-
den of sNKG2D ligands was correlated with relapsed or primary tumor diagnosis as well as 
tumor staging (Figure 6).  
 
Figure 6: sNKG2D ligand plasma levels correlate with HNSCC disease stage. 
(A/B) Cumulative sNKG2DL levels (sum of sMICA/B, sULBP1-3) grouped according to primary vs. 
relapsed tumors or disease stage (early = stage I+II; advanced = III+IV). (C) sMICA/B, sULBP1-3 
plasma levels grouped according to disease stage (early = stage I+II; advanced = III+IV). Data are 
presented as mean ± SEM of representative experiments. Analysis of significance was performed by 
one-way ANOVA. * p = 0.01 - 0.05, ** p = 0.001 - 0.01, *** p < 0.001. 
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Whereas no significant alterations in sNKG2D ligand levels between patients with primary 
and relapsed tumors (Figure 6A) could be detected, sNKG2D ligands were found to peak in 
the plasma of patients with advanced disease (stage III+IV; Figure 6B). This stage dependen-
cy was also seen for the individual sNKG2D ligands, which increased until the pre-metastatic 
stage III (Figure 6C). The further subdivision of treatment naïve patients at initial diagnosis or 
recurrent disease confirmed that patients with relapsed disease and in advanced stages showed 
overall high sNKG2D ligand levels (Figure 7). In contrast, patients with relapsed disease cur-
rently under palliative chemo- or radiotherapy had lower sNKG2D levels. Interestingly, pa-
tients after tumor resection without indication of disease had sNKG2D levels similiar to those 
of patients at early disease stage with low tumor burden.  
 
Figure 7: Impact of therapeutic treatment on sNKG2D ligand levels.  
Comparison of sNKG2D ligand levels of treatment naïve patients, patients under treatment at time of 
plasma sample collection and healthy controls. Treatment naïve patients were grouped according to 
early and advanced disease at initial diagnosis and recurrent disease (relapse). Patients with treatment 
were grouped according to palliative therapy (radio- and/or chemotherapy) in comparison to patients 
after tumor resection without indication of tumor burden. Statistical significance was analyzed using 
one-way ANOVA, * p < 0.05, ** p < 0.005, *** p < 0.001. 
 
These results are in accordance with the studies of Tamaki et al. [304] and Kloess et al. [320] 
analyzing sMICA, showing that NKG2D-depenent tumor immune escape is not an early event 
during tumor formation but rather is correlated to the tumor burden and disease progression. 
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Furthermore, radio- and chemotherapy might show a beneficial effect but could not lead to 
total clearance of sNKG2D ligands or tumor burden. Moreover, patients without primary tu-
mor had in fact lower sNKG2D ligand levels, but tumor resection did not lead to a complete 
decrease comparable to ligand levels of healthy patients. This might be due to additional fac-
tors favoring expression and release of sNKG2D ligands like cytokine release and cellular 
stress induced by the treatments. 
 
3.1.3 Immunosuppressive Cytokines contribute to HNSCC Immune Es-
cape 
HNSCC is characterized as a highly heterogeneous cancer including different neoplasms with 
a highly immunosuppressive tumor microenvironment [396, 397]. Beside cancer cells them-
selves, which promote an inflammatory milieu by production of proinflammatory and/or im-
munosuppressive factors (e.g. TGF-1, IL-6, IL-8, IL-10, IL-1β, MCP-1, TNF-), also tumor-
residing immune cells, like tumor-associated macrophages (TAMs) and myeloid-derived sup-
pressor cells (MDSCs), directly contribute to tumor growth, angiogenesis and invasion [398]. 
Moreover, immunosuppressive factors impair the antitumor functions of cytotoxic T and NK 
cells [281, 399]. To further understand the mechanism of tumor immune escape in HNSCC 
patients, plasma levels of the cytokines TGF-1, IL-6, IL-8, IL-10, IL-1β, IFN-, TNF- and 
the chemokines MIP-1, MIP-1, RANTES and MCP-1 were analyzed using cytometric bead 
array (CBA). Compared to healthy controls, markedly elevated levels could be detected for 
TGF-1 (3890 ± 289.8 pg/ml vs. 187.8 ± 106.9 pg/ml), MIP-1 (1112.4 ± 21.95 pg/ml vs. 
5.15 ± 2.43 pg/ml), RANTES (23720 ± 2683 pg/ml vs. 2204 ± 218.6 pg/ml), IL-8 
(286.6 ± 126.4 pg/ml vs. 10.38 ± 0.99 pg/ml), MCP-1 (208.5 ± 29.86 pg/ml vs. 
65.62 ± 6.95 pg/ml), and IL-6 (34.45 ± 4.91 pg/ml vs. 12.15 ± 1.02 pg/ml). Interestingly, 
plasma of HNSCC patients showed no significant differences in the levels of IFN-, TNF-, 
IL-10, IL-1β and MIP-1 when compared to healthy controls (Figure 8A). Notably, a high 
variability in plasma levels between patients could be seen (Figure 8B). Due to the heteroge-
neity the expression patterns of most of the cytokines and chemokines could not be directly 
correlated to disease progression or therapeutic treatment. Moreover, no correlation of the 
individual immune factors and sNKG2D ligand release could be seen. 
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Figure 8: Elevated immunosuppressive factors in HNSCC patients.  
Patients’ plasma was analyzed for the levels of the cytokines TGF-β1, IL-6, IL-8, IL-10, IL-1β, IFN-γ, 
TNF-α and chemokines MIP-1α, MIP-1β, RANTES and MCP-1 by cytometric bead array (CBA). (A) 
Quantification of chemokine and cytokine levels compared to healthy controls. Each dot represents 
one plasma sample as mean of duplicates. Statistical significance was determined by Student’s t-test 
for p < 0.05, **** p < 0.0001. (B) Heat-map representation of sNKG2DL levels (see also Figure 5), 
cytokine and chemokine levels as x-times median control (CO; of 12 healthy donors) grouped accord-
ing to disease stage (I - IVC). Color code: yellow = normal; orange = elevated; and red = highly ele-
vated.   
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Interestingly, TGF-1 plasma levels were highly upregulated throughout all patients analyzed 
and showed an increase during advanced disease from 2677 pg/ml to 5358 pg/ml between 
disease stage I - IV (Figure 9A).  In contrast, no differences between primary and relapsed 
tumors could be observed (Figure 9B).  
Figure 9: TGF-1 plasma levels correlate with disease progression. 
TGF-1 plasma levels of HNSCC patients and healthy volunteers determined by cytometric bead ar-
ray (CBA) were grouped according to (A) disease stage (early = stage I+II; advanced = III+IV) and 
(B) primary vs. relapsed tumor and compared to healthy controls. Statistical significance was deter-
mined by one-way ANOVA. *** p < 0.001, **** p < 0.0001 
 
These data demonstrate the high complexity of the immune system and tumor microenviron-
ment. The aberrant cytokine and chemokine levels, especially regarding TGF-1, are indica-
tive for an imbalanced immune system and thus impaired tumor surveillance. Due to the indi-
vidual immune status of the patients no comprehensive correlations of individual soluble 
factors to disease progression or direct contribution to NKG2D-dependent tumor immune 
escape could be seen for the patient cohort analyzed.  
 
3.1.4 Inhibition of NK Cell Cytotoxicity by sNKG2D Ligands in HNSCC Pa-
tients’ Plasma 
NKG2D ligand expression on tumor cells leads to NKG2D engagement and subsequent NK 
cell activation. In contrast, binding of shed NKG2D ligands inhibits NKG2D and thus aug-
ments tumor escape from immunosurveillance by NKG2D-expressing cells [315, 400]. In 
order to investigate the inhibitory potential of sNKG2D ligands in the plasma of HNSCC pa-
tients, flow cytometry-based cytotoxicity assays were performed using IL-2 activated primary 
human NK cells after pre-incubation with plasma from HNSCC patients, healthy donors or 
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anti-NKG2D blocking antibodies (gating strategy Figure S2). As target cells, the human cer-
vix squamous cell carcinoma cell line (SiHa) was used whose killing is strongly dependent on 
NKG2D as shown by blocking experiments with anti-NKG2D antibodies (see Figure 18). For 
the relative quantification of tumor cell lysis, the mean lysis of NK cells pre-incubated with 
different healthy donor plasma was used for normalization of NK cell lysis with HNSCC 
plasma or blocking antibody incubation. 
 
Figure 10: sNKG2D ligand-dependent inhibition of NK cell cytotoxicity.  
(A) Cytotoxicity assay of NK cells with CFSE-labeled target cells (E:T = 15:1; 2 h). NK cells were 
pre-incubated overnight with HNSCC plasma prior to the assay. NK cells pre-incubated with healthy 
plasma (CO) or NKG2D blocking antibodies (B) served as controls. Target cell lysis was calculated by 
flow cytometry and analysis of dead (CFSE+/SytoxBlue+) and viable (CFSE+/SytoxBlue-) cells. Data 
were normalized to CO (mean of six samples) and are represented as mean ± SEM of triplicates of an 
independent experiment. (B) Lysis of target cells (see A) grouped according to sNKG2DL (+ low = 0 -
 2.5 ng/ml and +++ high > 2.5 ng/ml) and TGF-β1 (+ low = 0 - 3000 pg/ml and ++ high > 3000 pg/ml) 
plasma levels. Statistical significance was analyzed using one-way ANOVA. ns = non-significant for 
p > 0.05, * p = 0.01 - 0.05, ** p = 0.001 - 0.01, *** p < 0.001 and **** p < 0.0001. 
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Most of the HNSCC plasma samples significantly inhibited target cell killing compared to 
plasma of age-matched healthy donors (Figure 10A). Incubation with NKG2D blocking anti-
bodies showed the high degree of NKG2D-dependent tumor cell lysis. To further elucidate the 
impact of NKG2D-depedent NK cell inhibition in HNSCC plasma, tumor cell lysis was corre-
lated to plasma contents. Since patients’ plasma contained high levels of TGF-β1, which is 
known to contribute to NKG2D downregulation [295, 401], the lytic capacity of NK cells pre-
incubated with patients’ plasma was correlated to the plasma levels of sNKG2D ligands and 
TGF-β1. Patients’ plasma containing high levels of both, sNKG2D ligands (> 2.5 ng/ml; me-
dian: 7.6 ng/ml) and TGF-β1 (> 3000 pg/ml; median: 5319 pg/ml) showed lower NK cell cy-
totoxicity when compared to patients’ plasma with low sNKG2D ligands (< 2.5 ng/ml; medi-
an: 1.4 ng/ml) and TGF-β1 (< 3000 pg/ml; median: 2045 pg/ml) levels (Figure 10B). 
Interestingly, sNKG2D ligands and TGF-β1 had an additive effect on NK cell inhibition com-
pared to plasma containing only high amounts of only one factor.   
Human plasma is a complex protein mixture containing various soluble factors, which could 
contribute to impaired NK cell function. To verify the impact of the sNKG2D ligands in pa-
tients’ plasma on NK cell cytotoxicity, sNKG2D ligands were removed by selective depletion 
of sMICA, sMICB, sULBP1, sULBP2 and sULBP3 with a cocktail of anti-NKG2D ligand 
antibody-coupled beads. The depletion efficiencies were verified by ELISA and ranged be-
tween 61.9% and 93.2% for the cumulative ligand plasma levels (Figure 11A). To ensure no 
disturbing effects on cytotoxicity assays due to bead incubation and removal of other soluble 
factors or residual antibodies, healthy plasma samples were incubated with antibody-coupled 
beads as controls. Cytotoxicity assays with depleted and non-depleted plasma showed that the 
removal of sNKG2D ligands from patients’ plasma efficiently restored NK cell cytotoxicity 
compared to healthy plasma controls (Figure 11B), whereas depletion of healthy plasma con-
taining no/low levels of sNKG2D ligands had no effect on NK cell cytotoxicity. Collectively, 
these in vitro experiments demonstrate that the sole depletion of sNKG2D ligands was suffi-
cient to restore NK cell cytotoxicity, assuming shedding of ligands as a key mechanism of 
NKG2D-dependent tumor immune escape. 
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Figure 11: Restoration of NK cell cytotoxicity by sNKG2D ligand depletion. 
(A) NKG2D ligands were depleted from patients’ plasma using antibody-coupled magnetic beads. 
Depletion of healthy plasma served as control. Plasma levels pre-/post depletion were determined by 
respective NKG2D ligand ELISAs and are depicted as sum of sNKG2D ligands of individual patients 
presented as mean ± SEM of duplicates. (B) NK cells were incubated overnight with patients’ plasma 
(PS; high sNKG2DL levels) or sNKG2D ligand-depleted plasma (PS depleted) prior to cytotoxicity 
assays. NK cells incubated with healthy/healthy-depleted plasma (CO) served as controls. Data were 
normalized to CO and are presented as mean ± SEM, measured in triplicates of an independent exper-
iment. Statistical significance was analyzed using one-way ANOVA. ns = non-significant for p > 0.05, 
* p = 0.01 - 0.05, ** p = 0.001 - 0.01, *** p < 0.001 and **** p < 0.0001. 
 
To further verify the direct effect of the soluble ligands on NKG2D-dependent NK cell cyto-
toxicity, the NKG2D expression levels on plasma-treated NK cells were analyzed by flow 
cytometry. Compared to the expression levels of NK cells treated with healthy plasma, a re-
duction of NKG2D expression was observed for patients’ plasma-treated NK cells or NK cells 
incubated with anti-NKG2D blocking antibodies (Figure 12). Moreover, the degree of 
NKG2D downregulation was correlated with the amount of sNKG2D ligands in the plasma as 
shown exemplarily for two plasma samples (patient 13a and 43, see Figure 11A and 12B). In 
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contrast, NKG2D expression on NK cells incubated with NKG2D ligand-depleted plasma was 
not reduced.  
 
Figure 12: NKG2D-dependent NK cell inhibition in HNSCC plasma.  
(A) Flow cytometric analysis of NKG2D surface expression on primary human NK cells treated with 
HNSCC plasma or healthy plasma samples pre-/or post sNKG2D ligand depletion. Grey = healthy 
control plasma, red = as indicated: NKG2D blocking antibody, patient plasma or depleted pa-
tient/healthy plasma. One representative experiment of three is shown. (B) NKG2D surface expression 
on NK cells treated with non-depleted or sNKG2D ligand-depleted healthy plasma (CO), patient 
plasma (PS) or NKG2D blocking antibody (B). Data are represented as MFI ratio normalized to 
healthy plasma (CO) as mean ± SEM of duplicates of a representative experiment. Statistical signifi-
cance was analyzed by Student’s t-test with * p < 0.05, **** p < 0.0001. 
 
In these studies, a direct correlation of the cumulative sNKG2D ligands in HNSCC patients’ 
plasma to impaired antitumor NK cell function due to NKG2D receptor blocking and down-
regulation upon sNKG2D ligand engagement could be shown. Moreover, NK cell cytotoxic 
activity could be efficiently restored by sNKG2D ligand depletion. 
 
3.1.5 sNKG2D Ligand and TGF-β1 Plasma Levels correlate with Tumor 
Burden 
In a single case study of one representative patient, plasma samples were taken directly before 
and after surgery of the primary tumor. Determination of sNKG2D ligand and TGF-β1 levels 
showed reduced load of soluble molecules after surgery (Figure 13A). As expected, incuba-
tion of primary NK cells with plasma containing lower levels of sNKG2D ligands showed a 
higher cytotoxic activity compared to the plasma sample with higher sNKG2D ligand titers 
(Figure 13C). Furthermore, a patient with high sNKG2D ligand and TGF-β1 levels at initial 
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diagnosis had reduced but reappearing levels of sNKG2D ligands and TGF-β1 with relapsed 
disease after tumor resection and palliative chemotherapy (Figure 13B/D).  
 
Figure 13: sNKG2D ligands and TGF-1 plasma level correlate with tumor burden. 
(A/B) Individual and cumulative plasma levels of sNKG2D ligands and TGF-1 analyzed by ELISA 
or CBA of one representative patient pre- and post surgery (A) and one patient at initial diagnosis and 
after relapse diagnosis after chemotherapy (post CT) (B) presented as mean ± SEM of duplicates. 
(C/D) NK cell cytotoxicity against SiHa target cells measured by flow cytometry of NK cells pre-
treated with HNSCC plasma pre- and post-surgery (C) or at initial and relapse diagnosis (D). Data was 
normalized to healthy control (CO) and bars correspond to mean ± SEM of triplicates. Statistical sig-
nificance was analyzed using one-way ANOVA. ns = non-significant for p > 0.05, * p < 0.05, 
** p = 0.005, *** p = 0.0001 and **** p < 0.0001. 
 
These findings demonstrate a direct link between tumor burden, NKG2D ligand shedding and 
TGF-β1 release in HNSCC and confirm the importance of the cumulative sNKG2D ligand 
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levels as a diagnostic and/or prognostic marker for tumor immune escape from NK cell im-
munosurveillance. 
 
3.1.6 Low Lymphocyte Infiltration in primary HNSCC Tumors 
The tumor microenvironment (TME) is a highly dynamic network of tumor cells and non-
malignant cells, which can comprise 50% of the primary tumor mass [402]. Tumor infiltrating 
lymphocytes (TILs) including cytotoxic CD8+ T cells, CD4+ T helper cells, B cells and NK 
cells are frequently found in tumors mediating tumor immunogenicity, as well as tumor asso-
ciated macrophages (TAMs), which can either have pro- or antitumor functions [398, 403]. 
Moreover, NK cell antitumor activity can coincide with their tumor infiltrating potential 
which is associated with a better prognosis in several cancer entities such as colorectal cancer, 
non-small cell lung cancer, and clear cell renal cell carcinoma [404-406]. To evaluate lym-
phocyte infiltration, primary tumor sections of eleven HNSCC patients were stained accord-
ing to the expression markers for CD20+ B cells, CD3+ T cells, CD8+ cytotoxic T cells and 
CD56+ NK cells (and NKT cells). Additionally, TAMs were stained for the linage marker 
CD68, recognizing activated and resting macrophages, and the M2 phenotype-specific mac-
rophage marker CD163 (Figure 14A). The primary tumor samples were randomly selected 
including different epithelial origins, tumor stages and HPV status. Infiltrating cells were ana-
lyzed separately for the invasive margin (IM) or tumor core (TC) by counting the cells in high 
power fields (HPF) of the tumor samples (Figure 14B). In all tumor samples, moderate T cell 
numbers were found in the invasive margin (CD3+ T cells: mean 71 cells/HPF; CD8+ T cells: 
mean 50 cells/HPF). In contrast, only a small number of lymphocytes could infiltrate into the 
tumor core (CD3+ T cells: mean 17 cells/HPF; CD8+ T cells: mean 20 cells/HPF). The cyto-
toxic CD8+ T cells showed a similar distribution as the whole CD3+ T cell population, with 
only weak infiltration into the tumor core. Whereas high numbers of CD20+ B cells (CD20+ B 
cells: 200 cells/HPF) were located in the invasive margin, very low B cells infiltrated into the 
tumor core (CD20+ B cells: 4 cells/HPF). Interestingly, only very low numbers or a complete 
absence of NK cells could be found in the tumor tissues (IM/TC: mean 2 cells/HPF). Moreo-
ver, TAMs could be found throughout the tissue showing an equal distribution between the 
invasive margin and tumor core without correlation to the lymphocyte infiltration potential. 
Interestingly, most TAMs were of the M2 phenotype, which is characterized by its pro-
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tumoral functions. The low infiltration potential of the different lymphocyte populations and 
the presence of M2 macrophages are indicative for the insufficient tumor rejection and immu-
nosuppressive TME of primary tumors in HNSCC patients.  
  
Figure 14: Low lymphocyte infiltration in primary HNSCC tumors.  
Paraffin sections of primary tumors were stained for CD3+, CD8+, CD20+ and CD56+ lymphocytes or 
CD68+/CD163+ macrophages. (A) Consecutive sections of a representative patient are shown at 200x 
magnification. Dotted line represents the border between tumor core (TC) and invasive margin (IM). 
(B) Number of infiltrated lymphocytes and macrophages quantified by counting infiltrating cells in the 
tumor core (TC) and invasive margin (IM) in high power fields (HPF) of the tumor slides. Total cell 
numbers/HPF of 11 patients are plotted with mean ± SEM.  
 
For further analysis, HNSCC patients’ peripheral blood mononuclear cells (PBMCs) and cor-
responding dissociated tumor samples were subjected to flow cytometry experiments. Analy-
sis of the CD45+ lymphocyte population showed that the total number of circulating CD3+ T 
cells was unaltered compared to the lymphocytes of healthy controls (Figure 15A). No chang-
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es in the ratio of CD4+ and the CD8+ T cell subpopulations could be detected within the CD3+ 
T cells. Analysis of the tumor infiltrating cells confirmed the data from immunohistochemical 
stainings showing that roughly 60% of the CD45+ TILs correspond to T cell populations. In-
terestingly, the CD4+/CD8+ ratio in the tumor samples correlated with the ratio of the circulat-
ing T cells in the blood. Moreover, as expected CD4+ T cells showed low NKG2D surface 
expression compared to the CD8+ cytotoxic T cells (Figure 15B).  
 
Figure 15: Analysis of T cells in PBMCs and tumor samples of HNSCC patients.  
(A) Flow cytometric analysis of CD3+ T cells and T cell subpopulations (CD4+ T-helper cells and 
CD8+ cytotoxic T cells) of patients’ PBMCs and corresponding tumor tissues. Healthy PBMCs served 
as control. CD3+ T cell numbers were calculated and plotted as % of CD45+ lymphocytes and subpop-
ulations as % of CD3+ cells (n = 9 patients; n = 4 healthy controls). (B) Corresponding NKG2D ex-
pression levels of T cell subpopulations plotted as MFI over background with mean ± SEM (n = 9 
patients; n = 4 healthy controls). Statistical significance was analyzed using one-way ANOVA, 
ns = non-significant for p > 0.05, ** p = 0.001 - 0.01, *** p < 0.001. 
 
Compared to healthy controls, only a 0.5-fold increase in NKG2D expression levels could be 
observed for the CD8+ cytotoxic T cells. Furthermore, NK cell subpopulations within the 
PBMCs and tumor samples of the HNSCC patients were analyzed. The total number of circu-
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lating NK cells in the CD45+ lymphocyte population of PBMCs was nearly unchanged com-
pared to healthy controls (Figure 16A). 
 
Figure 16: Analysis of NK cells in PBMCs and tumor samples of HNSCC patients.  
(A) Flow cytometric analysis of NK cells and NK cell subpopulations (regulatory: CD56bright/CD16+/- 
and cytotoxic: CD56dim/CD16+ NK cells) of patients’ PBMCs and corresponding tumor tissues. 
Healthy PBMCs served as control. NK cell numbers were calculated and plotted as % of CD45+ lym-
phocytes (n = 9 patients; n = 4 healthy controls). (B) Corresponding NKG2D expression levels of NK 
cell subpopulations plotted as MFI over background with mean ± SEM (n = 9 patients; n = 4 healthy 
controls). Statistical significance was analyzed using one-way ANOVA, ns = non-significant for 
p > 0.05, * p = 0.01 - 0.05, ** p = 0.001 - 0.01, *** p < 0.001 and **** p < 0.0001. 
 
Regarding regulatory (CD56bright/CD16+/-) and cytotoxic (CD56dim/CD16+) NK cell subpopu-
lations, HNSCC patients showed a slight shift towards regulatory NK cells. Analysis of tumor 
samples confirmed the histological staining showing that only a minor proportion of TILs 
were NK cells. Interestingly, the infiltrating NK cells were predominantly from the regulatory 
subpopulation, whereas cytotoxic NK cells were nearly absent. Moreover, analysis of NKG2D 
expression levels showed a small increase of 0.7 to 1.4-fold for the CD56bright cells and one-
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fold for the CD56dim population compared to healthy controls (Figure 16B). Taken together, 
immunohistochemical and flow cytometry analysis revealed an impaired immune response of 
NK cells and partly T cell subpopulations in the tumor tissue of HNSCC patients. 
 
3.2 Tumor Spheroids as in vivo-like Model System 
3.2.1 Characterization of Tumor Spheroids to study NK Cell Functions 
In order to further elucidate NKG2D-dependent tumor immune escape, 3D multicellular tu-
mor spheroids, which resemble many features of in vivo tumors and allow for systematic stud-
ies of molecular parameters in a highly controlled microenvironment, were used [387]. Tumor 
spheroid cultures possess a complex network of cell-cell contacts as well as pH, oxygen, met-
abolic and proliferative gradients analogous to the conditions found in poorly vascularized 
and avascular regions of solid tumors and micrometastases (Figure 17A) [407-410].  
 
Figure 17: Establishment of tumor spheroids.  
(A) Schematic representation of the microarchitecture of tumor spheroids, avascular tumor microre-
gions and developing micrometastases (based on Friedrich et al. [411]) highlighting the pathophysio-
logical similarities and differences. (B) Representative tumor spheroids derived from 2x103 cells are 
shown in an agarose-coated 96-well plate and by transmission microscopy at 50x magnification. 
 
Single tumor spheroids are formed by aggregation of several thousand cells [407, 409] on 
agarose-coated 96-well plates (Figure 17B) and are consequently comprised of an outer re-
Results 92 
  
 
gion of proliferating cells around a layer of quiescent cells and, if the tumor spheroid is large 
enough, a necrotic core [410].  
Tumor spheroids were grown from the primary tumor-derived HNSCC cell lines FaDu, 
CAL27 and Detroit562 of different epithelial origins and the cervical carcinoma cell line 
SiHa. NK cell killing showed a large degree of NKG2D-dependency as shown in cytotoxicity 
assays with primary human NK cells at different effector-to-target (E:T) ratios in the absence 
and presence of NKG2D-specific blocking antibodies. NKG2D blocking led to 50.4% and 
41.9% inhibition of NK cells’ cytotoxicity towards FaDu and Detroit562 cells, respectively 
(Figure 18). In contrast, NKG2D-mediated killing of CAL27 cells only accounts for 24.7%, 
whereas the cervical carcinoma cell line SiHa showed 71.2% NKG2D-dependency.  
Figure 18: NKG2D-dependent NK cell cytotoxicity of tumor cell lines. 
CFSE-labeled FaDu, CAL27, Detroit562 or SiHa cells were co-cultured with primary human NK cells 
overnight (4 h for SiHa cells) in different E:T ratios and analyzed by flow cytometry. To analyze 
NKG2D-dependent killing, NK cells were pre-incubated with anti-NKG2D blocking antibodies. Tar-
get cell lysis was calculated by gating on dead CFSE+/SytoxBlue+ or viable CFSE+/SytoxBlue- cells. 
Data are shown as mean ± SEM of triplicates of a representative experiment. Statistical significance 
was analyzed using one-way ANOVA with: * p < 0.05, ** p = 0.005, *** p = 0.0001 and 
**** p < 0.0001. 
 
Mature tumor spheroids formed within 24 - 48 h (d0) after seeding into agarose-coated 96-
well plates. Microscopic analyses revealed that tumor spheroids retained a spherical shape in 
solid state and were stable for roughly two to four days with minor compaction due to cellular 
rearrangement (Figure 19). Below a radius of 200 µm, the critical distance of free diffusion of 
nutrients, oxygen and metabolic waste products, tumor spheroids remained solid without 
signs of unwanted central necrosis. Thus, tumor spheroids are not loose or unsystematic cell 
aggregates, but preserve a complex and structured cellular network. To establish cytotoxicity 
assays with primary human NK cells, tumor cells were stained with CFSE prior to tumor 
spheroid formation for easy detection with flow cytometric-based assays. Moreover, the use 
Results 93 
  
 
of a 96-well plate format allowed for screening of individual tumor spheroids and was appli-
cable for high throughput screening. 
 
Figure 19: Growth kinetics of tumor spheroids. 
FaDu, CAL27, Detroit562 and SiHa tumor spheroids were monitored for three days after reaching the 
solid spheroidical state by phase contrast microscopy at 50x magnification. Representative phase con-
trast pictures are shown. Size bar corresponds to 100 µm. Tumor spheroid volume (in mm3) was calcu-
lated based on area determination using Fiji software of individual spheroids from six independent 
experiments. 
 
Tumor spheroid destruction was studied during co-culture with primary human NK cells at 
different E:T ratios for 48 h. The quantification by flow cytometry based on the loss of CFSE-
labeled target cells revealed that 69% of FaDu, 64% of CAL27, 69% of Detroit562 and 79% 
of SiHa cells were efficiently killed at an E:T ratio of 20:1 (Figure 20). Thereby, tumor sphe-
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roids showed an E:T dependent destruction by NK cells. Notably, they are more resistant to 
NK cell cytotoxicity due to their 3D architecture than corresponding monolayer cultures. 
Therefore, tumor spheroids resemble a versatile in vivo-like 3D model to study the antitumor 
functions of cytotoxic lymphocytes in high throughput screening and were further used to 
determine the influence of NKG2D-dependent tumor immune escape. 
 
Figure 20: NK cell cytotoxicity against tumor spheroids.  
CFSE-labeled FaDu, CAL27, Detroit562 and SiHa tumor spheroids were co-cultured with NK cells at 
different E:T ratios for 48 h. Tumor spheroid destruction was quantified by flow cytometry and eval-
uation of viable (CFSE+/SytoxBlue-) and dead target (CFSE+/SytoxBlue+) cells. Data are presented as 
percentage viable target cells with mean ± SEM of 8 individual tumor spheroids of a representative 
experiment. 
 
3.2.2 HNSCC Tumor Spheroids show a characteristic Signature of shed 
NKG2D Ligands 
HNSCC and SiHa cell lines showed a defined surface expression pattern of the NKG2D lig-
ands MICA, MICB and ULBP2/3 (Figure 21 and Table 11). Moreover, HNSCC cell lines 
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generated from primary tumors are usually low for ULBP1 due to loss of ULBP1 expression 
during cell line generation [412]. The differences of NKG2D ligand expression of primary 
tumor cells and cell lines can be explained by differential transcriptional regulation of the in-
dividual ligands mediated by environmental factors. 
 
Figure 21: NKG2D ligand surface expression on tumor cell lines. 
Surface expression of NKG2D ligands (MICA, MICB, ULBP1-3) on FaDu, CAL27, Detroit562 and 
SiHa tumor cells analyzed by flow cytometry. Grey = isotype control, red = NKG2DL antibody. One 
representative experiment of four is shown.  
 
The expression of the individual NKG2D ligands were compared and summarized as expres-
sion patterns for each cell line in Table 11. 
Table 11: NKG2D ligand expression patterns on cell lines.  
Expression calculated from median fluorescence intensities (MFI) presented as +/- = no/weak, 
+ = weak, ++ = moderate and +++ = high expression (n = 8).  
Cell line MICA MICB ULBP1 ULBP2 ULBP3 
FaDu +++ ++ +/- ++ + 
CAL27 ++ + + +++ +/- 
Detroit562 ++ + +/- ++ + 
SiHa +++ + + +++ +++ 
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In order to investigate NKG2D ligand shedding in HNSCC tumor spheroids, supernatants 
were probed for the levels of sMICA, sMICB, sULBP1, sULBP2 and sULBP3 over three 
days (d0, d1, d2) by respective ELISAs. Due to continuous shedding, soluble NKG2D ligands 
accumulated in the supernatant of FaDu, CAL27, Detroit562 and SiHa tumor spheroids reach-
ing saturation after three days of culture (Figure 22).  
Figure 22: Tumor spheroids continuously shed NKG2D ligands.  
Kinetics of sNKG2D ligand release analyzed in FaDu, CAL27, Detroit562 and SiHa tumor spheroids. 
Supernatants of tumor spheroids were collected on three consecutive days (d0-d2) and concentrated 
10-fold. sMICA, sMICB and sULBP1-3 concentrations were analyzed by respective ELISAs and data 
are shown as mean ± SEM in pg/ml/104 cells of three independent experiments, measured in dupli-
cates. 
 
The predominant ligands shed into the supernatant of tumor spheroids grown from these cell 
lines within two days were sMICA (FaDu: 1.3 ± 0.3 pg/ml per 104 cells; CAL27: 
1.2 ± 0.8 pg/ml per 104 cells; Detroit562: 1.7 ± 0.4 pg/ml per 104 cells; SiHa: 4.3 ± 1.8 pg/ml 
per 104 cells), sMICB (FaDu: 20.7 ± 6.2 pg/ml per 104 cells; CAL27: 8.1 ± 2.2 pg/ml 
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per 104 cells; Detroit562: 7.7 ± 0.5 pg/ml per 104 cells; SiHa: 4.3 ± 1.8 pg/ml per 104 cells) 
and sULBP2 (FaDu: 22.2 ± 1.4 pg/ml per 104 cells; CAL27: 25.2 ± 3.1 pg/ml per 104 cells; 
Detroit562: 11.8 ± 3.7 pg/ml per 104 cells; SiHa: 16.9 ± 0.4 pg/ml per 104 cells). Notably, 
sULBP3 and sULBP1 were low or close to the detection limit of the assay with sULBP3 
mainly found in supernatants of CAL27 and SiHa tumor spheroids (CAL27: 2.7 ± 1.6 pg/ml 
per 104 cells; SiHa: 2.0 ± 0.9 pg/ml per 104 cells). Interestingly, the kinetics of soluble 
NKG2D ligand release into the supernatant parallels the expression level and loss of MICA/B, 
and ULBP2/3 from the cell surface. Moreover, sNKG2D ligands accumulate in the superna-
tant after 48 h. Theses data demonstrate a continuous ligand shedding by tumor cells itself 
with a rapid reproduction and accumulation of sNKG2D ligands as it is seen in cancer pa-
tients.  
 
3.2.3 sNKG2D Ligands diminish NK Cell Cytotoxicity towards Tumor 
Spheroids 
To investigate the impact of sNKG2D ligands on NK cell cytotoxicity towards tumor sphe-
roids, solid tumor spheroids were co-cultured with primary human NK cells pre-incubated 
with CAL27 cell culture supernatant (CAL27 SN) containing high sNKG2D ligand levels 
(27.63 ng/ml), or sNKG2D ligand-depleted CAL27 supernatant (sNKG2D ligands: 
2.66 ng/ml; Figure 23B). NK cells pre-incubated in basal culture medium served as controls. 
NK cell cytotoxicity towards individual tumor spheroids was analyzed after 48 h co-
incubation by flow cytometry based on the loss of CFSE-labeled target cells. In the absence of 
sNKG2D ligands (kill CO), NK cells efficiently destroyed tumor spheroids with 59%, 58% 
and 43% lysis of FaDu, CAL27 and SiHa tumor spheroids, respectively (Figure 23A). By 
contrast, in the presence of shed NKG2D ligands (CAL27-SN), NK cell killing was strongly 
inhibited by 25% for FaDu and 46% for SiHa tumor spheroids demonstrating the large degree 
of NKG2D-dependency on NK cell killing as shown earlier with blocking antibodies in single 
cell cytotoxicity experiments. Moreover, 19% NKG2D ligand-dependent inhibition of tumor 
spheroid destruction could be seen for CAL27 cells, which are less susceptible to NKG2D-
dependent killing. Importantly, impaired tumor spheroid destruction could be restored by spe-
cific depletion of sNKG2D ligands (SN depleted) from cell culture supernatant (Figure 
23A/B). Again, sNKG2D ligand-dependent inhibition of NK cells’ cytotoxic function was 
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correlated with NKG2D inhibition and downregulation (Figure 23C). Thus, the inhibitory 
potential of sNKG2D ligands in HNSCC plasma and their role in tumor recognition and elim-
ination could be verified under in vivo-like conditions in the tumor spheroid model. 
 
Figure 23: NK cell cytotoxicity towards tumor spheroids is inhibited by sNKG2D ligands. 
(A) Primary human NK cells pre-incubated overnight with CAL27 SN, NKG2D ligand-depleted SN or 
medium (kill CO) prior to co-incubation with CFSE-labeled tumor spheroids for 48 h. FaDu, CAL27 
or SiHa tumor spheroid lysis measured by flow cytometric analysis of live (CFSE+/SytoxBlue-) and 
dead (CFSE+/SytoxBlue+) tumor cells (see also Figure S3). Bars correspond to mean ± SEM of 8 tu-
mor spheroids of a representative experiment. (B) sNKG2D ligand levels of non-/ and sNKG2D lig-
and-depleted CAL27 supernatant analyzed by ELISAs. Data are shown as mean ± SEM of duplicates 
of a representative experiment. Statistical significance was analyzed using one-way ANOVA with: 
ns = non-significant for p > 0.05, * p < 0.05, ** p = 0.005, *** p = 0.0001 and **** p < 0.0001. (C) 
Flow cytometric analysis of NKG2D surface expression on primary human NK cells after incubation 
with CAL27 SN or sNKG2D ligand-depleted SN. Data are represented as MFI ratio normalized to kill 
CO as mean ± SEM of duplicates of a representative experiment. Statistical significance was analyzed 
by Student’s t-test for p < 0.05. 
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3.2.4 sNKG2D Ligands impair NK Cell Infiltration in Tumor Spheroids 
NK cell infiltration is a prerequisite for NK cell function and tumor immunosurveillance 
[413]. Strikingly, NK cell infiltration into primary HNSCC tumor tissues was nearly absent as 
shown by imunohistochemical stainings for CD56+ cells. Up to now, many studies extensively 
investigated NK cell cytotoxicity in well-established functional assays, whereas little is 
known about NK cell infiltration due to the lack of appropriate model systems for solid tu-
mors. In this study, in vivo-like tumor spheroids were used as 3D model system for the long-
term analysis of tumor immunosurveillance and immune cell infiltration. For infiltration stud-
ies, primary human NK cells were mixed with tumor cells at a low E:T ratio of 1:1, to reduce 
tumor spheroid destruction and allow for the analysis of infiltrated NK cells, and seeded into 
1.5% agarose-coated 96-well plates. NKG2D-dependent cytotoxicity was inhibited by NK 
cell pre-incubation overnight with a cocktail of shed NKG2D ligands (CAL27 SN) or purified 
sMICA (20 ng/ml). Tumor spheroid integrity was monitored by light microscopy for 48 h. 
During co-incubation, NK cells proliferated and accumulated in the periphery of the tumor 
spheroids as seen in phase contrast pictures. At endpoint of analyses, cryosections of tumor 
spheroids were stained with CD45-specific antibodies for the detection of infiltrated NK cells 
(Figure 24A and Figure S4A/B). In the absence of sNKG2D ligands (Kill CO), NK cell kill-
ing was accompanied by massive infiltration into HNSCC and SiHa spheroids. Roughly 66%, 
38% and 65% of the cells comprising the FaDu, CAL27 or SiHa tumor spheroids, respective-
ly, were NK cells (Figure 24C). In contrast, NK cell infiltration was strongly inhibited in the 
presence of a cocktail of different sNKG2D ligands or sMICA. Here, only 38%, 21% and 
29% of the cells comprising the FaDu, CAL27 or SiHa tumor spheroids, respectively, were 
NK cells (Figure 24B). Interestingly, the same amount of sMICA alone was sufficient for NK 
cell inhibition when compared to the cocktail of all shed ligands in the CAL27 supernatant. 
These data support the finding, that the total burden of sNKG2D ligands is crucial for NK cell 
dysfunction in cancer patients. Furthermore, staining of tumor spheroid cryosections for apop-
tosis induction (anti-cleaved caspase-3 antibodies) demonstrated the degree of tumor cell lysis 
and moreover, that infiltrated, pre-treated NK cells were often double positive for CD45 and 
cleaved caspase-3 compared to untreated NK cells. Thus, NK cells might show an exhausted 
phenotype and therefore proliferate less and become apoptotic under inhibitory conditions. 
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Figure 24: NK cell infiltration into tumor spheroids is inhibited by sNKG2D ligands. 
NK cells pre-treated overnight with CAL27 SN, sMICA01 or untreated (kill CO) prior to co-culturing 
with FaDu, CAL27 or SiHa cells for 48 h (see also Figure S4). (A) Representative phase contrast pic-
tures of FaDu tumor spheroids at 50x magnification after 48 h are shown. Cryosections of spheroids 
were stained for NK cells (anti-CD45 antibody, red) and apoptosis (anti-active caspase-3 antibody, 
brown). Representative histology pictures are shown at 200x magnification. Size bar corresponds to 
200 µm. (B) Percentage of infiltrated NK cells in FaDu, CAL27 or SiHa tumor spheroids quantified in 
10 vision fields of cryosections under 200x magnification with ImageJ. Bars correspond to 
mean ± SEM of 10 vision fields counted individually and significance compared to CO was deter-
mined by Student’s t-test. ** p = 0.005, *** p = 0.0001 and **** p < 0.0001. 
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NK cells can be divided into two major sub-populations based on the relative expression of 
the markers CD16 and CD56. Whereas the CD56dim/CD16+ population is the pre-dominant 
population in peripheral blood and is characterized by its cytotoxic function, 
CD56bright/CD16dim/- NK cells are abundant cytokine producers and have an immunoregulatory 
role [414]. To further identify the infiltrated NK cells, expanded primary human NK cells 
were sorted for the cytotoxic (CD56dim/CD16+) and regulatory (CD56bright/CD16dim/-) popula-
tions. FaDu tumor spheroids were incubated for 48 h with either NK cell population at an E:T 
ratio of 1:1 for infiltration studies. Cryosections stained with CD45-specific antibodies re-
vealed, that both populations infiltrated tumor spheroids to the same extend (Figure 25). Thus, 
indicating that not only cytotoxic NK cells play a role in tumor elimination, but also regulato-
ry NK cells are needed for effective tumor immunosurveillance. 
 
Figure 25: Cytotoxic and regulatory NK cells infiltrate tumor spheroids. 
FaDu tumor spheroids were co-cultured with sorted pNK cells (cytotoxic CD56dim/CD16+ and regula-
tory CD56bright/CD16dim/-). Cryosections of tumor spheroids were stained for NK cell infiltration (anti-
CD45 antibody, red) and representative pictures are shown under 200x (top row) and 400x (bottom 
row) magnification. Size bar correspond to 200 µm and 100 µm, respectively. 
 
The presented infiltration studies demonstrated a direct correlation of NK cell cytotoxicity 
and infiltration for successful elimination of in vivo-like solid tumor spheroids. Moreover, 
tumor spheroid assays revealed for the first time an NKG2D-dependent inhibition of NK cell 
infiltration capacity. Thus, sNKG2D ligands impair NK cell functions not only on the cytotox-
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ic level, but also facilitate tumor escape due to the failure to infiltrate tumors. Further studies 
are needed to characterize phenotypic differences of infiltrating and non-infiltrating peripheral 
NK cell sub-populations. In this context, a MACS-based (magnetic activated cell sorting) 
protocol for the isolation and quantification of tumor spheroid infiltrated NK cells was estab-
lished, which allows for phenotypic analysis of the different NK cell subpopulations in future 
studies (see 5.1.4, Figure S5) [387].  
 
3.3 Adsorption Apheresis to deplete sNKG2D Ligands 
The analysis of HNSCC plasma suggests that the cumulative plasma level of all sNKG2D 
ligands is indicative for the extent of NKG2D-dependent tumor immune escape in HNSCC. 
Importantly, the specific depletion of sNKG2D ligands from HNSCC patients’ plasma or cell 
culture supernatant could efficiently restore NK cell functions. Consequently, plasma deple-
tion of sNKG2D ligands might be a clinical intervention strategy to significantly boost anti-
tumor efficacy of NKG2D+ cytotoxic lymphocytes. Moreover, combining cellular therapies 
with adsorption apheresis of sNKG2D ligands could not only be beneficial for autologous, but 
also for adoptively transferred immune cells after haploidentical stem cell transplantation. For 
this purpose, an adsorption apheresis procedure based on a bioreactive surface was developed 
for a new collaborative medical approach prior to cell-based therapies to improve the clinical 
outcome for cancer patients. 
 
3.3.1 Monoclonal Antibodies to deplete sMICA 
For a proof of concept study, monoclonal anti-MICA antibodies, raised by immunizing 
BALB/c mice with a mixture of MICA*01 and MICA*04 [296], were screened for their suit-
ability to generate a biofunctionalized surface for the depletion of sMICA from human plas-
ma. The MICA-specific antibody clone AMO1 and the MICA/B-specific antibody clone 
BAMO3, which were used in sandwich ELISA for sMICA detection, were further character-
ized. The antibody epitopes were determined using MICA peptide spot arrays (Figure 26B/D; 
see 5.1.6). The AMO1 antibody specifically recognizes an epitope (NKTWDRET) in the α1-
helical domain of MICA (Figure 26A/B), which is conserved throughout different allelic vari-
ants (see 5.1.9.1). In contrast, the BAMO3 antibody binds to an epitope (RICQGEEQRF) in 
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the α3-helical domain of MICA (Figure 26C/D), which is also present in the α3-helical do-
main of MICB (see 5.1.9.2). 
 
Figure 26: Epitope mapping of anti-MICA monoclonal antibodies.  
(A/C) Crystal structure of the unbound sMICA ectodomain (blue) containing the amino acids 23 - 297 
and the epitope of the (A) anti-MICA antibody (AMO1) in the α1-helical domain (NKTWDRET; red) 
and (C) the anti-MICA antibody (BAMO3) in the α3-helical domain (RICQGEEQRF; red); PDB 
1HYR. (B/D) Peptide spot arrays (18mer peptides; off-set of 4 amino acids) of the human MICA were 
incubated with the anti-MICA antibodies and detected with an anti-mouse IgG HRP-conjugated anti-
body. The signals of spots (B) A11-A16 mark the epitope region in the α1-helical domain and (D) 
B25-B27 the epitope region in the α3-helical domain. Corresponding sequences of the spots are de-
picted; overlapping amino acids are marked in red. Complete spot sequences are depicted in 5.1.6, 
antibody control in Figure S10. 
 
To test the depletion capacity of the monoclonal antibodies, either cell culture supernatant 
containing recombinant soluble MICA*01 and MICA*04 allelic variants or human plasma 
supplemented with sMICA*01/04 (production and purification of sMICA variants Figure S7) 
were incubated with antibody-coupled sepharose beads over night. Analysis of sMICA levels 
pre- and post-depletion showed efficient removal of sMICA from cell culture supernatant for 
both anti-MICA antibodies, whereas beads coupled to a mouse IgG antibody control had no 
effect (Figure 27). Unexpectedly, efficient depletion of sMICA from human plasma could 
only be achieved for the antibody with the epitope in the α1-helical domain (Figure 27A). In 
contrast, the antibody directed against the α3-helical domain could not mediate sMICA deple-
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tion. This failure was also seen for monoclonal antibodies raised against a specific peptide 
within the α3-helical domain of MICA (data not shown). Thus, the α3-helical domain of 
sMICA might possess a binding site for an additional factor in human plasma leading to the 
blocking of the antibody epitope. This hypothesis is supported by the existence of an interac-
tion site of the disulphide isomerase ERp5 needed for MICA proteolysis, which is also located 
in the α3-helical domain between the two cysteins (C225 and C282) [299]. Since plasma is a 
highly complex protein mixture, the identification of an interfering factor was not further ad-
dressed in this study.  
 
Figure 27: Depletion capacity of anti-MICA monoclonal antibodies. 
Human plasma or cell culture medium supplemented with recombinant sMICA*01 or sMICA*04 
(20 ng/ml) was incubated overnight with beads coupled to anti-MICA antibodies binding in the (A) 
α1-helical domain (AMO1) or (B) α3-helical domain (BAMO3). Beads with mouse IgG1 antibody 
served as control (CO). sMICA levels were measured by ELISA and normalized to the initial sMICA 
concentration. Data are represented as mean ± SEM of duplicates of a representative experiment. Sta-
tistical significance compared to CO was determined by Student’s t-test. ns = non-significant for 
p > 0.05, *** p < 0.001 and **** p < 0.0001. 
 
For further evaluation, the monoclonal antibody against sMICA with the epitope in the α1-
helical domain was covalently coupled to magnetic beads. To test the depletion efficacy of the 
anti-MICA antibody beads, human plasma of 20 different healthy donors was supplemented 
with recombinant sMICA*04. In vitro depletion experiments with the antibody-coupled beads 
showed a depletion efficiency of 97% for sMICA from human plasma independent of the do-
nor immune status or plasma contents (Figure 28A). Since MICA is a highly polymorphic 
NKG2D ligand with over 70 known allelic variants and the allelic identity of sMICA in pa-
tients’ serum is unknown, next the recognition and depletion capacity of the anti-MICA anti-
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body against sMICA allelic variants frequently found in the Caucasian population [249] was 
determined. Therefor, C1R cells transfected with the single MICA allelic variants MICA*01, 
MICA*04, MICA*07 and MICA*08 (see 5.1.9.1 alignment of MICA allelic variants) were 
used and MICA shedding/release was induced by serum starvation.  
 
Figure 28: sMICA depletion by adsorption apheresis using an anti-MICA antibody.  
 (A) Depletion of sMICA*04 (20 ng/ml) from human plasma (20 healthy donors) with AMO1 anti-
body-coupled beads overnight. Soluble MICA*04 plasma levels pre- (initial) and post-depletion (1 -
 20) were measured by ELISA and normalized to the initial sMICA*04 level. Data represented as 
mean ± SEM of duplicates of a representative experiment. (B) Depletion of sMICA allelic variants 
(sMICA*01, sMICA*04, sMICA*07 and sMICA*08) from C1R supernatants with AMO1 antibody-
coupled beads overnight. Beads with mouse IgG1 antibody served as control (CO). sMICA levels were 
measured by ELISA and normalized to the initial sMICA levels. Data are represented as mean ± SEM 
of two experiments measured in duplicates. Statistical significance compared to CO was determined 
by Student’s t-test; **** p < 0.0001. (C) Flow cytometric analyses of AMO1 antibody binding to C1R 
cell transfectants expressing sMICA allelic variants (sMICA*01, sMICA*04, sMICA*07 and sMI-
CA*08) or C1R mock transfected (neo) cells. The antibody was directly conjugated to APC. 
Grey = isotype control; red = AMO1 antibody. 
 
Staining of the different C1R cell clones with the antibody showed comparable surface ex-
pression of the MICA allelic variants (Figure 28C). The in vitro depletion of the cell superna-
tants containing the distinct sMICA allelic variants demonstrated a high depletion capacity of 
89% for all sMICAs tested (Figure 28B). Moreover, these data show, that beside soluble 
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NKG2D ligands also exosomes containing NKG2D ligands (MICA*08) could be efficiently 
removed. 
In a next step, the anti-MICA antibody was covalently coupled to a sepharose matrix to gen-
erate an adsorber cartridge for sMICA apheresis. In an ex vivo apheresis-like experiment the 
cartridge containing the antibody-functionalized sepharose was coupled to a pumping-system 
(Äkta Prime System) and depletion efficacy was evaluated using a 200 ml human plasma res-
ervoir supplemented with sMICA*04 (Figure 29A). The residual sMICA*04 plasma levels 
were determined by ELISA after each plasma volume exchange through the adsorber car-
tridge with a flow rate of 25 ml/min. Efficient removal of sMICA from human plasma could 
be achieved after one volume exchange with 50% residual sMICA compared to the initial 
plasma level (Figure 29B). Moreover, after several rounds of plasma exchange 90% of sMI-
CA*04 could be removed. 
 
Figure 29: Ex vivo depletion of sMICA*04 from human plasma using an adsorber cartridge. 
(A) Schematic overview of the ex vivo sMICA depletion from human plasma under apheresis-like 
conditions using an Äkta Prime System with an adsorber cartridge containing the anti-MICA antibody 
covalently coupled to a sepharose matrix. (B) Human plasma (200 ml from a healthy volunteer) was 
supplemented with sMICA*04 (20 ng/ml) and the plasma was run through the adsorber cartridge with 
a flow rate of 25 ml/min. After each plasma exchange (run 1 - 6) sMICA*04 concentrations were 
measured by ELISA and normalized to the initial sMICA*04 plasma concentration. Data are repre-
sented as mean ± SEM of two independent experiments measured in duplicates. 
 
The characterization and in vitro depletion experiments using the functionalized sepharose 
matrix clearly demonstrated that the anti-MICA monoclonal antibody directed against a con-
served epitope in the α1-helical domain is a promising candidate for an adsorption apheresis 
of sMICA from plasma of cancer patients.  
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3.3.2 Pan-specific Depletion of sNKG2D Ligands using NKG2D Proteins 
Analyses of HNSCC patients’ plasma revealed an individual pattern for NKG2D ligand re-
lease. Moreover, it could be shown that the cumulative level of sNKG2D ligands is important 
for the extent of NKG2D-dependent inhibition of cytotoxic lymphocytes. Regarding different 
cancer entities, the individual impact of NKG2D ligands to tumor immune escape can vary. 
Therefore, the simultaneous removal of all sNKG2D ligands might be important for a clinical 
intervention strategy aiming at a broad patient cohort independent on the individual clinical 
situation. For this purpose, different recombinant NKG2D proteins were generated and char-
acterized for their suitability as a pan-specific tool to generate a biofunctionalized surface for 
the simultaneous adsorption apheresis of all sNKG2D ligands from human plasma. 
 
3.3.2.1 NKG2D Proteins expressed in E. coli 
NKG2D is a homodimeric type II transmembrane protein with an extracellular C-type lectin-
like domain [243]. The production of high amounts of functional homodimeric recombinant 
protein is challenging with regard to correct protein folding and formation of disulfide bonds. 
The most popular and well-established expression host for the fast and efficient generation of 
recombinant proteins in high amounts at low costs is Escherichia coli [415]. Most E. coli 
strains have disadvantages such as lack of posttranslational modifications (i.e. glycosylation) 
or are incapable of disulfide bond formation, and therefore overexpression of recombinant 
proteins often results in protein aggregation and formation of intracellular inclusion bodies 
[416, 417]. Inclusion body formation might be favored to yield high amounts of proteins, 
which are protected from proteolytical degradation. These proteins allow for the generation of 
native-folded proteins due to in vitro refolding strategies [418]. In this thesis, the NKG2D 
extracellular domain was produced in the BL21 (DE3) E. coli strain using an optimized 
IMAC purification and refolding protocol adapted from Steinle et al. [249]. Two rNKG2D 
variants were produced containing different affinity-tags for immobilization to generate a bio-
functionalized matrix. The rNKG2D-Biotin protein containing a C-terminal His-tag for affini-
ty purification and an additional N-terminal Avi-tag, which allows for in vitro biotinylation of 
the protein, was purified from inclusion bodies and refolded (Figure 30). Analysis of the elu-
tion fractions after affinity purification from inclusion bodies revealed high amounts of pure 
unfolded rNKG2D protein with a molecular mass of about 17 kDa which accounts for mono-
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meric proteins (Figure 30A). Moreover, protein aggregates or dimeric protein forms with a 
molecular mass of 35 kDa could be detected. After refolding, to ensure formation of intramo-
lecular disulfide bonds and thus correct protein folding, the protein was in vitro biotinylated to 
generate the actual rNKG2D-Biotin and further purified by SEC (Figure 30B/C). Although 
highly pure biotinylated dimeric rNKG2D could be produced as shown by SDS-PAGE and 
immunoblot analyses, most of the protein purified from inclusion bodies precipitated during 
the refolding procedure and formed aggregates as seen in the SEC chromatogram (fraction *). 
Only around 2-5% of protein isolated from inclusion bodies (0.3 mg protein per litre of E. coli 
culture) showed the correct folding and could be used for further functional assays. 
 
Figure 30: Affinity purification and biotinylation of NKG2D produced in E. coli.  
(A) Reducing SDS-PAGE (Coomassie-stained) and immunoblot (anti-His HRP-conjugated antibody) 
of aliquots (input, flow-through (ft), wash and eluate fractions) after affinity purification via Ni-NTA 
agarose from E. coli inclusion bodies. M =  monomeric rNKG2D.  (B) Size exclusion chromatography 
(SEC) of refolded and in vitro biotinylated rNKG2D on a HiLoad 16/600 Superdex 200 pg column. 
Peaks correspond to * = aggregated protein (~135 kDa), ** = biotinylated NKG2D dimers (~40 kDa), 
# = unbound biotin. (C) Pooled peak fractions (*; **) of SEC were analyzed by non-reducing (- DTT) 
Coomassie-stained SDS-PAGE and immunoblot (streptavidin HRP-conjugate). A = aggregates; 
D = dimers. 
 
The high amounts of aggregated proteins during refolding and in vitro biotinylation of 
rNKG2D-Biotin substantially decreased the protein yield of dimeric rNKG2D. To improve the 
production of rNKG2D and to analyze the impact of the affinity-tags on protein folding, in a 
second approach rNKG2D-His was produced containing a C- or N-terminal His-tag only. 
Compared to the biotinylated rNKG2D, IMAC purification of rNKG2D-His from inclusion 
bodies showed higher protein yield and reduced aggregate formation (shown exemplarely for 
rNKG2D with N-terminal His-tag, Figure 31A). Moreover, CD spectrometric analysis of 
rNKG2D with the N-teminal His-tag after refolding showed that the protein had a homogene-
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ous fold consisting of predominantly β-sheet secondary structures (Figure 31B) which is in 
accordance with the crystal structure of NKG2D published by Li et al. [243]. SDS-PAGE 
analysis under non-reducing conditions showed a highly pure rNKG2D-His protein compris-
ing the monomeric and dimeric form (Figure 31C). Around 1 mg of rNKG2D-His could be 
obtained per litre of E. coli culture. In contrast, although the rNKG2D with the C-terminal 
His-tag resembled the N-terminal tagged protein in SDS-PAGE, this protein showed a more 
α-helical secondary structure after refolding in CD spectroscopy and was not functional in 
binding studies on NKG2D ligand expressing cells as shown by J. Havenstein (group of J. 
Koch, Georg-Speyer-Haus, Frankfurt am Main [419]). Thus, the positively charged His-tag 
positioned at the C-terminus impaired the folding of the protein, whereas positioning at the 
truncated N-terminus of rNKG2D was favorable. The N-terminal tagged protein was further 
used in functional studies in comparison with the rNKG2D-Biotin. 
 
Figure 31: Characterization of E. coli derived rNKG2D-His.  
(A) Reducing SDS-PAGE (Coomassie-stained) and immunoblot (anti-His HRP-conjugated antibody) 
of aliquots (input, flow-through (ft), wash and eluate fractions) after affinity purification via Ni-NTA 
agarose from E. coli inclusion bodies. (B) CD-spectroscopy of refolded rNKG2D-His (N-terminal His-
tag) showing homogeneous protein folding with a prominent β-sheet structure. (C) Pooled peak frac-
tions of SEC were analyzed by non-reducing (- DTT) and reducing (+ DTT) Coomassie-stained SDS-
PAGE and immunoblot (anti-His HRP-conjugated).  
 
Functional analyses of rNKG2D-Biotin and rNKG2D-His showed binding of cell surface 
NKG2D ligands expressed on HEK293T cells (Figure 32A/C; NKG2D ligand expression pat-
tern see Figure S12). Moreover, in ELSA measurements, both proteins bound the sNKG2D 
ligands sMICA/B and the sULBP1-3. As indicated by different adsorption units, rNKG2D 
showed different affinities for the individual ligands (Figure 32B/D). This is in accordance 
with binding studies for human and mouse NKG2D showing binding affinities between 
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0.3 µM and 1 µM for the corresponding ligands [243, 248, 252]. Moreover, binding of glyco-
sylated sNKG2D ligands expressed in mammalian cells was independent on glycosylation 
status of rNKG2D as described earlier [249].  
 
Figure 32: NKG2D ligand recognition and depletion with rNKG2D proteins.  
Binding of rNKG2D-Biotin (A) and rNKG2D-His (C) to HEK293T cells expressing NKG2D ligands 
(NKG2D ligand expression pattern of HEK293T see Figure S12) was analyzed by flow cytometry 
with an anti-NKG2D PE-conjugated antibody. Grey = antibody control, red = NKG2D binding. Bind-
ing of rNKG2D-Biotin (B) and rNKG2D-His (D) to individual recombinant NKG2D ligands analyzed 
by ELISA. B7H6::hIgG1-Fc served as control. Data are represented as mean ± SEM of one representa-
tive experiment out of three. 
 
To validate the sNKG2D ligand depletion capability of rNKG2D, the proteins were immobi-
lized on streptavidin magnetic beads via Biotin or anti-His beads, respectively. Supernatants 
supplemented with recombinant sMICA/B and sULBP1-3 were incubated with respective 
rNKG2D-Biotin or rNKG2D-His beads (Figure 33). The sNKG2D ligands bound specifically 
to rNKG2D-Biotin coupled beads as shown by immunoblot analysis of bead eluates, whereas 
no binding could be observed for biotin-coupled control beads or soluble B7H6 fusion pro-
teins, an activating ligand for NKp30 (Figure 33A). Moreover, analysis of the supernatants 
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after depletion with rNKG2D-His coupled beads clearly demonstrated a reduction in 
sNKG2D ligand levels with an overall depletion efficacy of 74.7 ± 8.2% (Figure 33B). The in 
vitro depletion experiments clearly demonstrated the suitability of rNKG2D proteins for the 
pan-specific sNKG2D ligand depletion. 
 
Figure 33: Depletion of sNKG2D ligands using rNKG2D coupled beads. 
Depletion of recombinant NKG2D ligands from supernatants with rNKG2D-Biotin coupled magnetic 
Streptaividin-beads (A) or rNKG2D-His magnetic beads (B). Immunoblot analyses of NKG2D ligands 
in the supernatant (input) before depletion and in bead eluates (NKG2D) (anti-MICA antibodies in 
combination with anti-mouse HRP-conjugated antibodies or anti-human Fc-HRP). Biotin-loaded 
Streptavidin beads served as controls (CO). (B) NKG2D ligand levels in supernatants pre- (initial) and 
post-depletion determined by respective ELISAs. BAG6-His coupled beads served as control (CO). 
Ligand levels were normalized to the initial levels and are shown as mean ± SEM measured in dubli-
cates of a representative experiment. Statistical significance was determined by Student’s t-test; 
*** p < 0.001; **** p < 0.0001. 
 
Since the expression and purification strategy for the rNKG2D-His protein showed higher 
amounts of correctly folded protein at high purity compared to the rNKG2D-Biotin, the His-
tagged protein was produced for the generation of a biofunctionalized sepharose matrix for 
the use in adsorption apheresis. Unexpectedly, the amine-reactive coupling methods used 
failed to stabley immobilize functional rNKG2D proteins to the sepharose. One possible ex-
planation is the disruption of the NKG2D structure at the binding interface comprising lysine 
residues with primary amine groups, which might be addressed by the coupling reaction. Ad-
ditionally, a further aspect was taken into account. Proteins produced in E. coli have the dis-
advantage of high endotoxin (lipopolysaccharide, LPS) contaminants, which might negatively 
influence protein immobilization and moreover can cause side effects in human organisms 
and are therefore not applicable for clinical use. Consequently, a new strategy for the produc-
tion of a NKG2D recombinant protein for the use in adsorption apheresis was developed. 
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3.3.2.2 NKG2D::hIgG1-Fc Fusion Proteins 
Soluble Fc-based fusion proteins are suitable tools for the in vitro study of receptor-ligand 
interactions, as shown for NCR receptors [154, 377], and are of interest as therapeutic agents 
in immunotherapies addressing various diseases [420]. Usually, the proteinaceous molecule of 
interest is directly linked to the flexible hinge region of a human IgG1 Fc-part. The ad-
vantages of fusion to the Fc-part are (i) expression of high amount of soluble proteins in con-
ventional mammalian producer cell lines, (ii) improved protein stability, (iii) the formation of 
stable homodimers mediated by the Fc-part and (iv) cost-effective purification and immobili-
zation via Protein A/G matrices [421]. In this thesis, the fusion of the NKG2D extracellular 
domain to the N-terminus of the human Fc-part did not lead to the expression of functional 
proteins (data not shown). Since NKG2D is a type II transmembrane protein it can be hypoth-
esized that the Fc-part induced dimerization of the fusion proteins leads to sterical hindrances 
and might cause an inverse homodimer formation of the extracellular NKG2D domain, when 
the protein was fused with its C-terminus to the N-terminal Fc-hinge region. Consequently, 
new fusion protein constructs were generated with the NKG2D extracellular domain fused to 
the C-terminus of the Fc-part. The resulting NKG2D::hIgG1-Fc proteins were transiently ex-
pressed in HEK293T cells, secreted into the culture supernatant and affinity purified via Pro-
tein A (see Figure S9A). In functional assays the NKG2D fusion protein efficiently bound to 
NKG2D ligands expressed on cell lines as shown by flow cytometry (see Figure S9B). Unex-
pectedly, Fc-directed immobilization to different bead matrices (i.e. anti-human IgG-Fc or 
Protein A magnetic beads) for depletion experiments resulted in partial loss of NKG2D func-
tionality (see Figure S9C). This might be attributed to steric disturbances in the NKG2D ex-
tracellular domain located at the C-terminal end of the Fc-part upon immobilization. Addi-
tionally, insertion of a longer flexible glycine-serine linker between NKG2D and the Fc-part 
could not improve immobilization of functional fusion proteins (see Figure S9C). To ensure 
immobilization directed to the N-terminus of the Fc-part, an additional Avi-tag was fused to 
the IgG-Fc hinge region. Co-transfection of mammalian cells with plasmids encoding for Bi-
rA ligase with an endoplasmatic reticulum or secretion signal sequence allowed for direct in 
vivo biotinylation of Avi-tagged proteins. In vivo biotinylated NKG2D::hIgG1-Fc proteins and 
BirA ligase were transiently expressed in HEK293T cells and the fusion protein was affinity 
purified from cell culture supernatant via Protein A (Figure 34). Out of 250 ml culture super-
natant (corresponding to 1x108 cells) 0.5 - 1 mg biotinylated NKG2D fusion proteins could be 
Results 113 
  
 
purified with high homogeneity and purity with a molecular mass of around 100 kDa as 
shown by SEC analysis (Figure 34B). As expected, NKG2D fusion proteins formed stable 
homodimers due to the intermolecular disulfide bonds in the IgG1-Fc hinge region as shown 
by reducing and non-reducing SDS-PAGE (Figure 34C). 
 
Figure 34: Biotinylated NKG2D::hIgG1-Fc proteins assemble as homodimers.  
NKG2D::hIgG1-Fc proteins were expressed and in vivo biotinylated in 293T cells after transient trans-
fection. (A) Reducing SDS-PAGE (Coomassie-stained) and immunoblot (anti-human IgG-Fc HRP-
conjugated antibody) of aliquots (flow-through (ft), wash and eluate fractions) after affinity purifica-
tion via ProteinA sepharose from cell culture supernatants. (B) Size exclusion chromatography (SEC) 
of purified NKG2D::IgG1-Fc on a Superdex 200 10/300 GL column. (C) Pooled peak fractions were 
analyzed by non-reducing (- DTT) or reducing (+ DTT) Coomassie-stained SDS-PAGE and immunob-
lot (streptavidin HRP-conjugate). Under reducing conditions, the disulfide-linked IgG homodimeric 
NKG2D::hIgG1-Fc proteins disassemble to their monomeric forms. 
 
In flow cytometric analyses, biotinylated NKG2D::hIgG1-Fc proteins bound efficiently to the 
different NKG2D ligands expressed on C1R cell transfectants (Figure 35), whereas no Fc-
mediated background binding to NKG2D ligand negative C1R wildtype cells could be ob-
served. Moreover, the different fluorescence intensities indicated different binding affinities 
for the respective ligands, especially for the MICA allelic variants when compared to the ex-
pression profiles shown by anti-MICA antibody staining (see Figure S11). For further analysis 
of the binding properties, the approximate equilibrium binding constants (KD values) were 
determined by ELISA using immobilized recombinant sNKG2D ligands with graded amounts 
of NKG2D fusion proteins. Biotinylated NKG2D::hIgG1-Fc specifically bound with high 
affinity to the different NKG2D ligands in a dose dependent manner. The determined KD val-
ues corresponded to the flow cytometric results with C1R cells showing comparable binding 
affinities for the ligands sMICA*01, sMICB and sULBP1-3 with KD values ranging between 
19 - 75 nM (Table 12). All experiments were performed from the same NKG2D::hIgG1-Fc 
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protein dilution series and showed preserved Bmax values for sMICA*01, sMICB and 
sULBP1-3 as an indicator for the total amount of binding sites in the protein solution. 
 
 
Figure 35: Binding of biotinylated NKG2D::hIgG1-Fc on C1R transfectants. 
Binding of biotinylated NKG2D fusion proteins to C1R cell transfectants expressing individual 
NKG2D ligands (MICA allelic variants, MICB or ULBP1-3, see also Figure S11) were analyzed by 
flow cytometry. C1R mock transfected cells (neo) served as control. Grey = anti-human IgG-Fc anti-
body control, red = NKG2D::hIgG1-Fc. 
 
In contrast, the NKG2D::hIgG1-Fc binding affinity to sMICA*04 was 10-fold lower com-
pared to sMICA*01. The different affinities are related to the amino acid residue at position 
152 in the α2-helical domain of MICA, where methionine accounts for high affinity alleles 
such as MICA*01 and MICA*07 whereas the substitution to valine in MICA*04 and 
MICA*08 led to low affinity binding [249] (see 5.1.9.1; M152/V152 corresponds to 
M129/V129 (amino acid position without 23 aa signal sequence) in Steinle et al.). The slight 
differences in Bmax for the binding to sMICA*04 resulted from the 10-fold lower binding af-
finity and are attributed to the method of analysis. Thus, the equilibrium binding constants are 
regarded as approximate values. Importantly, binding affinities of NKG2D::hIgG1-Fc fusion 
proteins were 10- to 50-fold higher than for the rNKG2D variants produced in E. coli. The 
improved binding affinities of NKG2D fusion proteins might favor also the apheresis of 
sNKG2D ligands. 
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Figure 36: Binding kinetics of biotinylated NKG2D-Fc to NKG2D ligands.  
Binding of graded amounts of NKG2D-Fc (black circles) or NKp46-Fc (open circles) proteins to re-
combinant NKG2D ligands analyzed by ELISA. Data were fitted to a 1:1 Langmuir binding model to 
determine KD and Bmax values. A representative of three independent experiments is shown. 
 
Table 12: Equilibrium binding constants of biotinylated NKG2D::hIgG1-Fc  
Equilibrium binding constants (KD) and Bmax values of biotinylated NKG2D::hIgG1-Fc to its ligands 
as determined by ELISA (see Figure 36). 
NKG2D ligand KD [nM] Bmax 
sMICA*01 43 ± 6 0.521 ± 0.018 
sMICA*04 456 ± 59 0.928 ± 0.057 
sMICB 19 ± 3 0.693 ± 0.024 
sULBP1 36 ± 6 0.737 ± 0.032 
sULBP2 51 ± 6 0.670 ± 0.021 
sULBP3 75 ± 7 0.678 ± 0.018 
 
For in vitro depletion assays, the biotinylated NKG2D::hIgG1-Fc proteins were covalently 
coupled to streptavidin magnetic beads. Depletion capacity was evaluated using healthy hu-
man plasma supplemented with individual recombinant sNKG2D ligands (Figure 37A/B).  
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Figure 37: Biotinylated NKG2D::hIgG1-Fc proteins deplete sNKG2D ligands. 
(A/B) Depletion of recombinant NKG2D ligands supplemented to healthy human plasma (20 ng/ml of 
NKG2D ligands) with NKG2D::hIgG1-Fc coupled magnetic Streptaividin-beads. (A) Immunoblot 
analyses of recombinant sNKG2D ligands or NKp30-Fc control protein in the plasma before depletion 
(input) and in bead eluates (NKG2D) with respective anti-NKG2D ligand antibodies in combination 
with anti-mouse HRP-conjugated antibodies. Biotin-loaded Streptavidin-beads served as controls 
(CO). (B) Recombinant NKG2D ligand plasma levels pre- (initial) and post-depletion analyzed by 
respective ELISAs. Plasma levels were normalized to the initial plasma levels and are shown as 
mean ± SEM of three independent experiments. (C) Analysis of sNKG2D ligand levels in HNSCC 
patients’ plasma before (PS) and after depletion (PS depleted) with NKG2D::hIgG1-Fc coupled Strep-
tavidin-beads. Plasma levels are shown as mean ± SEM measured in dublicates. Statistical signifi-
cance compared to CO or PS, respectively, was determined by Student’s t-test; ** p = 0.005; 
**** p < 0.0001. 
 
The NKG2D-coupled beads specifically removed the recombinant sNKG2D ligands sMI-
CA/B, sULBP1-3 from human plasma as shown by immunoblot analysis of the bead eluates 
(Figure 37A). Furthermore, depletion of recombinant sULBP5/6 could be shown for the first 
time due to newly commercially available recombinant proteins. The depletion could be con-
firmed by determination of the residual sNKG2D ligand levels in the plasma. The depletion 
efficacies ranged between 82% and 94% for the ligands sMICA/B and sULBP1/2, and 72% 
for sULBP1 compared to the initial plasma levels (Figure 37B). As control, biotin coupled 
beads showed no reduction in sNKG2D ligand levels. Moreover, sULBP5/6 plasma levels 
could not be determined due to missing antibody combinations for the establishment of spe-
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cific sandwich ELISAs. To further evaluate the simultaneous depletion capacity for naturally 
shed sNKG2D ligands, plasma samples of HNSCC patients were incubated with the NKG2D-
coupled beads. The analysis of the patients’ plasma pre- and post-depletion revealed efficient 
removal of sNKG2D ligands resulting in a median depletion of 88.8 ± 9.1% of the initial cu-
mulative sNKG2D ligand burden (Figure 37C). The simultaneous depletion of sNKG2D lig-
ands from patients’ plasma using biotinylated NKG2D::hIgG1-Fc coupled beads was inde-
pendent of the patients’ individual sNKG2D ligand pattern and cumulative plasma level. 
Notably, NKG2D removed the ligands with the same efficacy as the bead cocktail of mono-
clonal anti-NKG2D ligand antibodies (shown in Figure 11A).  
In conclusion, in this thesis a functional in vivo biotinylated, homodimeric NKG2D::hIgG1-
Fc fusion protein could be generated in a mammalian cell system showing high affinity bind-
ing to the different NKG2D ligands. Importantly, the NKG2D fusion protein efficiently de-
pleted sNKG2D ligands from patients’ plasma comparable to anti-NKG2D ligand monoclonal 
antibodies. Thus, NKG2D fusion proteins are suitable tools for the generation of a pan-
specific adsorber matrix for the simultaneous adsorption apheresis of sNKG2D ligands. Pan-
specific adsorption apheresis would allow for the treatment of a broad patient cohort, inde-
pendent of the individual patients’ sNKG2D ligand composition and burden. Moreover, the 
NKG2D::hIgG1-Fc proteins would even allow for improvement of binding affinities to cog-
nate ligands as shown exemplarily in an affinity maturation study using NKG2D::hIgG1-Fc 
mutant proteins with single amino acid substitutions bioinformatically calculated for high 
affinity binding to sMICA (see 5.1.8). 
 
3.4 Preclinical Evaluation of Adsorption Apheresis in Rhesus Ma-
caques  
The in vitro depletion experiments using an anti-MICA antibody or NKG2D::hIgG1-Fc func-
tionalized matrices demonstrated a successful and efficient removal of sNKG2D ligands from 
human plasma and could restore NK cells’ functions in cytotoxicity experiments. To investi-
gate the applicability of the newly generated adsorber matrix for a clinical therapy, a pre-
clinical in vivo validation of sNKG2D ligand adsorption was performed. For this purpose, the 
anti-MICA adsorber matrix was used in a proof of concept study. Due to the fact that the gen-
eration of biotinylated NKG2D::hIgG1-Fc for pre-clinical application requires the time-
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consuming and expensive establishment for commercially high-scale clinical-grade protein 
production and protein coupling to the sephaose matrix, which was not feasible during this 
thesis, the pan-specific adsorber was not validated in the animal model.  
 
3.4.1 Pilot Study 
For the pre-clinical validation of adsorption apheresis, a rhesus macaque (Macaca mulatta) 
model was used. Human and rhesus MICA display a sequence identity of 79% (see 5.1.9.3), 
human and rhesus NKG2D of 94% (see 5.1.9.4). Moreover, the body weight of 7 - 10 kg and 
a blood volume of roughly 7% of the body weight make rhesus monkeys a suitable model 
system to validate the efficacy of sNKG2D ligand adsorption apheresis. Since no rhesus ma-
caque cancer disease models exist, only adsorption apheresis was investigated. Therefore, 
soluble human MICA was infused into the rhesus macaques prior to adsorption apheresis.  
In a pilot study, the body distribution and serum stability of human sMICA*04 after intrave-
nous injection was validated. Therefor, two rhesus monkeys were injected with 100 µg sMI-
CA*04 per liter of blood volume (BV) and sMICA plasma levels were analyzed over three 
hours by ELISA (Figure 38A/B). About 15 - 25% of the initially injected sMICA could be 
found in monkeys’ plasma 15 min after injection reflecting the process of natural body distri-
bution due to sMICA diffusion from the blood into the tissues. The injected sMICA showed 
an exponential plasma decrease during the first 150 min after injection reaching a stable 
plasma level with a diffusion equilibrium of about 3 - 5 ng/ml three hours after injection, 
which resembles the plasma levels found in cancer patients. Moreover, urine samples were 
analyzed for renal clearance of the administered sMICA (Figure 38C/D). Notably, no sMICA 
could be detected in the urine of the animals. Additionally, incubation of sMICA in rhesus 
plasma at 37 °C showed a stable plasma level without signs of sMICA degradation in the 
plasma (Figure 38G). These data indicate that the decreasing sMICA plasma levels were not 
caused by renal clearance or proteolytical degradation and are only due to the body distribu-
tion resulting in stable sMICA plasma levels, which allow for adsorption apheresis. Notably, 
these plasma levels were stable for at least 6 h post injection (data not shown). 
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Figure 38: Analysis of sMICA body distribution and plasma stability.  
Two animals (left/right) were injected with 100 µg/l blood volume sMICA*04 to evaluate sMICA 
body distribution. Blood and urine samples were taken before injection (basal) and during three hours 
after injection. (A/B) Analysis of sMICA*04 plasma levels by ELISA. Data are represented as 
mean ± SEM of duplicates. (C/D) Analysis of sMICA*04 in urine by ELISA to determine renal clear-
ance of sMICA. Data are represented as mean ± SEM of duplicates; nd = not detectable. (E) Rhesus 
macaque plasma was supplemented with sMICA*04 and incubated at 37 °C to analyze sMICA plasma 
stability. Plasma samples were measured every 20 min in duplicates by ELISA. Data are represented 
as mean ± SEM.   
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Additionally, analysis of NKG2D expression on CD3+ T cell and CD3- NK cell subpopula-
tions from rhesus PBMCs revealed that the basal NKG2D expression levels and cell numbers 
were not affected by human sMICA*04 (Figure 39 A/B). 
 
Figure 39: Analysis of rhesus monkey blood cells. 
Flow cytometric analysis of primary rhesus PBMCs from whole blood samples. (A) Gating strategy of 
viable (alive) PBMCs and determination of granulocyte (G), monocyte (M) and lymphocyte (L) popu-
lations (left). The lymphocyte fraction was further discriminated in B cells and CD20- lymphocytes 
(CD20- L; middle). CD3+/NKG2D+ T cell and CD3-/NKG2D+ NK cell subsets were determined from 
the CD20- L population (right). Representative dot plots of one animal are shown for blood samples 
taken directly before sMICA*04 injection and 1 h post injection. (B/C) Flow cytometric analysis of 
NKG2D surface expression on CD3+ T cells and NK cell over 3 h of two animals. 
 
Three weeks after sMICA injection, the plasma of the animals was probed for anti-MICA IgG 
and IgM antibody production. No anti-MICA antibodies of the IgG/IgM subclasses could be 
Results 121 
  
 
detected excluding antigenicity and related destruction of the administered human sMICA 
protein (Figure 40A/B).  
 
Figure 40: No adaptive immune response towards human sMICA*04 in rhesus macaques. 
(A/B) Determination of anti-MICA IgG/IgM antibodies in the plasma of two rhesus macaques three 
weeks after sMICA*04 injection. Different plasma dilutions of the two animals were probed for anti-
MICA IgG (black bars) or IgM (grey bars) antibody subclasses on sMICA*04 coated ELISA plates. 
Antibodies were detected with monkey IgG- or IgM-specific HRP-conjugated antibodies. Data are 
represented as mean ± SEM; nd = not detectable. 
 
Collectively, the data of the pilot study demonstrated that rhesus macaques are a suitable in 
vivo model for the pre-clinical validation of adsorption apheresis, which allows for human 
sMICA injection resulting in a stable plasma level without causing side effects or immune 
reactions against sMICA.  
 
3.4.2 In vivo Adsorption Apheresis 
For adsorption apheresis, an adsorber cartridge with the anti-MICA antibody-functionalized 
sepharose matrix was produced for the use in a Life18™ apheresis unit from Miltenyi Biotec. 
Two animals were injected with 100 µg/l BV sMICA*04 and the apheresis was started 15 min 
post-injection. The apheresis was run until three complete exchanges of the animals’ plasma 
volume were reached. The analysis of sMICA plasma levels showed that only three plasma 
volume exchanges were sufficient for efficient depletion of sMICA with 1.44 ± 0.06% and 
3.48 ± 1.79% remaining sMICA*04 in the plasma of the two animals, respectively (Figure 
41A/B). Apparently, the decline of sMICA in the plasma during the first 30 minutes of the 
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apheresis resembled the body distribution seen in the pilot study but the effect of sMICA re-
moval through the adsorber cartridge was detectable after one plasma volume exchange and 
showed a significant faster decline in the plasma when compared to the sole effects of body 
distribution with 24.17 ± 0.09% and 27.98 ± 0.46% remaining sMICA*04 in the plasma at the 
end of the experiment.  
 
Figure 41: In vivo adsorption apheresis of sMICA in two rhesus macaques. 
(A/B) Animals were injected with 100 µg/l blood volume sMICA*04. Apheresis was started 15 min 
post injection using a Life18™ apheresis unit (Miltenyi Biotec). sMICA plasma concentrations were 
determined by ELISA every 15 min and normalized to the initial sMICA (15 min post injection). Data 
are represented as mean ± SEM of duplicates. Pilot study (no apheresis) = body distribution: black 
open squares; apheresis: red open circles. Statistical significance was analyzed using Student’s t-test 
with * p < 0.05; ** p < 0.001; *** p < 0.0001. Arrows indicate the time points of consecutive plasma 
volume (PV) exchanges ((C) PV= 525 ml; (D) PV= 365 ml). 
 
The pre-clinical validation of the adsorber cartridge clearly demonstrated that adsorption 
apheresis is an effective therapeutic strategy to remove sNKG2D ligands from plasma in a 
living organism. Thus, adsorption apheresis prior to immune cell therapies might be a promis-
ing combinatorial medical approach for the treatment of cancer patients to augment immune 
cell functions of autologous and adoptively transferred lymphocytes by interfering with 
NKG2D-dependent tumor immune escape.  
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4 Discussion 
The human activating receptor NKG2D plays a major role in tumor immunosurveillance. 
However, the release of soluble ectodomains of NKG2D ligands from the tumor cell surface 
is a potent strategy mediating tumor evasion from NKG2D-dependent recognition and elimi-
nation by cytotoxic lymphocytes [373]. In this respect, NKG2D-dependent tumor immune 
escape has been described in a variety of cancers, including leukemia, neuroblastoma, cervical 
carcinoma, and multiple myeloma [422]. Although the NKG2D/NKG2D ligand system is 
well characterized, the complexity of this system still needs further investigation to improve 
the efficacy of tumor immunosurveillance and to develop new anti-cancer therapies [152, 
201]. This is due to i) the diverse expression patterns of the numerous stress-induced and 
structurally related NKG2D ligands in many different cancer entities [246, 422], ii) the heter-
ogeneity of the tumors and tumor microenvironment in individual cancer patients, and iii) the 
expression levels of the NKG2D receptor and its multiple functions in innate and adaptive 
immune cells [423, 424]. Moreover, most studies on NKG2D-dependent tumor immune es-
cape relied on the investigation of one or two sNKG2D ligands, mainly concentrating on 
sMICA/B and sULBP2. Therefore, the knowledge of the cumulative sNKG2D ligand levels 
and their impact is scarce. In this thesis, monitoring of HNSCC patients’ plasma revealed ele-
vated sNKG2D ligand levels, which impair NKG2D-dependent NK cell cytotoxicity. Based 
on tumor spheroids, besides reduced cytotoxicity, also inhibition of NK cell infiltration 
through sNKG2D ligands could be demonstrated. Furthermore, the specific depletion of 
sNKG2D ligands could restore NK cells’ antitumor functions. Thus, an adsober matrix for the 
depletion of sNKG2D ligands based on monoclonal antibodies or recombinant NKG2D pro-
teins was established and validated in a proof of concept study in rhesus monkeys.  
 
4.1 sNKG2D Ligands mediate Tumor Immune Escape in HNSCC 
HNSCC tumors overexpress the NKG2D ligands MICA and MICB, which renders them sus-
ceptible to NK cell lysis [425, 426]. Moreover, impaired NK cell functions in HNSCC impli-
cate an important role of NK cells in HNSCC immunosurveillance [427, 428]. Along this line, 
increased levels of sMICA could be identified in HNSCC patients’ plasma, which diminished 
NK cell cytotoxicity [304, 320, 321]. In this thesis, the impact of the sNKG2D ligands sMI-
CA/B and sULBP1-3 to NKG2D-dependent tumor escape was evaluated in 44 HNSCC pa-
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tients using sandwich ELISAs optimized for stable and reproducible detection in human 
plasma. It should be noted that sULBP4-6 could not be analyzed due to the lack of appropriate 
antibody pairs and recombinant proteins for establishing specific ELISAs. Profiling of 
HNSCC plasma revealed that the cumulative level of sNKG2D ligands is patient specific and 
correlates with disease progression and tumor load. The soluble ligands accumulated upon the 
pre-metastatic stage III characterized by locally established tumors without signs of metasta-
ses in regional lymph nodes. Thus, defective NKG2D-mediated tumor surveillance rather 
plays a role in advanced disease than being involved in tumor formation. This is in accord-
ance with studies from different malignancies such as prostate cancer, multiple myeloma and 
HNSCC showing a correlation of increased sMICA and sMICB plasma levels with disease 
staging and progression [303, 304, 324, 325, 429]. One explanation for the accumulation of 
sNKG2D ligands in advanced disease could be due to the upregulation of MMPs, which me-
diate ligand shedding, in association with increased tumor invasiveness [430-432]. Moreover, 
individual patients showed different patterns of sNKG2D ligands highlighting the heteroge-
neous nature of HNSCC. These data suggest a prominent role for sULBPs, especially 
sULBP1 and sULBP3, in HNSCC when compared to the levels of sMICA and sMICB. The 
diverse NKG2D ligand expression and release is in accordance with studies of other cancer 
entities showing distinct ligand patterns, but no tumor expressing all NKG2D ligands at the 
same time [258, 425]. This can be explained by differential transcriptional regulation of the 
ligands, which is influenced by many factors of the tumor microenvironment and cancer ther-
apies [246, 412]. Whereas MICA/B expression was shown to be upregulated by heat-shock 
and oxidative stress [223, 433], upregulation of ULBP expression could be correlated to the 
induction of the tumor suppressor p53 [434] or inhibition of proteasome activity [412, 435]. 
Upon cellular stress, NKG2D ligand expression is induced by the ATM/ATR (ataxia telangi-
ectasia mutated/ATM and Rad3-related) DNA damage response, which is constitutively active 
in advanced tumors and can be induced by DNA-damaging chemotherapeutic drugs or local 
radiation [274, 436]. Interestingly, palliative chemo- and/or radiotherapy had little effect on 
sNKG2D ligand levels in HNSCC patients’ plasma analyzed. The slight reduction of 
sNKG2D ligand plasma levels might be due to reduced tumor mass in patients currently under 
treatment. However, further studies including a larger patient cohort under therapy are needed 
to further evaluate the effect of chemo- and/or radiotherapy on tumor burden and sNKG2D 
ligand levels. Moreover, upregulation of NKG2D ligand surface expression on tumor cells 
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upon chemo- and radiotherapy should be analyzed for a better understanding of the impact of 
therapeutic strategies on the NKG2D/NKG2D ligand system. Thus, profiling of the sNKG2D 
ligand status of cancer patients as prognostic and/or diagnostic marker might be crucial for 
selection of strategies for personalized immunotherapy. 
 
4.2 Immunosuppressive Factors and low Lymphocyte Infiltra-
tion in HNSCC Patients 
Since HNSCC is characterized by an immunosuppressive tumor microenvironment, major 
tumor-associated cytokines and chemokines were analyzed in HNSCC patients’ plasma. In 
contrast to previous reports, no significant alterations in TNF-α or IL-10 levels and only a 
non-significant decrease of IFN-γ when compared to healthy control plasma could be detected 
[320, 366, 437]. In the present study, RANTES, MIP-1β, MCP-1 and IL-6 were significantly 
elevated but showed no significant correlation with disease characteristics. The most promi-
nent factor analyzed was TGF-β1, which increased during disease progression. Overall, al-
tered cytokine and chemokine levels found in HNSCC patients are highly heterogeneous and 
patient specific, but commonly show an immunosuppressive, pro-inflammatory and pro-
angiogenic phenotype accounting for the aggressive malignant behavior of HNSCC [438, 
439]. Up to now, several studies showed variations in distinct cytokine levels for HNSCC. 
However, it should be noted that the level of cytokines could vary using different assays such 
as ELISA or flow cytometry-based cytokine bead arrays (CBA) and depends on the material 
analyzed, since the complex cytokine network is modulated not only by tumor cells itself but 
also by immune cells. In the study of Bose et al. [366] cytokines were analyzed from PBMC 
culture supernatants isolated from HNSCC patients rather than from plasma of HNSCC pa-
tients. Other studies analyzed cytokine levels in primary tissue or HNSCC cell lines. Conse-
quently, comparison of different studies might be difficult with regard to sample origin, meth-
od of analysis and comparison to healthy controls. Therefore, a uniform diagnostic method 
should be established to evaluate the cytokine status of patients in the clinic. 
Immunohistochemistry of primary HNSCC tumors further confirmed the immunosuppressive 
status of HNSCC patients. In this respect, TAMs of the M2 phenotype were frequently found 
in primary HNSCC tumors, which are critical modulators of the immunosuppressive (e.g. by 
secretion of immunosuppressive factors and inhibition of T and NK cell proliferation and ac-
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tivation) and pro-tumorigenic (e.g. promoting angiogenesis, invasion and tumor growth) mi-
croenvironment [396, 440]. In contrast, low numbers of CD3+/CD8+ tumor-infiltrating lym-
phocytes could be found in the tumor core and nearly no infiltration of CD56+ NK cells (and 
presumably NKT cells) could be detected. This observation is in accordance with a study of 
Mukhopadhyaya et al. [441] reporting that tumor infiltrating lymphocytes in tumor tissues 
and diseased lymph nodes of HNSCC patients showed a decreased percentage of CD3+ and 
CD4+ T cells and significantly low numbers of NK cells, which showed highly compromised 
cytotoxic activity [442]. Analysis of HNSCC patients’ PBMCs showed reduced numbers of 
peripheral cytotoxic CD56dim/CD16+ NK cells, whereas the number and distribution of pe-
ripheral CD4+/CD8+ T cell subsets were unchanged. In contrast to other reports analyzing 
lymphocytes from whole blood samples or isolated NK cells, no decrease in overall NK cell 
numbers or circulating regulatory NK cells could be seen in the analyzed isolated PBMCs 
from HNSCC patients [366, 427]. Interestingly, only a slight increase of NKG2D expression 
could be detected on the patients’ immune cells compared to those of healthy controls, further 
indicating a low activation status and impaired NKG2D-mediated antitumor functions of 
these cells. There is accumulating evidence that immune cell invasion into solid tumors is an 
important factor for survival of patients [443-448], and also for the success of cellular thera-
pies [449]. Thus, low T cell infiltration and especially the absence of infiltrating NK cells, in 
particular cytotoxic NK cells, are indicative for insufficient immunosurveillance of HNSCC 
and account for the need of immunotherapies to redirect and activate cytotoxic immune cells 
to the tumor site to improve HNSCC patients’ outcome.  
 
4.3 sNKG2D Ligands and TGF-β1 in Patients’ Plasma impair NK 
Cell Cytotoxicity  
The impact of shed NKG2D ligands in patients’ plasma on NK cell cytotoxicity was evaluated 
in in vitro cytotoxicity assays using primary IL-2 pre-activated NK cells of healthy donors 
[385] and a target cell line (SiHa), which is highly susceptible to NKG2D-mediated cytotoxi-
city. NK cells pre-incubated with plasma of HNSCC patients showed drastically reduced cyto-
toxicity by NKG2D blocking, and presumably downregulation, when compared to NK cells 
incubated with plasma of healthy donors. Correlation of plasma levels and tumor cell lysis 
revealed an additional inhibitory effect on NK cell cytotoxicity when HNSCC plasma con-
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tained high levels of both sNKG2D ligands and TGF-β1. Moreover, analysis of the plasma of 
a patient before and after surgery demonstrated a direct correlation of high sNKG2D ligands 
and TGF-β1 plasma levels with tumor burden. This is in agreement with a recent study by 
Kloess et al. [320] showing a synergistic effect of high sMICA and TGF-β1 plasma levels in 
HNSCC patients on NKG2D-dependent NK cell inhibition, and correlation of increased sMI-
CA and TGF-β1 levels with advanced disease stage. In this respect, several studies showed 
that high plasma levels of individual sNKG2D ligands from different tumor entities correlated 
with impaired NK and T cell functions via NKG2D blocking and/or internalization [302, 305, 
314-317]. However, some reports have failed to confirm receptor downregulation by soluble 
NKG2D ligands [297, 298]. Several explanations for the conflicting results can be considered. 
On the one hand, NKG2D downregulation could depend on the nature and affinity of the re-
leased ligand. In this respect, it was shown that incubation of NK cells with supernatants con-
taining exosomal MICA*08 or ULBP3 triggered significantly more NKG2D downregulation 
compared to supernatants with monovalent soluble ULBP2 or soluble MICA*019 indicating 
that multivalent ligands on exosomes can mediate cross-linking of the receptors, which is 
necessary to induce receptor internalization [246, 311, 312]. Interestingly, a recent study by 
Quatrini et al. [450] showed that ligand stimulation induced ubiquitylation of DAP10 leading 
to the endocytosis of NKG2D-DAP10 complexes, which was required for the activation of 
NK cell functions, such as the secretion of cytotoxic granules and IFN-γ. Thus, NKG2D 
downregulation upon persistent exposure to NKG2D ligands on the surface of tumor cells 
might contribute to the functional regulation of NK cell effector functions. Moreover, Deng et 
al. [451] showed that the soluble form of the mouse ligand Mult1 secreted by tumor cells ac-
tivated mouse NK cells by upregulation of NKG2D surface expression and stimulated tumor 
rejection in vivo. The authors proposed that the high-affinity of soluble Mult1 compared to the 
lower affinities of sMICA/B might be an explanation for the opposed effects, and that soluble 
Mult1 mediate NK cell stimulation by a different mechanism. Morover, it could not be ex-
cluded that sNKG2D ligands form multivalent proteins in plasma, which can bind and cross-
link the receptor despite a low affinity or concentration. In this respect, recombinant monova-
lent soluble MICA derived from HEK293T cells and E. coli failed to downregulate NKG2D 
and to inhibit NK cell cytotoxicity in functional assays (data not shown). The molecular basis 
remains unknown, however, it might be attributed to subtle differences in protein folding or 
posttranslational modification, since sMICA purified from tumor cell lines after shedding 
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could inhibit NKG2D as shown in cytotoxicity experiments. In addition, the different affini-
ties of the ligands may account for the extent of NKG2D downregulation. Therefore, the ef-
fect on NK cell functions might depend on the individual composition of sNKG2D ligands in 
patients’ plasma. On the other hand, reduced receptor staining upon sNKG2D ligand exposure 
may reflect blockade of the epitope recognized by NKG2D-specific antibodies (most com-
mercially available anti-NKG2D antibodies block NKG2D-dependent NK cell activation) 
rather than reduced receptor surface expression. In most studies it could not be excluded that 
other components (e.g. TGF-β1 [293, 295]) in patients’ plasma contributed and mediated 
NKG2D downregulation. Elevated levels of TGF-β1 were found in plasma of lung cancer, 
colorectal cancer and glioma patients and inversely correlated with NKG2D surface expres-
sion on NK cells and CTLs of these patients [293, 401]. It could be shown that TGF-β1-
induced NKG2D downregulation was partially dependent on transcriptional regulation of 
NKG2D and due to repression of DAP10, which leads to retention and lysosomal degradation 
of NKG2D [149, 452]. Therefore, the exact molecular mechanism of sNKG2D ligand- and 
TGF-β1-mediated NKG2D inhibition needs further investigation. Importantly, in this thesis it 
could be shown that NKG2D-dependent NK cell dysfunction was predominantly mediated by 
sNKG2D ligands in HNSCC patients’ plasma, since the specific depletion of sNKG2D lig-
ands from patients’ plasma restored NKG2D-dependent killing and thus blocking and/or 
downregulation of the NKG2D receptor on NK cells. Although the sole depletion of sNKG2D 
ligands was sufficient to restore NKG2D-depenent cytotoxicity in vitro, it should be noted, 
that the impact of TGF-β1 to NKG2D inhibition in vivo might be stronger by not only directly 
decreasing the expression level on NK cells, but also by acting through the suppressive func-
tion of Tregs [294]. Tregs were shown to be increased in HNSCC patients and can further 
mediate their suppressive functions by downregulation of T cell, NK or NKT cell subtypes as 
well as by interfering with the antigen-presentation function of dendritic cells [366]. Taken 
together, this leads to the assumption that NKG2D-dependent tumor immune escape can be 
mediated by a synergistic effect of sNKG2D ligands and other effector molecules (e.g. TGF-
β1) and is dependent on disease progression in a patient specific manner. Therefore, combin-
ing therapeutic strategies targeting sNKG2D ligands and TGF-β1 might be considered to fur-
ther promote and restore antitumor functions of cytotoxic lymphocytes. 
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4.4 Reduced NK Cell Cytotoxicity correlates with decreased In-
filtration in Tumor Spheroids 
Tumor spheroids have been widely applied in investigative drug screens for chemo- and radi-
osensitivity [410], and their metabolic and proliferative profiles have been well determined. 
However, little work has been done applying spheroids in the context of immunosurveillance 
of tumor cells by NK cells. Previous studies showed NK cell resistance of Ewing’s sarcoma 
cells that were cultured in a 3D culture model [453] and activity of PBMCs or  T cells in 
tumor spheroids [454, 455]. In this thesis, tumor spheroids were used as a model system for 
the analysis of NKG2D-dependent tumor immune escape and NK cell functions based on 
flow cytometry assays and immunohistochemistry. This novel application of tumor spheroids 
enables the analysis of cytotoxic functions and infiltration of immune cells under in vivo-like 
conditions using commercially available reagents and commonly used cell biological meth-
ods. Furthermore, the used 96-well plate format allows for high throughput screening of sin-
gle spheroid arrays with high reproducibility.  
Tumor spheroids grown from HNSCC cell lines of different epithelial origin or of the cervical 
carcinoma cell line SiHa varied in their susceptibility to NKG2D-dependent killing as shown 
by blocking experiments. Interestingly, destruction of a three-dimensional tumor spheroid 
took much longer when compared to the parental monolayer cultures, highlighting their valid-
ity for the in vivo situation. Characterization of tumor spheroids showed distinct expression 
patterns of the different NKG2D ligands, with usually low ULBP1 expression. This is in 
agreement with other studies showing altered ligand expression and a loss of ULBP1 expres-
sion during HNSCC cell line generation [412]. Continuous shedding of sMICA/B and 
sULBPs could be detected in tumor spheroid supernatants reaching saturation after approxi-
mately 48 h. This rapid re-production and accumulation of sNKG2D ligands in the superna-
tants further highlight their role for tumor immune escape. The re-production of sNKG2D 
ligands by tumor cells, the sNKG2D ligand levels in patients’ plasma and the serum half-live 
of 6 days for sMICA/B [297] indicate that a considerable time frame of several days might 
exists for depletion of sNKG2D ligands as intervention strategy to boost antitumor functions 
of NK cells. 
Since human plasma is a complex and elusive mixture of soluble factors such as cytokines 
and chemokines originating from various cell types, the NKG2D-dependent tumor immune 
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escape was further elucidated in tumor spheroid assays using tumor cell line supernatants con-
taining a cocktail of sNKG2D ligands or purified sMICA (generated by shedding). As ex-
pected, sNKG2D ligands in the supernatant of CAL27 cells blocked NKG2D on NK cells and 
inhibited related NK cell cytotoxicity towards tumor spheroids, as it was seen with single cell 
suspensions using HNSCC plasma for NK cell pre-incubation. Although tumor spheroids are 
more complex and showed higher resistance to NK cell cytotoxicity, the inhibition of tumor 
spheroid destruction was in accordance with the different NKG2D-dependencies of the cell 
lines used showing the strongest effect for SiHa tumor spheroids compared to FaDu or 
CAL27 spheroids. Again, depletion of sNKG2D ligands from CAL27 supernatant showed 
restoration of NKG2D-dependent tumor spheroid destruction as it was seen for patients’ 
plasma. Thus, tumor-like spheroids further confirmed the importance of NKG2D-mediated 
tumor immune escape in cancer. Moreover, the same amount of sMICA, purified from super-
natant of tumor cells after shedding, inhibited NK cell cytotoxicity to the same extent as the 
cocktail of sNKG2D ligands in cell culture supernatant. This supports the hypothesis, that the 
extent of NKG2D inhibition is dependent on the composition of sNKG2D ligands in the 
plasma and the level of high-affinity ligands. 
It was shown that tumor infiltration of NK cells coincides with antitumor activity and is asso-
ciated with a better prognosis in several cancer entities such as colorectal cancer, non-small 
cell lung cancer, and clear cell renal cell carcinoma [404, 405, 413, 443, 456]. Although NK 
cells hold promise for anti-cancer therapy, NK cell infiltration into tumors and their pheno-
type and function within the tumor has not yet been extensively investigated. This is partly 
due to a lack of appropriate model systems [404, 405, 413, 456-460]. Due to their 3D struc-
ture with a complex network of cell-cell contacts, tumor spheroids were used in this thesis for 
the investigation of NK cell infiltration. As demonstrated by co-staining of tumor spheroid 
cryosections with antibodies specific for CD45 and active capsase-3, it became evident that 
NK cell cytotoxicity was accompanied by a massive NK cell infiltration. However, in the 
presence of sNKG2D ligands or sMICA, NK cell numbers in tumor spheroids as well as NK 
cell killing were reduced. These data demonstrate a direct correlation between inhibition of 
NK cell cytotoxicity via NKG2D-dependent immune escape and decreased NK cell infiltra-
tion into tumor spheroids. The reduced infiltration into tumor spheroids also reflects the low 
or absent NK cell infiltration observed in primary tumor tissue of HNSCC patients. However, 
the molecular details of NKG2D-dependent inhibition of immune cell infiltration need further 
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analysis in primary tumor samples. Interestingly, sNKG2D ligand pre-treated NK cells in tu-
mor spheroids were often double positive for CD45 and cleaved caspase-3 compared to un-
treated NK cells. Therefore, it might be speculated that under inhibitory conditions NK cells 
might proliferate less and become apoptotic. Diminished NK cell stability was also obsereved 
in peripheral IL-2 activated NK cells from HNSCC patients and healthy controls treated with 
patients’ plasma [320]. The decreased infiltration of sNKG2D ligand pre-treated NK cells 
indicate that sNKG2D ligands might also mediate suppressive mechanisms affecting the mi-
gratory capability and tumor chemoattraction of NK cells. Therefore, it is expected that 
HNSCC patients could benefit from immunotherapies interfering with NKG2D-dependent 
immune escape by boosting cytotoxic functions and redirect immune cells to infiltrate tumors. 
Moreover, data using sorted NK cell populations (cytotoxic CD3-CD16+CD56dim and regula-
tory CD3-CD16-CD56bright) indicate that both subtypes are capable to infiltrate into tumor 
spheroids to the same extend. However, the majority of NK cells accumulated and proliferat-
ed in the periphery of the tumor spheroids. These NK cell subpopulations could phenotypical-
ly differ from infiltrated NK cells. In this respect, a study of Horowitz et al. [461] could show 
the existence of more than 6,000 - 30,000 phenotypically distinct NK cell subsets in the blood 
of a single human [462]. Moreover, Bhat et al. [66] could show that NK cells were not equally 
active in forming contacts and killing targets but few ‘hyperactive’ NK cells were observed in 
cytotoxicity assays. Therefore, further characterization of these isolated subpopulations will 
be instrumental to decipher which factors determine infiltration and will help to improve cel-
lular therapies of solid cancers. In this respect, the newly established MACS-based isolation 
protocol (see 5.1.4) allows for the discrimination of infiltrating and peripheral subpopulations 
by isolation and enrichment of infiltrated NK cells from tumor spheroids and represents a 
versatile tool for further studies addressing the phenotypic analyses and influence of soluble 
factors on different immune cell subtypes. The contribution of the NKG2D/NKG2D ligand 
system to chemotaxis of NK cells, as shown in tumor spheroids, indicated other than yet an-
ticipated functions of NKG2D in tumor immunosuveillance. The determination of the mo-
lecular mechanisms by which sNKG2D ligands and TGF-β1 impair NKG2D-mediated NK 
cell cytotoxicity, migration and tumor chemoattraction is thereby of particular intrest for a 
better understanding of NKG2D-dependent tumor immune escape in solid cancers.  
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4.5 Cancer Therapies targeting NKG2D/NKG2D Ligands 
In the recent years, the NKG2D/NKG2D ligand system came into focus as target for new anti-
cancer therapies to overcome tumor immune escape and improve NKG2D-dependent immu-
nosurveillance. On the one hand, NKG2D ligands are highly expressed on a broad variety of 
tumor cells of different origin, whereas expression on healthy tissues is observed only poorly 
[226, 463]. On the other hand, the NKG2D receptor is monomorphic and expressed on all NK 
cells and several T cell subsets, providing multiple effector cells mediating NKG2D-
dependent antitumor functions [201, 246]. Thus, NKG2D and/or NKG2D ligand-targeting 
therapeutic measures hold promise for anti-cancer therapies applicable to a broad patient co-
hort suffering from different types of cancer. One considerable access point is the modulation 
of NKG2D ligand expression on tumor cells, which were selected for low NKG2D ligand 
profiles due to immunoediting. In this respect, conventional therapies such as local radiation 
and chemotherapy [274, 436], or administration of proteasome and HDAC inhibitors [464-
467] were shown to upregulate NKG2D ligand expression on tumor cells as a consequence of 
induction of cellular stress pathways (e.g. DNA damage response) enhancing their susceptibil-
ity to NKG2D-dependent elimination. However, the use and therapeutic regimen of these 
agents must be carefully considered regarding pleiotropic effects such as inhibition of NK cell 
activity by the drugs themself [468], NKG2D downregulation due to persistent NKG2D lig-
and exposure [287, 288], or the possibility of induction of ligand expression on healthy tis-
sues. Therapeutic approaches to enhance recognition of less immunogenic tumors can also be 
based on the administration of monoclonal antibodies or bi-specific proteins. Experimental 
studies showed substantial antitumor effects by improving NKG2D-dependent cytotoxicity 
when applying chimeric proteins of NKG2D ligands fused to a single-chain antibody frag-
ment or protein specific for a certain tumor antigen expressed on lymphoma and multiple my-
eloma cells (e.g. ULBP2-BB4 [333], anti-CD20-MICA [335] or anti-CEA-MICA [469]). A 
chimeric protein of the NKG2D receptor and a CD3ζ-specific single-chain fragment could 
retarget T cells to NKG2D ligand expressing tumors in mice [334]. Furthermore, Kellner et 
al. [470] showed a synergistic effect of ADCC- and NKG2D-mediated killing of lymphoma 
cells by combining therapeutic antibodies (e.g. rituximab) with an anti-CD20-ULBP2 chimer-
ic protein [335]. Up to now, several monoclonal antibodies were approved for cancer treat-
ment by the US Food and Drug Administration (FDA) as first or second line treatment of sev-
eral hematological malignancies and some solid tumors [471]. Antibody-based therapies can 
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act through several mechanisms to increase the hosts’ antitumor effects and enhance innate 
and adaptive immunity. These include checkpoint blockade antibodies (e.g anti-CTLA-4 or 
anti-PD1) targeting suppression of T cells, or antibodies against tumor-associated antigens 
(e.g. anti-HER2, anti-EGFR and anti-CD20) inhibiting signaling pathways, which are im-
portant for tumor cell proliferation, angiogenesis and metastasis, as well as inducing ADCC or 
complement-dependent cytotoxicity (CDC) [471, 472]. An example for successful antibody 
therapy is the anti-EGFR human-mouse chimeric monoclonal antibody cetuximab, which was 
approved by the FDA for the treatment of patients with advanced HNSCC. Cetuximab treat-
ment resulted in improved survival of patients in clinical trials when given in combination 
with radiotherapy or cisplatin chemotherapy [473]. However, administration of antibodies can 
result in adverse side effects (e.g. allergic reactions, hypertension or diarrhea) and toxicity 
caused by on- and/or off-target effects due to the choice of antigens or antibody construct 
[474]. In case of cetuximab skin toxicity could be observed due to the expression of EGFR in 
the basal layer of the epidermis. Moreover, some patients were less responsive to cetuximab 
treatment due to the expression of the mutant EGFRvIII variant on tumor cells and polymor-
phisms in the FcγRIIIa (CD16a) receptor, that impact binding of cetuximab to cytotoxic lym-
phocytes [473, 475]. A critical aspect for efficacy and applicability of antibody therapy is 
therefore the targeted tumor antigen. Most antigens are either not exclusively expressed by 
tumor cells, show a high degree of mutations in tumor entities or can be downregulated during 
tumor progression.  
In this respect, Salih and coworkers [476] introduced a recombinant fusion protein of the 
NKG2D ectodomain and a human IgG-Fc part as therapeutic option for the treatment of leu-
kemia and breast cancer, especially HER2/neu negative breast cancer cells, which were not 
susceptible to trastuzumab (monoclonal anti-HER2/neu antibody) treatment. They could show 
the induction of ADCC-mediated antitumor/-leukemia NK cell reactivity against NKG2D 
ligand expressing tumor cells in vitro by the NKG2D fusion protein with an ADCC-optimized 
Fc part [476, 477]. However, binding of the NKG2D fusion protein to NKG2D ligands on 
tumor cells blocked NKG2D-mediated activation and cytolytic function of NK cells. Moreo-
ver, the efficacy against tumors and the emergence of possible side effects (e.g on NKG2D 
ligand expressing healthy tissues) must be further addressed in in vivo studies. The develop-
ment of therapeutic anticancer agents is therefore dependent on the extensive and critical 
Discussion 134 
  
 
evaluation of their pharmacodynamics, pharmacokinetics, immunogenicity and effector func-
tions in laboratory and clinical trials. 
Besides, cellular therapies based on adoptive transfer of NKG2D+ cytotoxic lymphocytes (i.e. 
NK cells) showed promising therapeutic potential in patients suffering from leukemia and 
some solid tumors [478]. Several clinical trials showed a beneficial effect of ex vivo IL-2 ex-
panded and activated allogeneic NK cell transfusion or NK cell transfer in combination with 
IL-2 treatment in cancer patients without causing severe GvHD [479-482]. Moreover, redi-
recting genetically engineered T cells expressing an NKG2D-targeting CAR could induce 
tumor elimination of NKG2D ligand expressing cells in a TCR-independent manner and even 
activated the hosts’ antitumor immunity in mice [346-348, 483]. However, a recent study by 
vanSeggelen et al. [484] reported severe off-tumor toxicity of T cells expressing different 
NKG2D-CAR constructs in multiple mouse strains. The authors concluded that the high ex-
pression levels of highly active NKG2D-CARs led to the recognition of NKG2D ligands ex-
pressed on healthy tissues. The combination of CAR T cells and chemotherapy thereby en-
hanced toxicity by upregulation of NKG2D ligands in the lung of the mice. Moreover, they 
could show, that NKG2D-CAR expressing T cells secreted high levels of inflammatory cyto-
kines, which might contribute to severe toxicity, similar to those observed in several clinical 
trials with T cell therapies [485]. Due to the severe toxicity of NKG2D-CAR T cells in mice, 
the use of NKG2D-CAR T cells for therapeutic applications in humans should be carfully 
considered. Regarding the safety of cytokine-activated allogeneic NK cells in clinical trials 
and the enhanced antitumor efficacy of NKG2D-CAR transduced NK cells in mice [353], NK 
cell-based cellular therapies might be a promising alternative approach in cancer therapy.  
The efficacies of cellular therapies or the different NKG2D-targeting immunotherapeutic 
strategies, however, depend on a robust expression of the ligands on the tumor cell surface 
and the NKG2D receptor on cytotoxic immune cells, which can both be impaired by the re-
lease of NKG2D ligands. This could be demonstrated in a clinical phase I/II trial in which 
patients suffering from high-risk neuroblastoma were treated with allogeneic IL-2 stimulated 
NK cells after HSCT in order to improve the clinical outcome [305]. In this study, elevated 
levels of sMICA in patients’ plasma correlated significantly with impaired NKG2D-dependent 
cytotoxicity of the donor NK cells in vivo. This effect could only be temporarily reversed by 
infusion of large numbers of ex vivo stimulated NK cells expressing high NKG2D levels, 
which could retain cytotoxicity via non-occupied NKG2D receptors after sMICA scavenging. 
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Therefore, cellular immunotherapies should be combined with NKG2D-dependent tumor im-
mune escape intervention strategies to improve their antitumor efficacy. In this respect, neu-
tralizing monoclonal antibodies against the soluble NKG2D ligands might be considered. Ji-
nushi et al. [486] could show that patients treated with anti-CTLA-4 antibodies or vaccinated 
with autologous, irradiated tumor cells had high titers of anti-MICA antibodies, which corre-
lated with decreased sMICA levels and opsonized tumor cells for DC cross-presentation. 
However, the numerous NKG2D ligands would require the clinical administration of a cock-
tail of ligand-specific antibodies or the use of recombinant NKG2D proteins, which could 
both bind to membrane associated NKG2D ligands on tumor cells and therefor block the 
NKG2D-dependent tumor clearance by cytotoxic lymphocytes. Since NKG2D ligand shed-
ding is mediated by MMPs, targeting MMP activity might be a possibility for intervention. 
Due to the contribution of MMPs to aggressive tumor growth, metastases, angiogeneis and 
poor patients prognosis, several MMP inhibitors were studied in clinical cancer trials to inhib-
it tumor progression and angiogenesis [487]. MMPs are involved in many other processes 
such as tissue morphogenesis and tissue repair, therefore most of these trials failed due to se-
vere side effects of the early broad-range MMP inhibitors [488, 489]. However, the therapeu-
tic use of MMP inhibitors for intervention of NKG2D ligand shedding was not assessed in 
these trials. Combining MMP inhibitors for short-term treatment of cancer patients prior to 
cellular therapies could be a possible therapeutic strategy to enhance antitumor functions of 
immune cells. The re-production kinetics of sNKG2D ligands implicate that a short-term ap-
plication of MMP inhibitors might be sufficient to inhibit NKG2D ligand release and render 
tumor cells more susceptibile to NKG2D-dependent recognition. Thus, changing the thera-
peutic regimen of MMP inhibitors might reduce systemic effects of the drugs. 
 
4.6 Adsorption Apheresis of sNKG2D Ligands as new therapeutic 
Concept to improve Lymphocyte Functions 
Within this thesis, it could be shown that the depletion of sNKG2D ligands from patients’ 
plasma or cell culture supernatants was sufficient to restore NK cell cytotoxicity in vitro. 
Therefore, adsorption apheresis of sNKG2D ligands was considered as therapeutic strategy to 
overcome NKG2D-dependent tumor immune escape and to improve the efficacy of cytotoxic 
lymphocytes. As proof of concept, the monoclonal antibody AMO1 with an epitope in the α1-
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helical domain of the representative ligand MICA coupled to different matrices proofed useful 
to efficiently remove sMICA from human plasma at apheresis-like conditions in vitro. More-
over, the antibody epitope, which is located in a highly conserved region of MICA, ensured 
the recognition and depletion of different allelic variants and even MICA released on exo-
somes (MICA*08). This is of importance regarding the high polymorphism and the variable 
MICA allelic frequencies in a number of human populations as well as the lack of allele and 
haplotype profiles of most cancer patients [220, 490]. Interestingly, no antibody with an 
epitope in the α3-helical domain could efficiently deplete sMICA from plasma as shown for 
the BAMO3 antibody. This might be due to masking of the recognition site by soluble factors 
interacting with sMICA in the plasma, conformational changes in the flexible terminus after 
shedding, or the proteolytical cleavage of sMICA variants with staggered termini lacking parts 
of the epitope [296, 298]. Interestingly, binding of the BAMO3 antibody to sMICA from hu-
man plasma was not altered when BAMO3 was used as capture antibody in ELISA measure-
ments. In addition, the BAMO3 antibody could not inhibit shedding of sMICA (data not 
shown) although its binding region overlapped in parts with the binding site of the disulfide-
isomerase ERp5, which is needed for MICA cleavage and was proposed as target for MICA 
shedding intervention [299, 491]. Thus, antibodies for an intracorporeal intervention of MICA 
shedding or sMICA neutralization must be carefully analyzed with respect to toxicity, their 
epitope and binding properties as well as blocking NKG2D recognition of membrane-bound 
MICA on tumor cells. Adsorption apheresis is an extracorporeal application and the choice 
and development of antibody constructs or recombinant proteins might not be as critical, since 
the immunogenic side effects and toxicity mediated by therapeutic antibodies and proteins are 
due to the in vivo application. Moreover, choosing an antibody with an epitope in the NKG2D 
binding site does not interfere with NKG2D recognition of tumor cells in vivo. 
Although monoclonal antibodies are commonly used as therapeutic agents in several clinical 
settings and the bioprocessing technology for the large-scale production of clinical grade anti-
bodies advanced [492], generating an adsorber cartridge using multiple monoclonal antibodies 
for the different NKG2D ligands might not be applicable for the clinics due to unreasonable 
manufacturing efforts. The patient specific composition of the individual sNKG2D ligands in 
the plasma would further necessitate the generation of individualized adsorber matrices with 
different combinations and amounts of the respective anti-NKG2D ligand antibodies to ensure 
efficient removal of all ligands leading to NKG2D inhibition. The generation of an adsorber 
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containing six different antibodies or the use of six different adsorber cartridges in an aphere-
sis setup is technically demanding, uncommercialy, and the combination of numerous anti-
bodies might not be compatible with guidelines for FDA approval. Morover, the high poly-
morphism of the NKG2D ligands is critical for the selection of each individual antibody re-
regarding specificity to the ligands and the capability to recognize distinct allelic variants. In 
this respect, the biotinylated NKG2D::IgG1-Fc fusion protein developed in this thesis was 
validated for the efficient and simultaneous depletion of sNKG2D ligands from human plas-
ma. In contrast to the recombinant NKG2D proteins produced in E. coli, the fusion of the 
NKG2D ectodomain to the human Fc part containing a biotinylation sequence enhanced pro-
tein stability, improved the production and purification steps using a mammalian cell line and 
ensured the Fc-directed immobilization of functional proteins due to the biotin-tag. In vitro 
depletion experiments further demonstrated that the NKG2D fusion protein removed the 
sNKG2D ligands from human plasma with comparable efficacy as the cocktail of monoclonal 
antibodies used for the depletion prior to cytotoxicity assays. The NKG2D-functionalized 
matrix for adsorption apheresis would have several advantages: i) the production process of 
the NKG2D fusion proteins is comparable to that of recombinant monoclonal antibodies with 
regard to cell lines used and purification strategies [493], but would need the industrial clini-
cal-grade production of only one protein component, ii) the recombinant NKG2D proteins can 
bind to all different ligands and their allelic variants comparable to the NKG2D receptor on 
cytotoxic lymphocytes and antagonizes the key player of tumor immune escape, and iii) the 
pan-specific adsorber would therefore be applicable to a broad patient cohort independent of 
the sNKG2D ligand composition in the plasma. However, since the NKG2D protein was de-
veloped for the laboratory use, industrial high-scale production processes and coupling proce-
dures must be specially optimized from the currently used protocols and further characterized 
and validated for a pre-clinical study and future clinical application. 
To proof the feasibility of adsorption apheresis of sNKG2D ligands in a living organism, a 
pre-clinical study using the anti-MICA (AMO1) antibody-functionalized adsorber was con-
ducted in rhesus monkeys. Although murine models are a powerful tool to address immuno-
logical questions in cancer research, several genetical and functional differences in NK cell 
subpopulations, the different expression and function of inhibitory and activating receptors, 
especially of the NKG2D receptor and its diverse ligands [451, 494, 495], limit their use for 
analysis of NKG2D-dependent NK cell functions. Moreover, the small body size and related 
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blood volume of mice accounts for technical constraints for adsorption apheresis. In contrast, 
due to the high phylogenetic relatedness of humans and non-human primates, NK cell sub-
types and the NKG2D/NKG2D ligand system display a high degree of homology [496]. 
Moreover, the body size and blood volume of rhesus monkeys allowed for the validation of 
adsorption apheresis using the Life18TM apheresis unit, which is currently used for apheresis 
applications in the clinics. The proof of concept study in rhesus monkeys demonstrated that 
the quantitative removal of sMICA could be achieved after only three plasma volume ex-
changes and therefore proofed technically feasible and might be a supportive therapy for 
HNSCC patients in order to restore cytotoxicity of NKD2D+ immune cells. However, the non-
disease animal model could not reveal the re-production kinetics of sNKG2D ligands by tu-
mor cells in vivo. Since no inhibitory effect of human sMICA could be observed on basal 
NKG2D expression levels of non-activated NK cells during the experiment, the impact of 
sMICA depletion on the cytotoxic capacity of the animals’ immune cells could not be deter-
mined. These questions must be addressed in future clinical trials with cancer patients. How-
ever, based on the results from in vitro cytotoxicity experiments adsorption apheresis of 
sNKG2D ligands might help to maintain and prolong the cytotoxic activity of endogenous 
NKG2D+ NK cells and, if combined prior to administration of cellular therapies, of adoptively 
transferred immune cells after haploidentical stem cell transplantation. Besides healthy donor 
derived cell products this will also include T cells and NK cells which have been functional-
ized with CARs, especially NKG2D-CARs. Several studies showed that NKG2D is upregu-
lated on activated CD8+ T cells and enhanced T cell proliferation, Ca2+-mobilization as well 
as mediate TCR-independent killing of NKG2D ligand expressing tumor cells by CD8+ and 
γδ T cells [195, 215, 216, 266, 497, 498]. Moreover, sNKG2D ligands and TGF-β1 lead to 
impaired NKG2D expression levels and activation of T cells [315, 319, 401, 499]. Thus, alt-
hough NKG2D functions as co-stimulatory receptor in CD8+ T cells and γδ T cells it is sup-
posed that sNKG2D ligand apheresis might also improve the antitumor functions of these 
immune cells.  
Compared to NKG2D-dependent tumor immune escape interfering immunotherapies, which 
rely on the administration of therapeutic compounds, adsorption apheresis represents a mini-
mal invasive procedure similar to plasmapheresis in autoimmune diseases and hemodialysis 
of diabetic patients, which can be repeated several times to scavenge reappearing sNKG2D 
ligands from patients’ plasma without causing severe side effects [500, 501]. Therefore, ad-
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sorption apheresis represents an ideal supportive therapeutic concept, which can be combined 
with several immunotherapies such as adoptive immune cell transfer or antibody therapy to 
improve antitumor immunity. 
 
4.7 Concluding Remarks and Perspectives 
During the last years, the number of therapeutic strategies for cancer treatment increased due 
to advances in our understanding of tumor immunology. The development of new immuno-
therapies substantially increased the clinical outcome of cancer patients. However, a large 
number of patients fail to respond and succumb to progressive disease. A central goal in on-
cology is therefore the identification of new biomarkers and the use of combinatorial cancer 
therapies to individualize therapeutic regimens and to overcome tumor immune escape mech-
anisms.  
The results of this thesis demonstrated the impact of sNKG2D ligands in HNSCC. The pat-
terns of soluble immunosuppressive factors were shown to be patient specific and to depend 
on the individual clinical situation. Thus, profiling of sNKG2D ligands in patients’ plasma 
together with immunosuppressive cytokines, especially TGF-β1, should be considered in the 
clinics as diagnostic and/or prognostic marker combination. To ensure a stable diagnostic pro-
cedure, diverse NKG2D ligand ELISAs could be optimized for clinical use. Furthermore, the 
development of cytometric bead arrays for the multiple NKG2D ligands would allow for the 
rapid detection of multiple parameters from small plasma sample volumes. Regarding the 
numerous therapies targeting the NKG2D/NKG2D ligand system and the broad expression 
pattern of sNKG2D ligands in multiple cancer entities, including sNKG2D ligands in the di-
agnostics of cancer patients would help to stratify patient cohorts and select for individualized 
strategies to improve patients’ outcome.  
Along this line, adsorption apheresis of sNKG2D ligands might substantially increase the ef-
ficacy of tumor immunotherapy and might thus be a versatile supportive module in a variety 
of settings. The clinical-grade production of the NKG2D fusion proteins will allow for the 
evaluation of the pan-specific adsorber in a clinical study with a patient cohort selected for 
high sNKG2D ligand plasma levels. The clinical study will decipher the therapeutic potential 
of adsorption apheresis on the restoration of innate and adaptive immune cell functions as 
well as the reproduction kinetics of sNKG2D ligands by the tumor. Furthermore, adsorption 
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apheresis can be conducted in combination with subsequent cellular immunotherapy with al-
logeneic NK or T cells.  
Several lines of argumentation indicate that adsorption apheresis of sNKG2D ligands might 
be a powerful supportive strategy in cancer therapy. First, the overall sNKG2D ligand level 
correlates with tumor burden as shown by studies with patients pre- and post-surgery. Thus, 
the tumor load determines the maximum level of sNKG2D ligands in the plasma. Second, 
adsorption apheresis will increase the fraction of NKG2D+ immune cells that are capable of 
attacking NKG2DL+ tumor cells. In turn, the tumor mass and its capacity to reproduce 
sNKG2D ligands will be reduced. Third, adsorption apheresis is an extracorporeal application 
and does not interfere with antitumor NKG2D-dependent immune cell functions. Along this 
line, it is a minimal invasive strategy that can be repeated several times after cellular therapy 
in order to scavenge reappearing sNKG2D ligands from patients’ plasma. Moreover, previous 
results indicated that plasma levels of sNKG2D ligands (i.e. sMICA) remained low for more 
than 72 h after scavenging in neuroblastoma patients [305]. Therefore, a considerable time 
frame between two adsorption apheresis cycles might exists for improved antitumor activity 
of cytotoxic lymphocytes. Thus, the periodic boosting of the NKG2D+ immune cells by ad-
sorption apheresis will lead to constant shrinking of the tumor mass, sustained reduction of 
sNKG2D ligand plasma levels, and extended antitumor activity of NKG2D+ immune cells. 
Notably, the intervals between two cycles of adsorption apheresis might increase with tumor 
mass reduction. Furthermore, the apheresis concept could be easily expanded combining two 
adsorber cartridges to deplete further soluble immunosuppressive factors in particular TGF-
β1, which was shown to have an additive effect on NKG2D-dependent NK cell inhibition. 
Whereas hematological malignancies are highly susceptible to immunotherapies, the devel-
opment of successful treatments for solid cancers is still challenging and often limited by low 
infiltration capacities of cytotoxic lymphocytes as seen in primary tumors of HNSCC patients. 
Different factors such as immunoediting, immunoevasion and the cellular crosstalk with other 
immune cells within the complex tumor microenvironment influence the antitumor activity of 
T and NK cells [281, 502-505]. Within this thesis, infiltration studies using tumor spheroids 
further indicated a potential role of sNKG2D ligands on inhibition of NK cell infiltration. 
However, the molecular mechanism how sNKG2D ligands reduce infiltration frequencies of 
NK cells in primary tumors must be further elucidated. Furthermore, the determination of the 
phenotype and functionality of infiltrating immune cells vs. immune cells in the tumor pe-
Discussion 141 
  
 
riphery might be of importance to establish and optimize protocols for the generation of effi-
cacious effectors for the use in cellular cancer therapies. Up to now, the majority of data about 
human NK cell subtypes were based on studies with peripheral blood lymphocytes and little is 
known about NK cells in human tissues due to their limited accessibility. Moreover, the use of 
syngeneic mouse models is limited due to phenotypical and functional differences of murine 
and human NK cell subsets [506]. The tumor spheroid model and the presented MACS-based 
NK cell isolation protocol (see 5.1.4) offers the possibility to separate NK cell subpopulations 
of the tumor periphery from infiltrated NK cells and allows for the quantitative recovery of 
viable infiltrated NK cells. In order to decipher phenotypic differences, which account for the 
ability to infiltrate tumor spheroids, these isolated and enriched NK cell subpopulations could 
be further used in comparative microarray analyses to determine mRNA expression profiles of 
inhibitory and activating receptors, cytokines/chemokines and integrins. In addition, proteo-
mic and gene expression profiles of NK cell subpopulations could be assessed using mass 
cytometry (CyTOF) or single cell PCR. Using NK cells pre-incubated with human plasma or 
cell culture supernatant will thereby help to decipher the modulatory potential of sNKG2D 
ligands and other soluble immunoregulatory factors on immune cell activity. The 3D spheroid 
model and MACS-based isolation protocol could be further adapted to different cytotoxic 
lymphocyte populations, such as NKT cells, CD8+ and γδ T cells. Furthermore, other cell 
types that might affect the tumor micromilieu can be included into the tumor spheroid assays 
to introduce further complexity of the tumor microenvironment and allow the analysis of the 
cellular cross-talk between different immune cells. Besides, tissue-derived tumor spheres and 
organotypic multicellular spheroids could be directly generated by dissection of primary tu-
mor tissues from cancer patients [507]. The phenotypic and transcriptional profiling data 
could not only increase the understanding of the diverse functions of NK cell subpopulations 
but could also be used for stratification of patient- or donor-derived immune cells to improve 
and personalize cellular immunotherapy. 
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5 Appendix 
5.1 Supplemental Data 
5.1.1 sNKG2D Ligand Patterns in HNSCC Patients’ Plasma 
 
Figure S1: sNKG2D ligand plasma levels of individual HNSCC patients.  
Patients’ plasma samples were analyzed for their sNKG2D ligand levels by respective ELISAs (see 
also Figure 5). HNSCC patients are indicated by number and are presented with increasing disease 
stage (I - IVC). The mean plasma levels of 12 age-matched healthy controls were used as controls 
(CO). Bars correspond to mean ± SEM of duplicates or the sum of sNKG2D ligands for each patient. 
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5.1.2 Gating Strategies of Cytotoxicity Assays 
Gating strategies of cytotoxicity assays for evaluation of tumor cell lysis in cell suspension 
(Figure S2; according to 3.1.4) and tumor spheroids (Figure S3; according to 3.2.3). Tumor 
(CFSE+) and NK (CD45-APC+) cell populations were separated. Tumor cell killing was cal-
culated based on live/dead cell discrimination according to SytoxBlue staining. The ratio and 
total cell count of live (CFSE+/SytoxBlue-) and dead (CFSE+/SytoxBlue+) cells was deter-
mined. Dot plots of representative experiments are shown for human plasma or CAL27 su-
pernatant pre-treated NK cells. 
 
Figure S2: Cytotoxicity assays with plasma-treated primary human NK cells.  
Flow cytometric analysis of cytotoxicity assay with human plasma pre-treated primary NK cells to-
wards SiHa target cells (see also Figure 11). Gating strategy on CFSE-labeled SiHa target (T) and anti-
CD45-APC stained effector (E) NK cells and analysis of live (CFSE+/SytoxBlue-) and dead 
(CFSE+/SytoxBlue+) cells in the target cell population (T). Dot plots of a representative experiment are 
shown for non-depleted and sNKG2D ligand-depleted healthy plasma and two HNSCC patients’ 
plasma (patient 13 and 43). NK cells pre-incubated with anti-NKG2D blocking antibodies served as 
control. 
 
Appendix 144 
  
 
 
Figure S3: Cytotoxicity assay of FaDu and SiHa tumor spheroids. 
Flow cytometric analysis of tumor spheroids cytotoxicity assays with CAL27 SN and NKG2D-ligand 
depleted SN pre-treated primary human NK cells (see also Figure 23). Gating strategy on CFSE-
labeled target (T) and analysis of live (CFSE+/SytoxBlue-) and dead (CFSE+/SytoxBlue+) target cells. 
Dot plots of one representative experiment are shown for FaDu and SiHa spheroids.   
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5.1.3 Infiltration of Tumor Spheroids 
 
Figure S4: NK cell infiltration into tumor spheroids.  
NK cells were pre-treated overnight with sMICA01 or were left untreated (kill CO) prior to co-
culturing with CAL27 (A) or SiHa cells (B) (see also Figure 24). Tumor spheroid formation was moni-
tored by light microscopy for 48 h. Cryosections of spheroids after 48 h were stained for NK cells 
(anti-CD45 antibody, red) and apoptosis (anti-active caspase-3 antibody, brown). Representative his-
tology pictures are shown at 200x magnification. Size bar corresponds to 200 µm. 
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5.1.4 MACS-based Protocol for the Isolation of Tumor Spheroid infiltrat-
ing NK Cells 
Solid SiHa tumor spheroids were co-cultured with primary human NK cells at a low E:T ratio 
of 3:1 for 24 h. Peripheral NK cells were removed from the spheroid fraction and disintegrat-
ed tumor spheroids were subjected to MACS isolation for the recovery of infiltrated CD45+ 
NK cells. The resulting three fractions were generated i) peripheral non-infiltrating NK cells 
in the tumor spheroid supernatant (P), ii) tumor cells in the flow through of the MACS col-
umn (F), and iii) infiltrated NK cells recovered after elution from the MACS column (E) 
(Figure S5A). Flow cytometric analysis of the individual cell fractions showed that the major-
ity of NK cells were detected in the periphery as seen earlier in microscopic analyses. A total 
count of 30.5 ± 4.8 x104 peripheral and 3.5 ± 1.3x104 (16.2% of total NK cells) infiltrated NK 
cells could be recovered from SiHa tumor spheroids (Figure S5B). Regarding cell viability, 
80.5 ± 0.5 % of the peripheral NK cells were viable (P fraction: 1.0 ± 0.0 % dead NK cells) 
compared to 74.3 ± 6.9 % viable infiltrated NK cells (E fraction: 12.7 ± 7.1 % dead NK cells; 
Figure S5C). Most importantly, infiltrated NK cells could be isolated with a high purity, with 
only 22.7 ± 2.7 % tumor cells (Figure S5C/D). Moreover, analysis of tumor cell viability 
demonstrated efficient tumor cell killing after 24 h co-incubation with 51.7 ± 1.4 % residual 
viable and 29.0 ± 3.2 % dead tumor cells in the flow through (F fraction) and only 7.0 ± 0.0 % 
viable and 11.5 ± 1.5 % dead tumor cells in the periphery (P fraction). Notably, tumor sphe-
roid destruction was incomplete due to the low E:T ratio used in these experiments focused on 
NK cell infiltration. Thus, the presented tumor spheroid assay proofed useful to investigate 
immunosurveillance and associated immune escape by soluble mediators as well as tumor 
spheroid infiltration. Furthermore, the MACS-based isolation protocol offers new possibilities 
to investigate and characterize infiltrated NK cell subpopulations in future studies.  
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Figure S5: Isolation and enrichment of infiltrated NK cells from tumor spheroids. 
(A) Work flow of MACS-based cell fractionation. Tumor spheroid co-cultures (E:T=3:1; 24 h) of a 96-
well plate were pooled, washed to remove peripheral NK cells (P) and residual spheroids were disinte-
grated and subjected to CD45 MACS-bead isolation leading to the flow through (F) containing tumor 
cells and the column eluate (E) containing infiltrated NK cells. Cells from all fractions were quantified 
by flow cytometry after SytoxBlue staining (live/dead discrimination). Tumor spheroids cultured 
without NK cells served as controls. (B) Total number of viable CD45+ NK cells per fraction. Quanti-
fication of cell viability for NK cells (C) and tumor cells (D). Data is represented as mean ± SEM of 
three individual experiments. 
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5.1.5 Production of recombinant Proteins 
Soluble MICA variants for ELISA (rMICA*01/04; sMICA*01/04), depletion (sMICA*01/04; 
MICA*01/04::hIgG1-Fc) or adsorption apheresis (sMICA*04) studies. 
 
5.1.5.1 E. coli derived rMICA*01/04 
 
Figure S6: Production and purification of rMICA*01/04 from E. coli. 
Recombinant proteins rMICA*01 (upper panel) and rMICA*04 (lower panel) were expressed in 
E. Coli and purified from inclusion bodies. (A) Reducing SDS-PAGE (Coomassie-stained) and im-
munoblot (polyclonal anti-MICA antibody in combination with an anti-goat HRP-conjugated anti-
body) of aliquots (input, flow-through (ft), wash and eluate fractions) of rMICA*01/04 (ectodomain 
containing a C-terminal His-tag) after affinity purification via Ni-NTA agarose from solubilized inclu-
sion bodies. (B) Size exclusion chromatography (SEC) of purified and refolded rMICA*01/04 on a 
HiLoad 16/600 Superdex 200 pg column. * = MICA ~33 kDA; ** = degradation products ~5 kDA 
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5.1.5.2 sMICA*01/04 produced in HEK293T Cells 
 
 
Figure S7: Characterization of recombinant sMICA proteins. 
Recombinant proteins sMICA*01 (upper panel) and sMICA*04 (lower panel) were expressed in 
HEK293T cells after transient transfection. (A) Reducing SDS-PAGE (Coomassie-stained) and im-
munoblot (polyclonal anti-MICA antibody in combination with an anti-goat HRP-conjugated anti-
body) of aliquots (input, flow-through (ft), wash and eluate fractions) of sMICA*01/04 (ectodomain 
containing a C-terminal His-tag) after affinity purification via Ni-NTA agarose from HEK293T cell 
culture supernatants. (B) Size exclusion chromatography (SEC) of purified sMICA*01/04 on a Super-
dex 200 column. Peaks correspond to MICA proteins with a molecular mass of ~65 kDa. (C) Deglyco-
sylation of purified sMICA*01/04 proteins. Reducing SDS-PAGE (Coomassie-stained) and immunob-
lot (polyclonal anti-MICA antibody in combination with an anti-goat HRP conjugated antibody) of 
untreated (glycosylated; lane 1), PNGaseF treated (removal of N-linked glycans; lane 2) or enzyme 
mix treated (removal of N- and O-linked glycans; lane 3) sMICA*01/04. The equivalent non-
glycosylated sMICA variants produced in E. coli served as control (CO; lane 4). 
 
 
 
 
 
 
 
Appendix 150 
  
 
5.1.5.3 MICA*01/04::hIgG1-FcEQ produced in HEK293T Cells 
 
Figure S8: Production and purification of MIA*01/04::hIgG1-Fc proteins.  
MICA*01(A) and sMICA*04 (B) Fc fusion proteins were expressed in HEK293T cells. Non-reducing 
SDS-PAGE (Coomassie-stained) and immunoblot (anti-human IgG HRP-conjugated antibody) of ali-
quots (flow-through (ft), wash and eluates) from Protein A purification of culture supernatants. 
 
5.1.5.4 NKG2D::hIgG1-Fc produced in HEK293T Cells 
Figure S9: Characterization of NKG2D::hIgG1-FcEQ produced in HEK293T cells.  
(A) NKG2D::hIgG1-Fc expressed in HEK293T cells. Non-reducing SDS-PAGE (Coomassie-stained) 
and immunoblot (anti-human IgG HRP-conjugated antibody) of aliquots (flow-through (ft), wash and 
eluates) after purification via Protein A from culture supernatants. (B) Binding analysis of 
NKG2D::hIgG1-Fc to HEK293T cells by flow cytometry with an anti-human IgG-Dylight649 anti-
body. Grey = antibody control, red = NKG2D. (C) Depletion of sMICA allelic variants using 
NKG2D::hIgG1 coupled to Protein A- or anti-human IgG magnetic beads (left) or fusion proteins con-
taining a short (GSSG) or long ((GGGS)3) flexible linker. Beads coupled with NKp30::hIgG1-Fc 
served as controls. MICA levels before and post depletion were determined by ELSIA and normalized 
to the initial sMICA levels. Data are represented as mean ± SEM of a representative experiment out of 
three. 
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5.1.6 Peptide Spot Sequences 
MICA amino acid sequence (Q29983; aa 23 - 308); spots of 18mer peptides, off-set of 4 ami-
no acids: 
A1  AEPHSLRYNLTVLSWDGS 
A2  SLRYNLTVLSWDGSVQSG 
A3  NLTVLSWDGSVQSGFLTE 
A4  LSWDGSVQSGFLTEVHLD 
A5  GSVQSGFLTEVHLDGQPF  
A6  SGFLTEVHLDGQPFLRCD 
A7  TEVHLDGQPFLRCDRQKC  
A8  LDGQPFLRCDRQKCRAKP  
A9  PFLRCDRQKCRAKPQGQW  
A10 CDRQKCRAKPQGQWAEDV  
A11 KCRAKPQGQWAEDVLGNK  
A12 KPQGQWAEDVLGNKTWDR  
A13 QWAEDVLGNKTWDRETRD  
A14 DVLGNKTWDRETRDLTGN  
A15 NKTWDRETRDLTGNGKDL  
A16 DRETRDLTGNGKDLRMTL  
A17 RDLTGNGKDLRMTLAHIK  
A18 GNGKDLRMTLAHIKDQKE  
A19 DLRMTLAHIKDQKEGLHS  
A20 TLAHIKDQKEGLHSLQEI  
A21 IKDQKEGLHSLQEIRVCE  
A22 KEGLHSLQEIRVCEIHED  
A23 HSLQEIRVCEIHEDNSTR 
A24 EIRVCEIHEDNSTRSSQH 
A25 CEIHEDNSTRSSQHFYYD 
A26 EDNSTRSSQHFYYDGELF 
A27 TRSSQHFYYDGELFLSQN 
A28 QHFYYDGELFLSQNLETK 
A29 YDGELFLSQNLETKEWTM 
A30 LFLSQNLETKEWTMPQSS 
A31 QNLETKEWTMPQSSRAQT 
A32 TKEWTMPQSSRAQTLAMN 
A33 TMPQSSRAQTLAMNVRNF 
A34 SSRAQTLAMNVRNFLKED 
A35 QTLAMNVRNFLKEDAMKT 
A36 MNVRNFLKEDAMKTKTHY 
B1  NFLKEDAMKTKTHYHAMH 
B2  EDAMKTKTHYHAMHADCL 
B3  KTKTHYHAMHADCLQELR 
B4  HYHAMHADCLQELRRYLK 
B5  MHADCLQELRRYLKSGVV 
B6  CLQELRRYLKSGVVLRRT 
B7  LRRYLKSGVVLRRTVPPM 
B8  LKSGVVLRRTVPPMVNVT 
B9  VVLRRTVPPMVNVTRSEA 
B10 RTVPPMVNVTRSEASEGN 
B11 PMVNVTRSEASEGNITVT 
B12 VTRSEASEGNITVTCRAS 
B13 EASEGNITVTCRASGFYP 
B14 GNITVTCRASGFYPWNIT 
B15 VTCRASGFYPWNITLSWR 
B16 ASGFYPWNITLSWRQDGV 
B17 YPWNITLSWRQDGVSLSH 
B18 ITLSWRQDGVSLSHDTQQ 
B19 WRQDGVSLSHDTQQWGDV 
B20 GVSLSHDTQQWGDVLPDG 
B21 SHDTQQWGDVLPDGNGTY 
B22 QQWGDVLPDGNGTYQTWV 
B23 DVLPDGNGTYQTWVATRI 
B24 DGNGTYQTWVATRICQGE 
B25 TYQTWVATRICQGEEQRF 
B26 WVATRICQGEEQRFTCYM 
B27 RICQGEEQRFTCYMEHSG 
B28 GEEQRFTCYMEHSGNHST 
B29 RFTCYMEHSGNHSTHPVP 
B30 YMEHSGNHSTHPVPSGKV 
B31 SGNHSTHPVPSGKVLVLQ 
B32 STHPVPSGKVLVLQSHWQ  
 
 
 
Figure S10: Peptide spot array control corresponding to Figure 26. 
Peptide spot arrays (18mer peptides; off-set of 4 amino acids) of the human MICA were incubated 
with anti-mouse IgG HRP-conjugated antibody.  
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5.1.7 Expression of NKG2D Ligands on C1R and HEK293T Cells 
 
 
Figure S11: Surface expression of NKG2D ligands on NKG2D ligand transfected C1R cells.  
Flow cytometric analyses of NKG2D ligand surface expression on C1R cell transfectants expressing 
sMICA allelic variants (sMICA*01, sMICA*04, sMICA*07 and sMICA*08), MICB, ULBP1-3 or 
C1R mock transfected (neo) cells. Respective cell clones were stained with monoclonal mouse anti-
NKG2D ligand antibodies (all R&D systems) and anti-mouse IgG1 or anti-mouse IgG2a/b APC-
conjugated secondary antibodies. Grey = secondary antibody control; red = NKG2D ligand antibodies. 
 
 
 
Figure S12: Surface expression of NKG2D ligand on HEK293T cells.  
Flow cytometric analyses of NKG2D ligand surface expression on HEK293T cells. Cells were stained 
with monoclonal mouse anti-NKG2D ligand antibodies (all R&D systems) and anti-mouse IgG1 or 
anti-mouse IgG2a/b APC-conjugated secondary antibodies. Grey = secondary antibody control; 
red = NKG2D ligand antibodies. 
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5.1.8 Affinity Maturation of NKG2D Proteins 
The binding affinity of protein-protein interactions determines the effect of biosensors, anti-
bodies, small molecules or chemical compounds. Consequently, manipulation of binding af-
finities is an important point for the design and development of therapeutics. In this thesis, 
recombinant NKG2D proteins proofed to be a promising tool for the pan-specific adsorption 
of sNKG2D ligands from patients’ plasma. Although NKG2D’s binding affinities to the dif-
ferent ligands varied, successful depletion could be achieved for all ligands tested. Neverthe-
less, it was of interest, if the binding properties of NKG2D could be further improved. There-
for, a structure-based method for the rational prediction of single point mutations in the 
receptor-ligand binding interface that enhance binding affinities was used [508]. As proof of 
concept, point mutations for the enhanced binding to MICA were predicted depending on the 
crystal structure of the NKG2D-MICA complex (PDB; 1HYR) [243]. Single point mutations 
were bioinformatically calculated using the molecular modeling program Rosetta [509] by A. 
Metz (group of H. Gohlke, Computational Pharmaceutical Chemistry and Molecular Bioin-
formatics, Heinrich-Heine University, Düsseldorf, Germany).  
 
Figure S13: Production of NKG2D::hIgG1-Fc MICA-affinity mutants. 
(A) Crystal structure of the NKG2D homodimer (blue) bound to the sMICA α1/2-helical domain 
(grey); PDB 1HYR. Amino acids in the NKG2D binding interface for mutation analyses are highlight-
ed. Green = S117; red = K150; yellow = S151; purple = I182; orange = K186. (B) Reducing SDS-
PAGE (Coomassie-stained) and immunoblot analyses (anti-human IgG-Fc HRP conjugated antibody) 
of affinity-purified NKG2D-Fc proteins containing the mutations K150M; K150R; K150W; I182R; 
I182W; K186M; S117E and S151D.  
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Based on the bioinformatical data, eight single mutations in the NKG2D’s binding interface 
(Figure S13A) were chosen for laboratory characterization. The mutations comprise the ami-
no acid substitutions of the lysine at position 150 to methionine (K150M), arginine (K150R) 
or tryptophan (K150W), the lysine at position 186 to methionine (K186M), the isoleucine at 
position 182 to arginine (I182R) or tryptophan (I182W), the serine at position 117 to glutamic 
acid (S117E) as well as the serine at position 151 to aspartic acid (S151D). Since changing the 
hydrophobic surface area can influence protein folding, NKG2D mutants produced in E. coli 
resulted in refolding problems for some mutants (data not shown). Therefor, the single muta-
tions were introduced into the NKG2D::hIgG1-Fc protein and all eight mutants could be suc-
cessfully expressed in HEK293T cells (Figure S13B). 
Functional studies showed efficient binding of the mutants to HEK293T cells expressing dif-
ferent NKG2D ligands (Figure S14A). Interestingly, only slight differences in binding of the 
mutants compared to the wildtype NKG2D fusion protein could be observed. Further evalua-
tion of the binding affinities to sMICA*01 by ELISA measurement revealed that the amino 
acid substitution K150R had no effect on binding affinity, whereas substitutions K150M, 
K150W, I182W and S151D led to the loss of sMICA*01 binding and the substitutions I182R 
and K186M had lower binding affinities compared to wildtype NKG2D::hIgG1-Fc. Interest-
ingly, only the mutant with the S117E substitution showed a highly improved affinity to sMI-
CA*01, which was 10-fold stronger than the binding of the wildtype NKG2D fusion protein 
(Figure S14B). The ELISA results are in accordance with the results from flow cytometry 
experiments indicating that the slight differences of cell surface binding are caused by the 
altered MICA recognition, whereas binding to the other ligands expressed on HEK293T cells 
seems to be unchanged. One explanation for the difference of the laboratory results and the in 
situ calculations could be the failure of the program to calculate the single point mutations 
simultaneously for both monomeric NKG2D binding sites. Thus, the impact on the structure 
and binding interface of the dimeric fusion proteins might be stronger than predicted. Never-
theless, the structure-based prediction of high affinity point mutations led to the generation of 
a NKG2D::hIgG1-Fc protein containing the amino acid substitution S117E with high affinity 
for MICA. In principal, these data show the possibility to further improve the binding proper-
ties of NKG2D. However, the use of the mutant protein as therapeutic agent might be critical, 
since changes in the binding interface could also affect the specificity of the NKG2D protein. 
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Therefore, further studies are needed for the detailed characterization of the mutant protein 
regarding binding affinity for cognate ligands and allelic variants as well as its specificity.   
 
Figure S14: Binding characteristics of NKG2D::hIgG1-Fc mutant proteins. 
(A) Flow cytometric analyses of NKG2D::hIgG1-Fc mutant proteins binding to HEK293T cells. 
Grey = antibody control; blue = wildtype NKG2D-Fc; red = NKG2D-Fc mutants. (B) Binding kinetics 
of graded amounts of NKG2D-Fc fusion proteins to sMICA analyzed by ELISA. Wildtype NKG2D-Fc 
protein served as control (black). Respective mutant proteins are highlighted in red, blue and green. 
Data are represented as mean ± SEM of a representative experiment of three independent experiments. 
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5.1.9 Protein Sequence Alignments 
5.1.9.1 Human MICA allelic Variants 
Sequences of MICA*01 (UniProtKB Q29983), MICA*04, MICA*07 (G9FRT9) and 
MICA*08 (L0L8F7). Identical amino acids (dash), signal peptide sequence (grey, underlined), 
N-linked glycosylation sites (blue), M152/V152 (red), the AMO1 antibody epitope (red box) 
and the BAMO3 antibody epitope (grey box).  
MICA*01    1 MGLGPVFLLLAGIFPFAPPGAAAEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCD 
MICA*04      ----------------------------------------------A-----------Y- 
MICA*07      ----------------------------------------------A------------- 
MICA*08      ----------------------------------------------A-----------Y- 
 
MICA*01   61 RQKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCE 
MICA*04      ------------------------------------------------------------ 
MICA*07      ------------------------------------------------------------ 
MICA*08     P------------------------------------------------------------ 
 
MICA*01  121 IHEDNSTRSSQHFYYDGELFLSQNLETKEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTHY 
MICA*04      ------------------------V--E---V---------------------------- 
MICA*07      ---------------------------E-------------------------------- 
MICA*08      ---------------------------E---V---------------------------- 
 
MICA*01  181 HAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRSEASEGNITVTCRASGFYPWNITLSWR 
MICA*04      ---------------E-S-----R------------------------S---R----T-- 
MICA*07      ------------------------------------------------------------ 
MICA*08      ---------------E--------------------------------S---R--I-T-- 
 
MICA*01  241 QDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKV 
MICA*04      ------------------------------------------------------------ 
MICA*07      ------------------------------------------------------------ 
MICA*08      ---------------------------------R-------------------------- 
 
MICA*01  301 LVLQSHWQTFHVSAVAAAA  IFVIIIFYVR CCKKKTSAAEGPELVSLQVLDQHPVGTS 
MICA*04      -------------------AA---------- ---------------------------- 
MICA*07      -------------------  ---------- ---------------------------- 
MICA*08      -----------------GC  CY FCYY-FLL 
 
MICA*01  361 DHRDATQLGFQPLMSDLGSTGSTEGA 
MICA*04      -------------------------- 
MICA*07      -------------------------- 
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5.1.9.2 Human MICA and Human MICB 
Sequence alignment of human MICA (UniProtKB Q29983) and human MICB (Q29980). 
Identical amino acids (dash), signal peptide sequence (grey, underlined), N-linked glycosyla-
tion sites (blue), the AMO1 antibody epitope (red box) and the BAMO3 antibody epitope 
(grey box). 
 
MICA_HUMAN   1 MGLGPVFLLLAGIFPFAPPGAAAEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCD 
MICB_HUMAN     ----R-L-F--VA------A------------M---Q-E-------A-G---------Y- 
 
MICA_HUMAN  61 RQKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCE 
MICB_HUMAN     ---R--------------A----T--E---E--Q---R--T------G------------ 
 
MICA_HUMAN 121 IHEDNSTRSSQHFYYDGELFLSQNLETKEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTHY 
MICB_HUMAN     ----S---G-R----------------Q-S-V-------------T--W----------- 
 
MICA_HUMAN 181 HAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRSEASEGNITVTCRASGFYPWNITLSWR 
MICB_HUAMN     R--Q-----K-Q-------AI-----------C--V------------S---R----T-- 
 
MICA_HUMAN 241 QDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKV 
MICB_HUMAN     --------N-----------------------R-----------------G--------- 
 
MICA_HUMAN 301 LVLQSHWQTFHVSAVAAAAIFVIIIFYVRCCKKKTSAAEGPELVSLQVLDQHPVGTSDHR 
MICB_HUMAN     -----QRTD-PYVSA-MPCFVI---LC-P---------------------------G--- 
 
MICA_HUMAN 361 DATQLGFQPLMSDLGSTGSTEGA 
MICB_HUMAN     --A---------AT--------- 
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5.1.9.3 Human MICA and M. mulatta MIC homologs 
Sequence alignment of the human MICA protein (UniProtKB Q29983, MICA_HUMAN) and 
the Macaca mulatta MIC homologs MIC1 and MIC3 (UniProtKB O98268, MIC1_MACMU; 
Q9XS20, MIC3_MACMU). Identical amino acids (dash), the MICA signal peptide sequence 
(grey, underlined), N-linked glycosylation sites (blue) and the AMO1 antibody epitope (red 
box).  
 
MICA_HUMAN   1 MGLGPVFLLLAGIFPFAPPGAAAEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCD 
MIC1_MACMU             F--S-----R------L------V----R---------A-G-----L--LY- 
MIC3_MACMU                            -L------V----R------E--G-G---S-L-V-Y- 
  
MICA_HUMAN  61 RQKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCE 
MIC1_MACMU     ------R---E-S-----A----T--G---E-------------G--G--------K--- 
MIC3_MACMU     -ETR--R-------A---A----T--G---E------R--T--EG--G------D-QN-- 
  
MICA_HUMAN 121 IHEDNSTRSSQHFYYDGELFLSQNLETKEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTHY 
MIC1_MACMU     -------GGLR----------------Q---EL---------L-I---W---T------- 
MIC3_MACMU     -Y--G--GG-R-------R---L--A-Q---VA-----------   -W---T---N--- 
  
MICA_HUMAN 181 HAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRSEASEGNITVTCRASGFYPWNITLSWR 
MIC1_MACMU     RTVQ----KK-QQ--E-R-AV---A-------H-------------------R--A-T-- 
MIC3_MACMU     ---Q----KK----Q--R-AV---A-------H-------------------R--A-T-- 
  
MICA_HUMAN 241 QDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKV 
MIC1_MACMU     ------N-NA----GI---Q------------R-------A------------------- 
MIC3_MACMU     ------N--A----GI---Q------------R-------A------------------- 
  
MICA_HUMAN 301 LVLQSHWQTFHV      SAVAAAAIFVIIIFYVRCCKKKTSAAEGPELVSLQVLDQHPV 
MIC1_MACMU     --F--Q-LDIPYVLAVAAA  V---AIFV--L--L-----------------RT------ 
MIC3_MACMU     --F--Q-LDIPYVLGVAAA------AIFV--L--L------------              
  
MICA_HUMAN 361 GTSDHRDATQLGFQPLMSDLGSTGSTEGA 
MIC1_MACMU   --G------                     
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5.1.9.4 Human NKG2D and M. mulatta homolog 
Sequence alignment of the human NKG2D protein (UniProtKB P26718, NKG2D_HUMAN) 
and the Macaca mulatta homolog (UniProtKB Q9MZJ7, NKG2D_MACMU). Identical ami-
no acids are indicated as dash. 
 
NKG2D_HUMAN  MGWIRGRRSRHSWEMSEFHNYNLDLKKSDFSTRWQKQRCPVVKSKCRENASPFFFCCFIA 
NKG2D_MACMU  --------P--NL--------K-G-A-------C-------I----------L------- 
 
NKG2D_HUMAN  VAMGIRFIIMVAIWSAVFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNW 
NKG2D_MACMU  -----------T------------------------------------------N----- 
 
NKG2D_HUMAN  YESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLT 
NKG2D_MACMU  ------------------------------------------------------------ 
 
NKG2D_HUMAN  IIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTV 
NKG2D_MACMU  ------------------------I----------- 
 
5.2 Protein Sequences 
Unless otherwise denoted, nucleotide sequences originate from commercial plasmid vectors 
or can be found at the NCBI database (www.ncbi.nlm.nih.gov). Respective accession numbers 
and used base pairs are indicated for each fragment. Respective plasmid numbers of the in-
tralaboratory database are depicted. Amino acids depicted in black result from the cloning 
strategy. Signal sequences are depicted in grey and are underlined, the different affinity tags 
(N-/C-terminal fusion indicated by subscripted characters) are shown in red, IgG1-FcEQ in 
green and the respective NKG2D and NKG2D ligand protein sequences in blue. Amino acids 
for single point mutations are in bold and underlined.  
 
5.2.1 NKG2D Proteins  
 NKG2D protein: UniProtKB P26718; Ref.Seq. NM_007360 
The different protein domains are separated by dashes, amino acid color scheme: or-
ange = cytoplasmic domain (CYD aa 1 - 51); purple = transmembrane domain (TMD aa 52 -
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 72); blue = extracellular domain (ECD aa 73 - 216). For the following constructs, only the 
NKG2D ECD (bp 217 - 651) was used. 
MGWIRGRRSRHSWEMSEFHNYNLDLKKSDFSTRWQKQRCPVVKSKCRENAS|PFFFCCFIAVAMGIRF
IIMVAIWSAVFL|NSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASL
LKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIEN
CSTPNTYICMQRTV 
 
 HisN-NKG2D: plasmid no. 1901 
HHHHHHHHHHSSGHIEGRHMNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASC
MSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASS
FKGYIENCSTPNTYICMQRTV 
 
 AviN-NKG2D-Flag/HisC: plasmid no. 5802 
MDYKDDDDKGMV|HHHHHHSAEGSGNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYE
SQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCA
LYASSFKGYIENCSTPNTYICMQRTVLNDIFEAQKIEWHE  
 
 IL2ss-IgG1-FcEQ::NKG2D: plasmid no. 6837 
The ECD sequence of wildtype NKG2D is shown in blue. Amino acids exchanged by single 
point mutations for the generation of mutant NKG2D fusion proteins for affinity maturation 
(see 5.1.8; plasmid no. 6838 - 6845) are depicted in bold and are underlined. 
 
MYRMQLLSCIALSLALVTNSISAMVRSDKTHTCPPCPAPELEGGPSVFLFPPKPKDTLMISRTPEVTC
VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSSGNSLFNQEVQIPLTE
SYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIP
TNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTV 
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 IL2ss-Avi-IgG1-FcEQ::NKG2D: plasmid no. 6846 
MYRMQLLSCIALSLALVTNSISAMSGLNDIFEAQKIEWHEVRSDKTHTCPPCPAPELEGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS
SGNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDL
LKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQ
RTV 
 
5.2.2 MICA Proteins 
 MICA*01 protein: UniProtKB Q29983; Ref.Seq. NM_001177519 (L14848, EMBL) 
The different protein domains are separated by dash, amino acid color scheme: grey, under-
lined = signal peptide; blue = extracellular domain (ECD, aa 24 - 307); purple = trans-
membrane domain (TMD, aa 308 - 328); orange = cytoplasmic domain (CYD, aa 329 - 383). 
For MICA*01 constructs only the ECD (aa 24 - 299; bp 70 - 879) was used. 
 
MGLGPVFLLLAGIFPFAPPGAAA|EPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAK
PQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYY
DGELFLSQNLETKEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLKSGVVLRR
TVPPMVNVTRSEASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATR
ICQGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHW|QTFHVSAVAAAAIFVIIIFYVR|CCKKKTSA
AEGPELVSLQVLDQHPVGTSDHRDATQLGFQPLMSDLGSTGSTEGA 
 
 MICA*01-HisC: plasmid no. 5701 
MEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAKPQGQWAEDVLGNKTWDRETRDLT
GNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGELFLSQNLETKEWTMPQSSRA
QTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRSEASEGNITVTCR
ASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHP
VPSGKHHHHHH   
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 MICA*04-HisC: Ref.Seq. U56943 (bp 1 - 828); plasmid no. 5801 
Amino acid differences to MICA*01 are marked in yellow. 
MEPHSLRYNLTVLSWDGSVQSGFLAEVHLDGQPFLRYDRQKCRAKPQGQWAEDVLGNKTWDRETRDLT
GNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGELFLSQNVETEEWTVPQSSRA
QTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLESSVVLRRRVPPMVNVTRSEASEGNITVTCR
ASSFYPRNITLTWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHP
VPSGKHHHHHH 
 
 IL2ss-sMICA*01-HisC: plasmid no. 8502 
MYRMQLLSCIALSLALVTNSMEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAKPQG
QWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGE
LFLSQNLETKEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLKSGVVLRRTVP
PMVNVTRSEASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQ
GEEQRFTCYMEHSGNHSTHPVPSGKHHHHHH 
 
 IL2ss-MICA*04-HisC: Ref.Seq. U56943 (bp 1 - 828); plasmid no. 8504 
MYRMQLLSCIALSLALVTNSMEPHSLRYNLTVLSWDGSVQSGFLAEVHLDGQPFLRYDRQKCRAKPQG
QWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGE
LFLSQNVETEEWTVPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLESSVVLRRRVP
PMVNVTRSEASEGNITVTCRASSFYPRNITLTWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQ
GEEQRFTCYMEHSGNHSTHPVPSGKHHHHHH 
 
 IL2ss-MICA*01::IgG1-FcEQ: plasmid no. 6834 
MYRMQLLSCIALSLALVTNSMEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAKPQG
QWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGE
LFLSQNLETKEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLKSGVVLRRTVP
PMVNVTRSEASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQ
GEEQRFTCYMEHSGNHSTHPVPSGKRSDKTHTCPPCPAPELEGGPSVFLFPPKPKDTLMISRTPEVTC
VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
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 IL2ss-MICA*04::IgG1-FcEQ: plasmid no. 6835 
MYRMQLLSCIALSLALVTNSMEPHSLRYNLTVLSWDGSVQSGFLAEVHLDGQPFLRYDRQKCRAKPQG
QWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGE
LFLSQNVETEEWTVPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLESSVVLRRRVP
PMVNVTRSEASEGNITVTCRASSFYPRNITLTWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQ
GEEQRFTCYMEHSGNHSTHPVPSGKRSDKTHTCPPCPAPELEGGPSVFLFPPKPKDTLMISRTPEVTC
VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
5.2.3 NKG2D Ligands 
The NKG2D ligands MICA (allelic variants 001, 004, 007 and 008), MICB and ULBP1-3 
were expressed as full-length constructs in C1R cells (inducible MICA*01 in UKF-NB3). All 
constructs were fused to the MICA signal peptide (ss; bp 1 - 69; grey, underlined). 
 
 ss-HisN-MICA*01: Ref.Seq. L14848 (bp 70 - 1152); plasmid no. 9102 
MGLGPVLLFLAGIFHFAPPGAAADHHHHHHEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDR
QKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRS
SQHFYYDGELFLSQNLETKEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLKS
GVVLRRTVPPMVNVTRSEASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQ
TWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHWQTFHVSAVAAAAIFVIIIFYVRCCKK
KTSAAEGPELVSLQVLDQHPVGTSDHRDATQLGFQPLMSDLGSTGSTEGA 
 
 ss-HisN-MICA*04: Ref.Seq. U56943 (bp 1 - 822); plasmid no. 9104 
MGLGPVLLFLAGIFHFAPPGAAADHHHHHHEPHSLRYNLTVLSWDGSVQSGFLAEVHLDGQPFLRYDR
QKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRS
SQHFYYDGELFLSQNVETEEWTVPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLES
SVVLRRRVPPMVNVTRSEASEGNITVTCRASSFYPRNITLTWRQDGVSLSHDTQQWGDVLPDGNGTYQ
TWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHWQTFHVSAVAAAAAAIFVIIIFYVRCC
KKKTSAAEGPELVSLQVLDQHPVGTSDHRDATQLGFQPLMSALGSTGSTEGA 
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 ss-HisN-MICA*07: Ref.Seq. U56946 (bp 1 - 822); plasmid no. 9106 
MGLGPVLLFLAGIFHFAPPGAAADHHHHHHEPHSLRYNLTVLSWDGSVQSGFLAEVHLDGQPFLRCDR
QKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRS
SQHFYYDGELFLSQNLETEEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLKS
GVVLRRTVPPMVNVTRSEASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQ
TWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHWQTFHVSAVAAAAIFVIIIFYVRCCKK
KTSAAEGPELVSLQVLDQHPVGTSDHRDATQLGFQPLMSDLGSTGSTEGA 
 
 ss-HisN-MICA*08: Ref.Seq. U56947 (bp 1 - 822); plasmid no. 9108 
MGLGPVLLFLAGIFHFAPPGAAADHHHHHHEPHSLRYNLTVLSWDGSVQSGFLAEVHLDGQPFLRYDR
QKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRS
SQHFYYDGELFLSQNLETEEWTVPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLES
GVVLRRTVPPMVNVTRSEASEGNITVTCRASSFYPRNIILTWRQDGVSLSHDTQQWGDVLPDGNGTYQ
TWVATRICRGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHWQTFHVSAVAAGCCYFCYYYFLCPLL 
 
 ss-HisN-MICB: UniProtKB Q29980; Ref.Seq. NM_005931.4 (bp 69 - 1152);  
plasmid no. 9110 
MGLGPVLLFLAGIFHFAPPGAAADHHHHHHEPHSLRYNLMVLSQDESVQSGFLAEGHLDGQPFLRYDR
QKRRAKPQGQWAEDVLGAKTWDTETEDLTENGQDLRRTLTHIKDQKGGLHSLQEIRVCEIHEDSSTRG
SRHFYYDGELFLSQNLETQESTVPQSSRAQTLAMNVTNFWKEDAMKTKTHYRAMQADCLQKLQRYLKS
GVAIRRTVPPMVNVTCSEVSEGNITVTCRASSFYPRNITLTWRQDGVSLSHNTQQWGDVLPDGNGTYQ
TWVATRIRQGEEQRFTCYMEHSGNHGTHPVPSGKVLVLQSQRTDFPYVSAAMPCFVIIIILCVPCCKK
KTSAAEGPELVSLQVLDQHPVGTGDHRDAAQLGFQPLMSATGSTGSTEGA 
 
 ss-HisN-ULBP1: UniProtKB Q9BZM6; Ref.Seq. AF304377 (bp 85 - 735);  
plasmid no. 9112 
MGLGPVLLFLAGIFHFAPPGAAADHHHHHHTHCLCYDFIITPKSRPEPQWCEVQGLVDERPFLHYDCV
NHKAKAFASLGKKVNVTKTWEEQTETLRDVVDFLKGQLLDIQVENLIPIEPLTLQARMSCEHEAHGHG
RGSWQFLFNGQKFLLFDSNNRKWTALHPGAKKMTEKWEKNRDVTMFFQKISLGDCKMWLEEFLMYWEQ
MLDPTKPPSLAPGTTQPKAMATTLSPWSLLIIFLCFILAGR 
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 ss-HisN-ULBP2: UniProtKB Q9BZM5; Ref.Seq. AF304378 (bp 88 - 741);  
plasmid no. 9114 
MGLGPVLLFLAGIFHFAPPGAAADHHHHHHPHSLCYDITVIPKFRPGPRWCAVQGQVDEKTFLHYDCG
NKTVTPVSPLGKKLNVTTAWKAQNPVLREVVDILTEQLRDIQLENYTPKEPLTLQARMSCEQKAEGHS
SGSWQFSFDGQIFLLFDSEKRMWTTVHPGARKMKEKWENDKVVAMSFHYFSMGDCIGWLEDFLMGMDS
TLEPSAGAPLAMSSGTTQLRATATTLILCCLLIILPCFILPGI 
 
 ss-HisN-ULBP3: UniProtKB Q9BZM4; Ref.Seq. AF349596 (bp 91 - 735);  
plasmid no. 9116 
MGLGPVLLFLAGIFHFAPPGAAADHHHHHHAHSLWYNFTIIHLPRHGQQWCEVQSQVDQKNFLSYDCG
SDKVLSMGHLEEQLYATDAWGKQLEMLREVGQRLRLELADTELEDFTPSGPLTLQVRMSCECEADGYI
RGSWQFSFDGRKFLLFDSNNRKWTVVHAGARRMKEKWEKDSGLTTFFKMVSMRDCKSWLRDFLMHRKK
RLEPTAPPTMAPGLAQPKAIATTLSPWSFLIILCFILPGI 
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Abbreviations 
The table of abbreviations does not contain SI (internationally accepted standard) based units 
or SI derived units, the one and three letter amino acid code or metric prefixes. 
Abbreviation Description 
A adenine 
A450 adsorbance at 450 nm 
aa amino acid 
ADAM a disintegrin and metalloprotease 
ADCC antibody dependent cellular cytotoxicity 
AKT anti-apoptotic kinase 
AML acute myeloid leukemia 
Amp ampicillin 
AmpR ampicillin resistance 
APC antigen-presenting cell 
APC allophycocyanin 
APS ammonium persulfate 
ATCC American Type Culture Collection 
ATM ataxia telangiectasia mutated 
ATP adenosine triphosphate 
ATR ATM and Rad3-related 
BAG-6 Bcl2-associated anthanogene 6 
Bcl-2 B-cell lymphoma protein 2 
BCR B cell receptor 
Bmax maximum number of binding sites 
bp base pare 
BSA bovine serum albumine 
C cytosine 
CAR chimeric antigen receptor 
CBA cytometric bead array 
CD cluster of differentiation 
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Abbreviation Description 
CD circular dichroism 
CDC complement-dependent cytotoxicity 
CFSE carboxyfluorescein succinimidyl ester 
CMV cytomegalovirus 
CTL cytotoxic T lymphocyte 
CTLA-4 cytotoxic T lymphocyte-associated protein 4 
CTx chemotherpapy 
CV column volume 
d day 
DA dalton 
DAMP danger-associated molecular pattern 
DAP DNAX activation protein 
DAPI 4’,6-diamidino-2-phenylindole 
DC dendritic cell 
DMEM Dulbecco’s modified Eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNAM-1 DNAX-accessory molecule 1 
dNTP deoxyribonucleotide triphosphate 
DTT dithiothreitol 
ECL enhanced chemoluminescence 
E. coli Escherichia coli 
EDTA ethylendiaminetetraacetic acid 
e.g. for example 
EGFR epidermal growth factor receptor 
ELISA enzyme linked immunosorbent assay 
EOMES eomesodermin 
ER endoplasmic reticulum 
ERp5 endoplasmic reticulum protein 5 
et al. et alii 
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Abbreviation Description 
EtBr ethidium bromide 
EtOH ethyl alcohol 
E:T ratio effector to target ratio 
FACS fluorescence-activated cell sorting 
Fas L Fas ligand 
FCS fetal calf serum 
Fc fragment crystallizable 
FDA US Food and Drug Administration 
FITC fluorescein isothiocyanate 
G guanine 
Gln L-glutamine 
Grb-2 growth factor receptor-bound protein 2 
GS linker glycine-serine linker 
GSH glutathion, reduced 
GSSG glutathione, oxidized 
GvHD graft versus host disease 
GvL/T graft versus leukemia/tumor 
HA hemagglutinin 
HCMV human cytomegalovirus 
HDAC histone deacetylase 
HEK human embryonic kidney 
HER2 human epidermal growth factor receptor 2 
hIgG human immunoglobulin G 
His-tag histidine-tag 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HNSCC head and neck squamous cell carcinoma 
HPV human papillomavirus 
HRP horseradish peroxidase 
HSCT hematopoietic stem cell transplantation 
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Abbreviation Description 
HTS high throughput sampler 
H60 histocompatibility antigen 60 
iDC immature dentritic cell 
IF immunofluorescence 
IFN interferon  
Ig immunoglobulin 
IHC immunohistochemistry 
IL interleukin 
ILC innate lymphoid cell 
IMAC immobilized-metal affinity chromatography 
IMDM Iscove’s modified Dulbecco’s medium 
IPTG isopropyl β-D-1-thiogalactopyranoside 
ITAM tyrosine-based activating motif 
ITIM tyrosine-based inhibitory motif 
KD equilibrium binding constant 
kDA kilo Dalton 
KIR killer cell Ig-like receptor 
LB lysogeny broth 
LMW low molecular weight 
LPS lipopolysaccharide 
mAb monoclonal antibody 
MACMU Macaca mulatta 
MACS magnetic activated cell sorting 
MAPK mitogen-activated protein kinases 
MCP-1 monocyte chemoattractant protein 1 
MEM modified Eagle medium 
MHC major histocompatibility complex 
MICA/B MHC class I chain-related protein A/B 
MIP-1 macrophage inflammatory protein 1 
MLL-5 mixed lineage leukemia 5 protein 
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Abbreviation Description 
MMP matrix metalloprotease 
mRNA messenger RNA 
Mult1 mouse ULBP-like transcript 1 
MW molecular weight 
MWCO molecular weight cut-off 
NCAM neural cell adhesion molecule (CD56) 
NCR natural cytotoxicity receptor 
nd not detectable 
n.d. not defined 
NEAA non-essential amino acid 
NK cell natural killer cell 
NKG2A/C/E natural killer group 2 member A/C/E 
NKG2D natural killer group 2 member D 
No. number 
ns non-significant 
NTA nitrilotriacetat 
OD optical density 
OE overlap extension 
p53 p53 tumor suppressor protein 
PAMP pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PBS-T phosphate-buffered saline supplemented with Tween20 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PDB protein data bank 
PD-1 programmed cell death protein 1 
PD-L1 programmed cell death protein ligand 1 
PE phycoerythrin 
PEI polyethylenimine 
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Abbreviation Description 
PerCP peridinin chlorophyll 
PFA paraformaldehyde 
PI3K phosphatidylinositol-3-kinase 
PLCγ-1/2 phospholipase Cγ 1/2 
PNGase F Peptide-N-Glycosidase F 
PRR pattern-recognition receptor 
RAE-1 retinoic acid early inducible-1 
RANTES regulated upon activation, normal T cell expressed and secreted 
RCTx radio-chemotherapy 
RNA ribonucleic acid 
RPMI roswell park memorial institute medium 
RT room temperature 
RTx radiotherapy 
scFv single chain variable fragment 
SDS sodium dodecyl sulfate 
SEC size exclusion chromatography 
SEM standard error of the mean 
SH2 Src homology 2 
SHP-1/2 Src homology 2 (SH2)-domain containing phosphatase 1/2 
SLAM signaling lymphocytic activation molecule 
sNKG2D ligand soluble NKG2D ligand 
sMICA/B soluble MICA/B 
Src sarcoma 
ss signal sequence 
sULBP soluble ULBP 
Syk spleen tyrosine kinase 
T thymine 
TAE Tris-acetate-EDTA 
TAM tumor-associated macrophage 
TBS tris-buffered saline 
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Abbreviation Description 
TBS-T tris-buffered saline supplemented with Tween20 
TCR T cell receptor 
TEMED N,N,N',N-tetramethylethylenediamine 
TGF-α/β transforming growth factor α/β 
TH T helper 
TIL tumor-infiltrating lymphocyte 
TM melting temperature 
TMB 3,3',5,5'-tetramethylbenzidine 
TME tumor microenvironment 
TNF tumor necrosis factor 
TRAIL TNF-related apoptosis-inducing ligand 
Treg regulatory T cell 
TRIS tris(hydroxymethyl)aminomethane 
U uracil 
UL16 unique-long 16 
ULBP UL16 binding protein 
UV ultraviolet 
V0 void volume 
Vr retention volume 
vs. versus 
v/v volume per volume 
WB Western blot 
wt wild type 
w/v weight per volume 
ZAP70 zeta chain-associated protein 70 
3D 3 demensional 
3’ three prime end 
5’ five prime end 
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